



# Effects of Welding on Health, Index—I through XIV



**American Welding Society®**

---



# **Effects of Welding on Health, Index—I through XIV**

Prepared for  
AWS Safety and Health Committee



**American Welding Society®**

8669 Doral Blvd., Doral, FL 33166

International Standard Book Number: 978-0-87171-827-3  
American Welding Society  
8669 Doral Blvd., Doral, FL 33166  
© 2012 by American Welding Society  
All rights reserved  
Printed in the United States of America

**Photocopy Rights.** No portion of this standard may be reproduced, stored in a retrieval system, or transmitted in any form, including mechanical, photocopying, recording, or otherwise, without the prior written permission of the copyright owner.

Authorization to photocopy items for internal, personal, or educational classroom use only or the internal, personal, or educational classroom use only of specific clients is granted by the American Welding Society provided that the appropriate fee is paid to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, tel: (978) 750-8400; Internet: <[www.copyright.com](http://www.copyright.com)>.

## Personnel

### AWS Safety and Health Committee

D. E. Clark, Chair	<i>Idaho National Engineering Laboratory</i>
D. Werba, Vice Chair	<i>Miller Electric Manufacturing Company</i>
S. P. Hedrick, Secretary	<i>American Welding Society</i>
S. E. Ferree	<i>ESAB Welding &amp; Cutting Products</i>
S. R. Fiore	<i>Lawrence Livermore National Laboratory</i>
K. A. Lyttle	<i>Praxair, Incorporated</i>
A. F. Manz	<i>A. F. Manz Associates</i>
K. M. Merlo	<i>Edison Welding Institute</i>
J. Petkovsek	<i>The Lincoln Electric Company</i>
M. N. Sas	<i>ITW Global Welding</i>

### Advisors to the Safety and Health Committee

D. A. Fink	<i>The Lincoln Electric Company</i>
D. G. Harvey	<i>Hobart Brothers</i>
J. F. Hinrichs	<i>Friction Stir Link, Incorporated</i>
J. D. Jennings	<i>Expert Services</i>
T. Lyon	<i>Consultant</i>
D. H. Sliney	<i>Consultant</i>
R. J. Tucker	<i>Consultant</i>

This page is intentionally blank.

## Foreword

This index was prepared for the Safety and Health Committee of the American Welding Society to provide key-word search capability for the series *Effects of Welding on Health*, Volumes I through XIV. These works review and evaluate research conducted throughout the world on the potential health effects associated with physical and chemical hazards produced by different welding processes. The first volume covered research published before 1978, while the latter thirteen covered the time periods between 1978 and 2005 (the last volume also included an appendix with short summaries of articles on the effects of welding on human health published between 2006 and 2009).

This page is intentionally blank.

# Effects of Welding on Health, Index—I through XIV

## A

- Abortion. *See* Spontaneous abortion
- Absenteeism. *See also* Sick leave rates  
 acute respiratory infection and, **IV**:14  
 hygiene and work practices, **XII**:34–35  
 illness-related absences, incidences of, **V**:3  
 neck and shoulder disorders, **VII**:38  
 respiratory disease-related absences, **IV**:xvi, **V**:14–15, **XIII**:21–22, 69–70
- Abstract reasoning, aluminum exposure studies, **XIV**:7, 16
- A.C. power systems  
 extremely low-frequency electromagnetic (ELF) exposure, **VIII**:5  
 symmetrical susceptibility bridge, particle retention studies, **VIII**:27
- Accidents. *See also* Injuries  
 construction welding incidents, **VIII**:24  
 contact lenses in welders, **VI**:37  
 cross-sectional surveys, **XIII**:20, **XIV**:27  
 electrocutions, **XII**:13  
 epidemiological studies, **IX**:8  
 explosions, **XII**:13  
 falls, **VIII**:9  
 fault tree analysis, **VIII**:19–20  
 hygiene and work practices, **VII**:6–7, 21, 23, **X**:9, 29, **XII**:13, 33–35  
 ignition hazard analysis, **VIII**:20  
 laser welding, **X**:8, 24–25  
 list by employee activity, **VIII**:22, 24  
 list by incident type, **VIII**:21  
 maritime welding incidents, **VIII**:25–26  
 neck and shoulder injuries, **IX**:11–12, 43–45  
 NIOSH-HETAB field investigations, **VIII**:20  
 partially chlorinated hydrocarbons, **VIII**:20  
 Pakistani welders, **XIV**:12  
 prevalence studies of, **XIII**:57–59  
 published searches, **VIII**:19  
 radiographic weld inspection, **VIII**:17–18  
 research overview, **VIII**:19–23  
 risk assessment studies, **IV**:11  
 statistical analysis of, **I**:41, **II**:xix–xx, 22  
 studies of fatalities, **VIII**:6  
 working conditions and, **IX**:28–29  
 by work location, **VIII**:23
- ACGIH noise exposure guidelines, **VIII**:34–36
- Actinic elastosis, epidemiologic studies, **IV**:xvii
- Actinic ray photokeratitis. *See* Keratoconjunctivitis
- Acute gastritis, welding and, **I**:34
- Acute myelocytic leukemia, **VIII**:31
- Acute nonlymphocytic leukemia, in children of welders, **IX**:37
- Acute respiratory disease  
 animal studies, **IV**:25  
 case studies, **VII**:8, 29–30  
 Finnish welders, **I**:7–8  
 fume exposure, **I**:5–7, **IV**:13–14, **VII**:8, 29–30  
 nitrogen oxide exposure, **I**:5–7  
 ozone exposure, **I**:5–6  
 phosgene exposure, **I**:5  
 prevalence of, **I**:7  
 in shipyard welders, **V**:3  
 siderosis and pneumoconiosis, **I**:7–11  
 welding fumes and, **III**:6, **IV**:11, 13–14
- Acute toxicity studies  
 aluminum exposure, **I**:xv  
 animal studies, **I**:83–85, 90–91  
   in guinea pigs, **I**:92–93  
   in rabbits, **I**:90–91  
   in rats, **I**:83–85  
   toxicity variations, **VI**:45–46  
 cadmium exposure, **I**:5, 7  
 fume exposure studies, **II**:9–13  
 gas shielded arc welding, **I**:xv  
 gas welding, **I**:xv  
 pneumoconiosis, causative agents, **II**:9–10  
 pulmonary function tests, **II**:11–12  
 pulmonary inflammation, **II**:10–11  
 radiation effects, **II**:12–13
- Acute tubular necrosis in welders, chromium exposure, **IX**:46, **X**:54–55
- Adaptometry, eye and vision injuries, **VII**:36
- Adrenal gland, in welders  
 epidemiological studies, **I**:36, **XIV**:38  
 neuroblastoma, incidence of, **V**:33
- Adrenalin levels in welders, fume exposure studies, **VI**:9, **VI**:39–40
- Aerosol exposure. *See also* Particle analysis  
 analytic studies, **VIII**:13–14, **X**:22  
 animal studies  
   cadmium exposure, **II**:26  
   pneumoconiosis, **V**:37–39  
   toxicologic effects, **III**:16–18
- Baum-Mulholland particle coagulation theory, **VI**:16
- cardiovascular effects of, **V**:3  
 composition analysis, **VI**:15–16  
 elimination pathways for, **III**:6–7  
 fume exposure studies, **IV**:xv, **XIII**:14



- fume generation rates, **V:7**, **IX:20**, 22  
 generation of, **III:1–2**  
 hard metal coatings, **X:39–40**  
 hemolysis and, **II:14**  
 laser welding hazards, **X:24–25**  
 morphology, **V:7**  
 photometric measurement, **VI:5**, 16  
 pulmonary function testing, **III:8–10**  
 radiation exposure studies, **IX:26–27**  
 respiratory tract studies, **IV:xvi**  
     toxicity studies, **II:8–9**  
 thoriated electrodes, **XIV:24**  
 workplace analysis, **XIII:18**, 49–51, **XIV:12**, 25
- Age-related studies  
 cancer in welders, **XIV:5**  
 chromium compound exposure studies, **V:8**  
 chronic respiratory disease, **I:17–19**  
 eye injuries and vision damage, **VI:8**  
 hemochromatosis, **XI:5**  
 pulmonary function testing, **IV:14–15**, **VI:7**  
 respiratory disease in welders, **V:11**  
 shipyard welders, abnormal chest x-rays, **I:8**  
 visual acuity and, **I:27**  
 in welders, **XI:54**
- Airborne contaminants, workplace exposure limits, **IX:22–23**
- Air carbon arc welding  
 lead exposure during, **X:8**  
 noise production, **I:77–78**
- Air cleaning equipment, hygiene and work practices, **IX:27**
- Aircraft industry welders, lung cancer in, **X:11**
- Air duct ventilation systems, workplace analysis, **XIII:52–59**
- Air flow analysis  
 deficits, current research, **X:3**  
 ventilation systems, **XIII:55–59**
- Air-line devices, impact of, on cardiovascular system, **VI:38**
- Air monitoring  
 aluminum exposure, **XIV:89**  
 bypass leakage problems, **X:7–8**  
 fume composition studies, **X:22**  
 ventilation systems, manganese exposure, **XIV:26**
- Air temperature, ventilation systems and, workplace analysis, **XIII:52–59**
- Airways responsiveness data, occupational asthma, **XI:30–35**
- AKI sampling technique, ozone exposure studies, **V:10**
- ALARA (As Low As Reasonable Achievable) exposure policy, **VIII:18**
- Albumin, liver function in welders and, **I:35–36**
- Aldehydes, incidental exposure studies, **IX:26**
- Algerian welders, pulmonary function testing, **XIV:81**
- Aliphatic hydrocarbons, nervous system effects, **VIII:7**
- Alkaline content of fumes  
 electrode composition, **V:6**  
 eye and vision effects of, **III:xiv**
- Alkaline digestion medium, chromium emission studies, **VI:21**
- Alkaline filter elution test, chromium exposure, **IX:50–51**
- Alkaline phosphatase activity, pulmonary function testing, **XIV:29**
- Allergic reactions  
 animal studies, **VII:12**, 45  
 asthma incidence, **XIV:30**  
 automotive assembly operations, **XIV:4**  
 case reports, **IX:9**  
 contact sensitivity  
     dermatitis, epidemiologic studies, **VII:9**, 37  
     fume component studies, **VI:37–38**, **VII:9**, 37–38  
 dermatoses, **IV:20**  
 epidemiologic studies, **III:14**, **IV:xviii**, **VII:9**, 37–38  
 fume components, **IV:23–24**  
 fume exposure studies, **II:15–16**, **III:6**, **XI:35**, **XIV:3**  
 incidental exposure studies, **IX:14**, 54  
 metal fume fever with, **VII:35**  
 metallic compound exposure studies, **II:xxi**  
 welding fumes and, **III:6**, **XI:35**
- Alternating current welding, thoriated electrodes, exposure studies, **XIV:11**, 24
- Aluminum exposure  
 acute poisoning, gas shielded arc welding, **I:xv**  
 alveolar macrophage incidence, **VI:32**  
 analytic techniques, **XII:11**, 23  
 animal studies  
     fume inhalation in rats, **I:86–88**  
     toxicology studies, **IV:27**  
 anti-oxidant systems, **VIII:6**  
 asthma in welders and, **XII:42**, **XIV:30–31**  
 biological monitoring, **VII:10–11**, 40, **VIII:40**, **IX:13**, 52–53, **XII:20**, 69, **XIV:89**  
     fume exposure studies, **VI:10**, 43, **VIII:12**  
     fume generation rates during GMAW, **IX:20–21**  
     welding-related diseases, **V:3**, 21–23  
 blood studies of welders, **I:42–43**  
 central nervous system function and, **X:14**, 52–53  
 cognitive function studies, **XII:17**  
 fibrosis and, **IV:13**  
 fume generation studies, **II:1**  
 gas exposure studies, **VI:6**  
 gas metal arc welding (GMAW), **VII:15**  
 gas tungsten arc welding, thoriated electrodes, **XIV:11**  
 metal fume fever, studies of, **V:3**, 20  
 nervous system effects, **IX:11**, 42–43, **XI:12**, 46, **XII:56**, **XIII:26–27**, 96–98, **XIV:1**, 7, 16, 42–43, 85  
 Norwegian workers, **XIV:3**  
 ozone generation, **I:3–4**, 73–74, **IV:xv**, **IX:24–25**  
     gas metal arc welding, **VI:15**  
 particle studies, **V:7**  
 plasma arc welding, **IX:32**  
 pneumoconiosis studies, **II:xx**, **IV:11**, **XIII:68–69**  
 pulmonary function testing, **VI:28–32**, **X:9–10**  
 radiation exposure studies, **VI:25**  
     line spectra, **I:76**  
     respiratory tract fume exposure studies, **V:19**  
     sarcoid-like granulomatous aluminum disease, **XIV:14**  
     thoriated electrodes, exposure studies, **XIV:24**  
     workplace analysis, **XIII:17–18**
- Aluminum-magnesium alloys, ozone production, **I:3**, 73–74
- Alveolar bronchiolization, animal studies of welding effects, **V:4**
- Alveolar macrophages. *See also* Bronchoalveolar lavage fluid (BALF)

- animal studies, **VI**:45–46, **VII**:41–42  
   gene expression, **X**:73–74  
   pneumoconiosis, **V**:38–39  
   *in vitro* animal studies, **X**:71  
 as defense mechanism, **II**:29  
 epidemiologic studies, **VIII**:6, 25, **X**:5  
 fibrogenic potential studies, **I**:xxii  
 fume and gas exposure studies, **VI**:27, 32  
 iron exposure, animal studies of, **II**:27  
 lung disease and, **X**:1, 3  
 mammalian cell studies, **VIII**:42–43  
 metal fume fever, **VII**:34–35, **X**:1, 48–49, 70  
 protein synthesis induction and, **X**:5  
 research on, **VII**:7, 24–25  
 respiratory tract infection and, **XIII**:5–6  
 ultrafine particle analysis, **XIII**:72–74  
*in vitro* studies, **V**:4, **VII**:12–13, **IX**:14, 55–56  
   animal studies, **X**:73–74  
   cytotoxicity, **VII**:47  
   toxicity assays, **V**:42  
 Alveolar proteinosis, animal studies, **VII**:11–12, 44–45  
 Alveolitis  
   asthma incidence, **XIV**:30  
   welding fumes and, **XIV**:3  
 Alzheimer's disease  
   ELF-EMF exposure and, **XIV**:16  
   epidemiologic studies, **XIV**:41–49  
 Amberlite La-2 ion-exchange resin, atomic absorption analysis,  
   **VIII**:13–14  
 Ambient air measurements  
   degreasing agents, **VI**:26–27  
   fume exposure studies, **VI**:15  
 American National Standards Institute (ANSI)  
   ANSI/ASC Z49.1-88, **VIII**:5, **X**:13, 50  
   ANSI/AWS F2.2-89, **VIII**:5  
   ANSI/AWS F3.1-89, **VIII**:5  
   ANSI C95.4 exposure guideline, **VIII**:17  
   welding standards, **VIII**:22  
 American Thoracic Society  
   occupational asthma studies, **XIV**:3  
   respiratory disease studies, **V**:16  
 American Welding Society (AWS) laboratory test methods  
   animal studies, inflammation and fibrosis, **VII**:11  
   AWS F1.2-79, Ames test, **I**:55  
   AWS F.12-1979, **III**:1, **X**:8, 22  
   fume condensates, **I**:xxii  
   fume exposure studies, **VI**:46–47  
   mild steel fume mutagenicity, **VI**:11, 14  
   mutagenicity studies, **I**:xxii, **V**:40–41  
   *in vitro* studies, **V**:4, **VII**:12, 46  
 $\delta$ -Amino levulinic acid (ALAU)  
   biological monitoring with, **X**:7, 21  
   lead exposure studies, **VI**:10, 43–44  
   urine levels of, **II**:16  
 $\delta$ -Amino levulinic acid dehydratase (ALA-D), fume exposure  
   studies, **II**:xxi, 16  
   urine levels, **II**:16  
 Amyotrophic lateral sclerosis (ALS), **XI**:12  
   ELF-EMF exposure and, **XIV**:16, 42–49  
   epidemiologic studies, **XI**:45–46  
   in welders, **IX**:11, 43  
 Anemia, in welders, **I**:xix, 31. *See also* Hematocrit levels in  
   welders  
 Animal studies. *See also* specific animals  
   acute respiratory disease, **IV**:25  
   aerosol exposure  
     cadmium exposure, **II**:26  
     pneumoconiosis, **V**:37–39  
     toxicologic effects, **III**:16–18  
   allergic reactions, **VII**:12, 45  
   aluminum exposure  
     fume inhalation in rats, **I**:86–88  
     toxicology studies, **IV**:27  
   alveolar bronchiolization, **V**:4  
   alveolar macrophages, **VI**:45–46, **VII**:41–42  
     pneumoconiosis, **V**:38–39  
   alveolar proteinosis, **VII**:11–12, 44–45  
   Ames test, inflammation and fibrosis, **VII**:11  
   anti-oxidants, **X**:18  
   arc welding radiation exposure, **I**:49, 105–106  
   arsenic toxicity, **VII**:11–12, 44–45  
   austenitic electrode toxicity, **VII**:44–45  
   barium exposure, **VII**:45–46  
   beryllium exposure, **II**:25–26  
   biochemical studies, **VII**:12, 45, **IX**:56–57  
     cadmium exposure, **II**:26–27  
     cobalt exposure, **II**:27  
     manganese exposure, **II**:28–29  
     nickel exposure, **II**:29  
     techniques, **IX**:56–57  
     toxicology research, **II**:23–30  
   blood analysis  
     biochemical studies, **VII**:45  
     cadmium exposure, **II**:26  
     toxicology studies, **IV**:26–27  
     whole-body effects of welding, **V**:39–40  
   body weight/lung weight ratio, toxicology studies, **IV**:25–26  
   bronchitis, fume inhalation studies, **I**:85–86  
   cadmium exposure, **II**:25–27  
   calmodulin exposure, **VII**:45  
   carbon monoxide exposure, **VI**:10–11, 45–46  
   carcinogenicity studies, **I**:48, 101–102, **V**:37  
     metals, **II**:29–30  
     welding compounds, **VI**:32–34  
   chromium exposure  
     allergic reactions, **VII**:12  
     biomarkers, **IX**:51  
     carcinogenicity studies, **V**:4, 37  
     fume exposure studies, **VI**:11, 45–46  
     fume inhalation in rats, **I**:83–85  
     pulmonary retention and clearance, **V**:40, **VII**:42–44  
     toxicology studies, **IV**:25–27, **VII**:44–45  
     whole-body effects, **V**:39–40  
   cobalt exposure, **II**:27  
   combined fume exposure measurements, **VI**:14  
   corneal injuries, **XIV**:40  
   distribution and excretion of inhaled fumes, **I**:97–101  
   electrode composition

- fume inhalation studies
  - guinea pigs, **I**:92–93
  - rabbits, **I**:91
  - rats, **I**:83–85
- inflammation and fibrosis, **VII**:11, 41–42
- rutile electrodes
  - inhalation studies, **I**:46, 85–86
  - pneumoconiosis, **V**:37–39
  - toxicology studies, **IV**:xviii–xix
- electromagnetic fields (EMFs), **X**:17, 69
- emphysema, **V**:4, **VI**:10–11, 45–46
- experimental techniques and design, **II**:24–25
- fecal analysis
  - toxicology of nickel compounds, **IV**:27–28
  - whole-body effects of welding, **V**:39–40
- fertility disorders, **IX**:4, 14, 54–55, **X**:17, 69–70
- fibrosis, **XIII**:33, 116–117, **XIV**:4, 20–21, 63–66
  - fibrogenicity and, **VI**:46, **VII**:11, 41–42, **IX**:55
- fluoride compounds, distribution and excretion, **I**:97–98
- flux-cored arc welding (FCAW)
  - pneumoconiosis, **V**:37–39
  - toxicology research, **II**:25
- fume exposure studies, **II**:23–30, **VI**:10–11, 45–46, **IX**:14–15, 56, **XI**:14, **XIV**:32
  - inhalation studies, **I**:45–54
  - techniques for, **II**:23–24
- fume generation rates, **III**:xv, 16–18
  - threshold limit values (TLVs), **VI**:10–11
- fume inhalation studies, **I**:45–54, 83–95, **III**:17–18, **IV**:27–28
- gas exposure studies, **VI**:45–46
  - toxicology studies, **IV**:xviii, 27
- gas metal arc welding (GMAW), **V**:4
  - fume exposure studies, **VI**:11
  - inflammation and fibrosis, **VII**:11, 41–42
  - pulmonary retention and clearance, **VII**:11, 42–44
  - toxicity effects, **III**:17–18, **VII**:44–45
  - whole-body effects, **V**:40
- gas tungsten arc welding (GTAW), **VI**:11, 46–47
- gene expression, **X**:18
- genotoxic compounds, **VI**:46–47
- hexavalent chromium, **V**:4
- implantation techniques, **V**:4
- infectivity, **XIV**:20, 60–63
- inflammatory response studies, **VII**:11, 41–42, **XIV**:20, 60–63
- influenza and tuberculosis, **I**:49, 103–104
- inhalation studies, **XIII**:116–120
- intraperitoneal effects, **I**:102
- intratracheal administration (instillation) techniques, **I**:94–97, **VI**:45–46, **VII**:7
  - biochemical effects, **VII**:45
  - fume carcinogenicity, **V**:37
  - fume exposure studies, **VI**:11
  - inflammation and fibrosis, **VII**:42
  - pneumoconiosis, **V**:38–39
  - toxicity studies, **III**:17–18, **IV**:27–28
- iron exposure, **II**:27–28, **III**:xv
  - fume inhalation studies
    - in rabbits, **I**:91
    - in rats, **I**:85
    - pulmonary retention and clearance, **V**:40
- kidney function, toxicology studies, **IV**:28
- LD50 values, **VII**:11–12
- leukocyte migration, **IV**:25
- limitations of, **II**:23–24, **III**:17
- lithium toxicity, **IV**:28
- liver studies, **I**:88–89
- lungs, in fume inhalation studies, **XIII**:32
  - in rabbits, **I**:90–91
  - in rats, **I**:83–86
- lung weight/body weight ratio, fume exposure studies, **VI**:10–11
  - pneumoconiosis, **V**:38–39
- magnesium exposure, **I**:86–88
- manganese exposure, **II**:28–29, **VI**:45–46, **XIV**:66
  - distribution and excretion studies, **I**:98–100
  - fume exposure studies, **VI**:10–11, 45–46
  - pulmonary retention and clearance, **VII**:11, 43
  - toxicity effects, **VII**:44–45
  - whole-body effects of, **V**:40
- metal compound analysis, **II**:25–30
  - immune response, **II**:29
  - serum lipoprotein changes, **II**:xviii
  - toxicology studies, **III**:xv, 16–18
- metal fume fever, **I**:48–49, 103, **X**:18, **XII**:20–21, 71–72, **XIII**:33, **XIII**:118–120
- methemoglobin studies
  - guinea pig studies, **I**:92–93
  - rabbits, **I**:91
  - rats, **I**:84–85
- mild steel (MS) welding
  - inflammation and fibrosis, **VII**:11
  - pneumoconiosis, **V**:37–39
- monoamine oxidase (MAO) analysis, **II**:28
- neutron activation analysis, mixed studies, **I**:101
- nickel exposure
  - allergic reactions, **VII**:12
  - biochemical effects, **IV**:24
  - carcinogenicity studies, **II**:29–30
  - fume exposure studies, **II**:28–29, **VI**:11, 45–46
  - pulmonary retention and clearance, **VII**:42–44
  - in rats, **I**:83–88
  - toxicity effects, **IV**:xviii, 27–28, **VII**:11–12, 44–45
  - whole-body effects of, **V**:40
- nitrogen oxide exposure, **VI**:10–11, 45–46
- ozone exposure, **VI**:10–11, 45–46
- particle analysis, **I**:45–54, 83–94, **V**:4, **VI**:46, **VII**:42–44
  - gas metal arc welding (GMAW), **VII**:42–44
  - particle size distribution, **III**:xv
- pneumoconiosis, **V**:37–39
- pneumonia
  - fume inhalation studies, **I**:84–85, 87–88, 92, 94, **V**:4
  - stainless steel, SMAW, **XIV**:1
- pneumonitis, **V**:4, **VII**:41
- pulmonary edema
  - cadmium exposure, **II**:26
  - fume inhalation studies, **VII**:41, 45–46

- guinea pig studies, **I**:93–94  
 pneumoconiosis, **V**:38–39  
 in rats, **I**:45–46, 84–85  
 pulmonary fibrosis, **XIII**:33, 116–117  
 pulmonary retention and clearance studies, **IV**:25–27, **V**:40, **VII**:11, 42–44  
 radiation effects, **I**:49, **III**:18  
 reproductive function  
   cadmium compound exposure, **II**:27  
   fume inhalation studies, in rats, **I**:89, **II**:25  
 research techniques, **II**:23–24, **VII**:11–12  
 toxicology studies, **III**:17–18, **IV**:28  
 respiratory system, **V**:4, **VI**:45–46  
   cadmium exposure, **II**:27  
   inflammation and fibrosis, **VII**:11  
   iron exposure, **II**:27–28  
   leukocyte migration, **IV**:xviii  
   nickel exposure, **II**:28  
 sampling techniques, toxicity studies, **IV**:28  
 serum enzyme testing  
   intratracheal fume administration, **I**:95–97  
   manganese levels, **II**:28  
   toxicology studies, **IV**:26–27  
 shielded metal arc welding (SMAW), **II**:25  
   allergic sensitivity, **VII**:45  
   fume exposure studies, **VI**:11, 46–47  
   inflammation and fibrosis, **VII**:11, 41–42  
   pneumoconiosis, **V**:4, 38–39  
   pneumonia, **XIV**:1  
   pulmonary retention and clearance, **VII**:11, 42–44  
   toxicology studies, **IV**:25–27  
   whole-body effects, **V**:40  
 siderosis, **I**:46, 92  
 silica compound exposure, **I**:99–100  
 silicon toxicity, **IV**:27  
 skin injury studies, **II**:25  
 stainless steel (SS) welding, **VI**:11  
   fume inhalation studies in rats, **I**:86  
   inflammation and fibrosis, **VII**:11  
   pneumonia and, **XIV**:1  
   pulmonary retention and clearance studies, **V**:4, 40, **VII**:43–44  
   toxicology studies, **IV**:xviii  
 subcutaneous effects, **I**:102–103  
 toxicity effects, **II**:xxii, 23, **IV**:xviii–xix, 25–28, **VII**:11–12, 44–45  
   acute toxicity, **I**:83–85, 90–93  
   DNA analysis, **IV**:27–28  
   elimination pathways, **III**:16–18, 23–30  
   exposure pathways, **II**:23–24  
   toxicity variations, **VI**:45–46  
 transmission electron microscopy (TEM), **VII**:43–44  
 tuberculosis and welding fumes, **I**:104  
 ultraviolet (UV) radiation effects, **I**:105–106  
 urine analysis in  
   fume exposure studies, **VI**:11  
   inflammation and fibrosis, **VII**:11  
   pneumoconiosis, **V**:38–39  
   whole-body effects, **V**:39–40  
   *in vitro* studies, **IV**:xix, **IX**:55–56, **X**:18, 71  
   weight change  
     in rabbits, **I**:91  
     in rats, **I**:84–85, 95–97  
   whole-body effects, **IV**:27–28, **V**:39–40  
   x-ray microanalysis, **VII**:43–44  
   zinc compound exposure, **V**:39–40, **VI**:45  
 Anion exchange high-pressure liquid chromatography,  
   chromium emission studies, **VI**:21  
 Anosmia, chromium exposure and, **XIII**:31, 111–112  
 Anoxia, carbon monoxide exposure and, **IV**:11  
 Anthropometry, respiratory tract studies, **V**:18  
 Antioxidants  
   animal studies, **X**:18, 70–71  
   epidemiologic studies, **VIII**:6, **X**:5, 16, 61  
   inflammation and oxidative stress and, **XIV**:6, 49–52, 88  
   lung disease and, **X**:1  
   pulmonary function testing, **XIV**:13, 28–29  
   respiratory tract exposure studies, **VIII**:25–26  
 Antiproteinases, alveolar macrophages, **VII**:25  
 Apolipoprotein D (apo-D), kidney disease in welders and,  
   **X**:54–55  
 Apprentice welders  
   asthma and metal fume fever in, **XIV**:13, 31  
   pulmonary function and asthma in, **XIV**:3  
 Arc eye. *See* Photokeratitis  
 Arc intensity, ultraviolet radiation exposure, **VIII**:15  
 Arc temperature, electrode composition, **V**:6  
 “Arc welder’s flash,” contact lenses and, **III**:13  
 Arc welder’s lung. *See* Siderosis  
 Arc welding  
   endocrine gland tumors and, **XIV**:38  
   fume generation rates and, **III**:2  
   particle generation by, **XIII**:72–74  
   radiation  
     animal studies, **I**:49, 105–106  
     electric current, **I**:77  
     obstruction, **I**:77  
     process differences, **I**:77  
     reflection, **I**:77  
     spectral variation, **I**:76  
 Argentina, lung cancer in welders, **XII**:49–53  
 Argon  
   electrode composition, **VIII**:12  
   as fume component, **IX**:19–20  
   fume generation studies, shielded welding, **V**:6, 26, **X**:19–20, **XIII**:36–37  
   nitrogen oxide production and, **I**:74  
   ozone generation, **IV**:6–7, **IX**:25  
     exposure studies, **V**:9–10, **XI**:17  
     shielded welding, **I**:6, 73–74  
   particle size distribution of welding fumes, **I**:71  
   pulmonary function and respiratory disease, **IX**:31  
 Aromatic amines, bladder cancer and, **XIV**:5  
 Arsenic  
   animal studies  
     toxicity effects, **VII**:44–45  
     trioxide toxicity, **VII**:11–12  
   carcinogenicity studies, **VII**:33–34

urine analysis studies, **II**:xiv  
 Arterial blood gas analysis, metal fume fever, **XIV**:38–39  
 Asbestos. *See also* Mesothelioma  
   cancer incidence and, **VII**:8–9, **VIII**:6, 30–31  
   carcinogenicity studies, **VI**:34  
   cardiovascular disease and, **XI**:50  
   chronic bronchitis and, **X**:33  
   epidemiologic studies, **II**:xxiii, **III**:16, **VIII**:9–10, 29–31  
   lung cancer epidemiology, **VII**:31, 33, **XII**:5, 15–16, 47–50  
     fume exposure covariates, **XIV**:5  
     incidence in welders, **IV**:18–19, **V**:2, 29, **X**:11–12, 41–44  
   mesothelioma incidence and, **IV**:18–19, **XIV**:14  
   pneumoconiosis and, **IV**:11  
   pulmonary function testing, **VIII**:28–29, **IX**:31–32, **X**:31–32, **XI**:3, 9  
   respiratory disease in welders, **IV**:xvi, **V**:11–12  
   shipyard welding and, **X**:3–4  
   stainless steel welders, lung cancer epidemiology, **X**:4  
 Asbestosis  
   case reports, **IX**:9, 32  
   epidemiologic studies, **X**:10, 37  
   incidence of, in welders, **V**:12  
   mesothelioma and, **X**:39  
 Aspartate aminotransferase (AST) levels, thoriated electrode exposure, **X**:45  
 Aspergillus pneumonia, case reports, **XIII**:69  
 Asphyxiation, welding and, **I**:29  
 Assessment techniques, respiratory effects of welding and, **III**:6, 8–11  
 Asthma  
   in apprentice welders, **XIV**:3  
   automotive assembly operations and, **XIV**:4  
   case reports, **IX**:9, 32–33, **XIV**:32–33  
   chromium compounds, **III**:8  
   duration of exposure and, **XI**:4–6  
   epidemiologic studies, **IX**:3, 9, **X**:10, 32–35, **XIII**:61–64, **XIV**:13, 82  
   hard metal coatings exposure, **X**:39–40  
   metal fume fever and, **XIV**:31  
   nickel compounds, **III**:8  
   occupational exposure studies, **XI**:3–4, 9–10, 30–35, **XIII**:4–5, 20–21, **XIV**:3–4, 30  
   pulmonary function testing, **IX**:29, **XIV**:28  
   respiratory changes in welders, **XII**:4, 14, 40–42  
   welding toxicity studies and, **III**:xiv, 8  
 Atherosclerosis, biochemical effects of welding and, **IV**:24  
 Atmospheric gases, hazard analysis, **II**:2  
 Atomic absorption spectrometry (AAS)  
   aerosol analysis, **VIII**:13–14  
   biological monitoring studies, **VII**:41  
   chromium compound exposure studies, **IV**:4–5, **V**:7–9  
   electrode composition, **VII**:16  
   fume exposure studies, **VII**:5, 17  
   kidney disease studies of welders, **V**:21  
   metal analysis in welders, **IX**:22  
   nickel analysis, **X**:7  
   urogenital tract studies, **VIII**:39–40  
   workplace exposure analysis, **XI**:20–21  
 Atopic dermatitis, epidemiology, **XI**:44–45

Atrial fibrillation, welding and, **I**:31–32  
 Augmentation index, cardiovascular effects of welding, **XIV**:87  
 Austenitic electrodes  
   animal studies of toxicity effects, **VII**:44–45  
   pulmonary function testing, **VII**:28–29  
 Austenitic stainless steel, workplace exposure analysis, **XIII**:18, 48–51  
 Australian welders  
   mesothelioma incidence in, **V**:30  
   retinal injury in, **XIV**:15, 40  
 Automated electron beam analysis, welding particles, **V**:7  
 Automotive welding  
   accident and injury studies, **XIV**:27  
   aluminum exposure, neurocognitive loss and, **XIV**:43  
   asthma and, **XIV**:4, 31–32  
   inflammation and oxidative stress in, **XIV**:88  
   lung cancer incidence and, **X**:41, **XIII**:7, **XIII**:78–79  
   manganese exposure effects, **XIII**:11–12, 99–101  
   pulmonary function testing, **XIV**:29, 81  
 Autopsies  
   pulmonary fibrosis studies, **IV**:13  
   respiratory tract studies, **IV**:xiii, xvi

## B

Back injuries. *See also* Lower back pain  
   epidemiologic studies, **VIII**:38, **IX**:11–12, 44–45, **XIV**:55  
 Bacterial assays, fume exposure studies, **VI**:11, 46–47, **VII**:12, 46  
 Bag filters, design requirements, **IX**:27  
 Barium exposure  
   animal studies, **VII**:45–46  
   biological monitoring of, **X**:16, 61–62  
   electrode composition, **VIII**:12  
   emission studies, **VI**:21–22  
     biological monitoring techniques, **VI**:43  
     fume generation rates, **IX**:20–21  
 Barrier curtains, laser welding, **IX**:25  
 Basal cell carcinoma  
   epidemiologic studies, **XII**:53  
   skin cancer, **XIII**:84–85  
   ultraviolet radiation overexposure and, **I**:40  
 Basal ganglia disorders  
   manganese exposure and, **XIV**:16, 45–49  
   in welders, **XIV**:9  
 Basic-cored wires, fume composition and, **X**:7  
 Baum-Mulholland particle coagulation theory, fume emission rates (FER), **VI**:16  
 Bauxite pneumoconiosis, **IV**:11  
 Beer consumption, chromium levels and, **IX**:5, 13  
 Benchmark dose method, manganese exposure studies, **XIV**:86  
 Bending and brazing operations, epidemiologic studies, correlation with welding effects, **II**:19–22  
 2-Benzyl-2-pyridylketone-2-pyridylhydrazone nickel analysis, **X**:8  
 Berylliosis  
   agents for production of, **II**:10  
   chronic and acute, **IX**:49–50

- epidemiologic studies, **VII**:38
- Beryllium  
 animal studies, **II**:25–26  
 cardiovascular disease and, **XI**:50  
 epidemiologic studies, **IX**:12–13, 49–50, **XI**:13, 52  
 fume generation studies, **II**:1, **III**:3  
 pneumoconiosis studies, **II**:xx
- Beta glucuronidase, *in vitro* studies, **VII**:47
- BHK-21 (baby hamster kidney) cells  
 cell transformation assays, **V**:41  
 fume exposure studies, **VI**:11, 47–49  
 mammalian cell studies, **VIII**:41–43  
*in vitro* studies of welding and, **V**:4
- Biliary tract cancer, epidemiologic studies, **XI**:11, 41
- Bioavailability studies  
 manganese exposure, **XIV**:9, 17, 49
- Biochemical effects of welding  
 animal studies, **VII**:12, 45, **IX**:56–57  
 cadmium compounds, **II**:26–27  
 cobalt exposure, **II**:27  
 manganese, animal exposure studies, **II**:28–29  
 nickel, animal exposure studies, **II**:28–29  
 toxicology research, **II**:23–30  
 epidemiologic studies, **IV**:xviii, 24–25  
 fume elimination studies and, **III**:19  
 fume exposure studies, **II**:16–17  
 of heavy metals in welding fumes, **III**:14–15  
 limitations on use of, **II**:xiii  
 testing techniques for, **II**:xiii, xxi, xxiii  
 toxicity studies, **III**:xiv–xv
- Biological Exposure Index, carbon monoxide compounds, **VIII**:14
- Biological monitoring. *See also* Blood analysis, Fecal analysis, Hair analysis, Urinary analysis  
 analytic techniques, **VII**:41  
 barium exposure, **X**:61–62  
 cadmium exposure, **X**:62–63  
 cobalt exposure, **X**:63–65  
 chromium, **X**:63, **XIV**:55  
 dioxin exposure, **XII**:28–29  
 epidemiologic studies, **VII**:4, 10–11, 17, 40–41, **XI**:14, 55  
 Finnish workplace exposure studies, **X**:23  
 fume exposure studies, **IV**:xiv, **VI**:9–10, 41–44  
 aluminum, **VI**:43  
 barium, **VI**:43  
 cadmium, **VI**:44  
 hair analysis, heavy metal monitoring, **VI**:44  
 lead, **VI**:43–44  
 manganese, **VI**:43  
 nickel and chromium compounds, **VI**:41–43  
 health effects of welding and, **V**:3, 21–22  
 inductively-coupled plasma mass spectroscopy, **XII**:23  
 lead exposure, **X**:65  
 manganese exposure, **X**:65  
 mercury exposure, **X**:65–66  
 metals analysis, **IX**:13, 22, 51–53, **X**:7, 21–22, **XII**:20, 67–70, **XIII**:32, 114–115, **XIV**:19  
 nickel, **XIV**:55  
 overview, **VIII**:7, 40–41  
 plutonium exposure, **X**:66  
 polycyclic aromatic hydrocarbons (PAHs), **XIV**:19, 55–57  
 summary of studies, **XIV**:89
- Biomagnetic techniques, epidemiologic studies and, **XI**:11
- Biomarkers  
 chromium exposure, **IX**:13, 50–51  
 epidemiologic studies, **XI**:14, 55–56  
 exposure studies using, **X**:17, 66–69  
 oxidative stress and inflammation in welders and, **XIV**:6, 17–18  
 polycyclic aromatic hydrocarbon monitoring, **XIV**:19
- Biopsies  
 kidney disease, **VII**:39  
 lung tissue, **VII**:5, **XIV**:13–14  
 nasal sinus cancer, **VII**:34  
 respiratory disease studies, **VI**:28
- Birth defects. *See also* e.g. Spina bifida, specific birth defects  
 animal studies of fetal development, **X**:69  
 children of welders, **X**:1, 4, 15, 57–58, **XI**:13, 51
- Bisphenol-A, incidental exposure studies, **IX**:26
- Bitumen storage tanks, accident analysis of, **X**:9, 29
- “Black lung,” brain tumors and, **II**:xxi
- “Black welding flux”  
 fume carcinogenicity studies, **II**:xxi  
 fume exposure studies, **II**:17
- Bladder cancer  
 epidemiologic studies, **IX**:4, 9–10, 36–37, **X**:4, 15–16, 71–72, **XII**:5, 16, 50–51, **XIV**:5, 37–38  
 fume carcinogenicity studies, **II**:xxi, 18–19  
 incidence of, in welders, **V**:31  
 in Israeli welders, **XIV**:14  
 mortality rates, **II**:21–22  
 smoking and, **X**:42
- Blakeley-Zatka technique, chromium compound exposure studies, **IV**:4–5, **V**:7–9
- Blood analysis. *See also* Hematocrit levels in welders  
 aluminum exposure, **V**:3, **X**:52–53, **XII**:23, **XIV**:85, 89  
 animal studies  
 biochemical studies, **VII**:45, **IX**:14–15  
 cadmium exposure, **II**:26  
 toxicology studies, **IV**:26–27  
 whole-body effects of welding, **V**:39–40  
 antioxidant enzymes, **XIV**:13  
 barium exposure, **X**:16, 61–62  
 biochemical effects of welding, **I**:30–31, 41–43, **IV**:24–25  
 monitoring techniques, **VII**:4, 10–11  
 biological monitoring, **XIV**:89  
 cadmium exposure, **VI**:38–39, 44, **IX**:46–47  
 animal studies, **II**:26  
 renal effects, **VI**:9  
 urogenital tract, **VII**:38–39  
 chromium exposure, **II**:xvi, **VII**:40–41, **X**:7, 16, 63, **XII**:67–68  
 biological monitoring techniques, **VI**:41–43, **XIV**:19, 55  
 biomarkers, **IX**:50–51  
 epidemiologic studies, **IX**:5, 13, 31, 51–52  
 copper levels, **II**:xvi  
 C-reactive protein levels, **XIV**:17–18  
 endocrine system effects, **XIV**:88

- fume exposure studies, **VI**:9–10  
 genotoxicity studies, **X**:17, 66–68, **XIV**:20, 58–59  
 iron exposure studies, **IX**:50  
 kidney disease in welders and, **V**:21  
 lead levels, **II**:xvi, 16, **III**:14, **IV**:xviii, **VI**:43–44, **X**:7–8, 16, 60, **XII**:68–69, 65, **XIV**:19, 57  
 manganese exposure, **II**:xviii, **VII**:40, **X**:16–17, 58, 65, **XII**:18, **XIV**:19, 57, 85–87, 89  
     neurophysiological effects, **XIV**:43  
 mercury exposure, **X**:15, 58–59, 65–66  
 metal fume fever, **XIV**:38–39  
     zinc levels, **V**:20  
 metallic compounds, **II**:xiii–xv, xx, xxiii, **IX**:13, **X**:17, 21  
 mutagenicity and carcinogenicity studies, **III**:15–16  
 nickel levels, **V**:3, **VIII**:41  
     animal studies, **II**:28–29  
     biological monitoring techniques, **XIV**:19, 55  
     exposure studies, **IX**:31, 52  
 oxidative stress and inflammation, **XIV**:50–52, 88  
 pulmonary function testing, **X**:31  
 readaptation time effects and, **III**:13  
 respiratory disease studies, **V**:13  
 serum ferritin levels, pneumoconiosis, **XIV**:13–14  
 thoriated electrode exposure, **X**:45  
 urogenital tract studies, **VIII**:39–40  
 vibration-induced white fingers (VWF) and, **X**:13, 55  
*in vitro* techniques, **IX**:56  
 whole-body effects of welding, animal studies, **V**:39–40  
 workplace exposure studies, **X**:22–23  
     zinc exposure, **IX**:53  
 Blood pressure measurements, cardiovascular system of welders and, **I**:xix, 32–34  
 Blue light radiation  
     exposure studies, **VII**:6, 19–20, 35–36, **VIII**:14–16, **XIII**:2, 15, 39–40  
     hazard analysis, **IV**:19  
 B lymphocytes, welding effects, **XII**:8–9  
 Body weight/lung weight ratio, animal toxicology studies, **IV**:25–26  
 Boilermakers, polycyclic aromatic hydrocarbon monitoring in, **XIV**:19, 55–57  
 Bone analysis, lead exposure, **X**:15, 59–61  
 Bone disorders, welding and, **I**:xix  
 Brain cancer  
     children of welders, **VIII**:32–33, **IX**:37, **XIII**:9, 23, 85  
     electromagnetic field exposure, **IX**:38, **X**:47–48  
     epidemiologic studies, **VII**:3–4, 9, **VIII**:6, 33, **XII**:5, **XIV**:37  
     diagnostic sensitivity bias in, **V**:32  
     fume carcinogenicity studies, **II**:xxi, 17–18  
     incidence in welders, **I**:28–29, **V**:2, 31–33, **XIV**:5, 14  
 Brain electric activity mapping (BEAM), manganese exposure studies, **XIV**:43–44  
 Braze welding  
     asthma incidence and, **XIV**:4  
     cadmium exposure, **X**:38  
     cobalt exposure, **X**:63–65  
     fume composition studies, **X**:7, 20  
     fume emission studies, **VI**:5, 20  
     ventilation systems analysis, **XIII**:55–59  
 Brazilian welders, eye injuries in, **XIV**:84  
 Breast cancer  
     electromagnetic field (EMF) exposure, **X**:12  
     in male welders, electromagnetic fields (EMF) exposure, **X**:48  
 Breathing zone measurements  
     fume exposure studies, **VI**:15, **VII**:15  
     impact of helmets on, **VI**:16  
     manganese, **VII**:40  
     genotoxicity studies, **X**:67–68  
     manganese exposure, **XII**:58–61  
     neurophysiological effects, **XIV**:43  
     particles and metals analysis, **X**:33–34  
     training for use of, **VII**:7, 24  
     ventilation systems, **XIII**:18–19, 51–59  
     workplace exposure studies, **XI**:8, 18–20  
 Breathlessness, pulmonary function testing, **VI**:29–32, **IX**:3  
 British Standards Institute (BSI) welding standards, **VIII**:22  
 British welders. *See* United Kingdom  
 Bronchiectasis, epidemiologic studies, **XI**:15  
 Bronchiolitis fibrosa obliterans, pathogenesis, **I**:81  
 Bronchitis  
     animal fume inhalation studies, **I**:85–86  
     chronic bronchitis  
         cardiovascular effects, **V**:20  
         epidemiologic studies, **IX**:3, 29–32  
         iron exposure studies, **IX**:50  
         oxidative stress biomarkers, **XIV**:6, 13, 28–29  
         particle retention studies, **V**:19  
         pulmonary function testing, **XI**:3, 9, **XIV**:3, 13, 28–29  
         respiratory disease studies of, **V**:17–18  
     death rates, **II**:8  
     effects of smoking incidence of, **III**:10  
     epidemiologic studies, **VIII**:6, **VIII**:27–29, **X**:10, 32–35, **XII**:42  
     ferrous materials, **I**:xv–xvi  
     fume exposure studies, **III**:6–7, **VI**:27  
         research techniques, **VII**:3, 7–8, 26–29  
     incidence in welders, **V**:2, 12–13, **VI**:7, **VII**:7–8, 26–29, **XII**:14  
     neurological symptoms accompanying, **VI**:38  
     pathogenesis, **I**:81  
     plasma arc welding, **IX**:32  
     prevalence of, in welders, **I**:13–14, 16–17  
     pulmonary function testing, **VI**:29–32, **IX**:8–9, 29–32  
     respiratory changes in welders, **XII**:4  
     smoking and, **VI**:30–32  
 Bronchoalveolar lavage fluid (BALF)  
     animal studies and cell cultures, **XII**:71–72  
     fibrosis, **XIV**:20–21, 64–66  
     infectivity and inflammation, **XIV**:20, 60–63  
     metal fume fever, **XIII**:33  
     cardiovascular disease in welders and, **XI**:50  
     duration of exposure and IL-6 concentrations in, **XI**:6  
     ferritin measurements, **XIII**:21, 67–68  
     fume exposure and lung disease, **XI**:57–59  
     inflammation in welders and, **XIV**:6, 49–52

metal fume fever studies, **VII**:35, **IX**:10, 39, **XII**:6, 17, 53–54  
 animal studies, **XIII**:118–120  
 pneumoconiosis and, **XIV**:34  
 pneumonia infection and, **XIV**:7  
 pulmonary inflammation, **XII**:72–75  
 siderosis in welders and, **IX**:32  
 ultrafine particle analysis, **XIII**:72–74  
 Bronchopneumonia, epidemiologic studies, **XIV**:14, 34–35  
 Bronchospasm, in metal fume fever studies, **II**:15–16  
 BSFR-2101 protable fan unit, ventilation systems analysis, **XIII**:53–59  
 Bubbling levels in flux, fume emission studies, **VI**:5, 20  
 Buccal cancer, epidemiologic studies, **VIII**:32  
 Bulgarian welders, reproductive disorders among, **X**:15, 58  
 Burn injuries  
 accident surveys, **XIII**:20  
 circumferential burn, **II**:13  
 comparison of welders and construction workers, **XI**:23–24  
 ear injuries, **I**:39, **III**:12, **VII**:35, **IX**:10, **X**:49–50  
 epidemiologic studies, **IV**:xiv, **V**:13, **X**:13, **XI**:3, 12, 45, **XIV**:54–55  
 eye injuries, **XIII**:93–95, **XIV**:39  
 flash burns, **IV**:19–20  
 hot metal on skin, **II**:13  
 hygiene and work practices, **XII**:13, 36  
 incidence of, in welders, **III**:1, **IV**:11  
 photosensitivity in welders and, **XIII**:13  
 radio frequency radiation, **VIII**:17  
 ray burn, **II**:xxi–xxii, 13  
 retinal damage from radiation, **IV**:19  
 skin, **I**:39–40, **III**:xiv, **IV**:xvii, 16, 20, **X**:50, **XIII**:26, 93–95  
 radiation-induced, **II**:xix  
 statistical analysis of, **II**:xix  
 ultraviolet radiation exposure, **VI**:24–25, 37  
 Bystander effect, lung function tests and, **IV**:15

## C

Cadmium exposure  
 acute respiratory disease, **I**:5, 7  
 animal exposure studies, **II**:25–27  
 biochemical effects, **II**:16–17, **IV**:24  
 biological monitoring, **V**:21–23, **X**:16, 62–63  
 blood level studies, **II**:xv  
 carcinogenicity studies, **VIII**:33  
 case reports, **X**:10, 38  
 DNA biomarkers, **X**:68  
 epidemiologic studies, **II**:19, **IX**:13, **XI**:13, 52  
 fertility and, **XI**:51  
 fume exposure studies  
 biological monitoring techniques, **VI**:10, 44  
 preheated fluxes, **VI**:20  
 similarity of toxicity to metal fume fever, **VI**:8, 34–35  
 fume generation studies, **III**:3  
 genotoxicity studies and, **X**:17  
 hair analysis, **II**:xvi, xviii, **VI**:44  
 human fatalities, **IV**:xviii  
 kidney disease and, **I**:31, **V**:3, 21, **VI**:9, 38–39, **VII**:4, 10, 38–39, **X**:14, 54  
 kidney function, **IX**:12, 46–48, **XIV**:18, 52–53  
 local exhaust ventilation systems and exposure to, **XIII**:19  
 lung cancer epidemiology, **XII**:48–50  
 metal fume fever, **II**:15–16, **VIII**:6, 34, **IX**:50  
 metallothionein levels, **X**:5  
 neutron activation analysis of, **V**:3  
 nervous system effects, **XIV**:85–86  
 pneumonitis incidence and, **XII**:15  
 in production coatings, exposure studies, **VI**:26  
 protective coatings, **IV**:7  
 pulmonary function tests, **III**:11, **IX**:50  
 pulmonary irritation from, **II**:11  
 respiratory tract effects of, **II**:xx, **VII**:24  
 urinary system effects of, **II**:xiv, 14  
 ventilation systems analysis, **XIII**:55–59  
 workplace analysis, **XIII**:17–18  
 Calcium  
 aerosol analysis, **VIII**:13  
 electrode composition, **V**:6  
 Calcite electrode coatings, **XIV**:11, 24  
 Calmodulin, animal studies of, **VII**:45  
 Canadian welders  
 asthma in, **XII**:41–42, **XIV**:13, 31  
 bladder cancer incidence in, **XIV**:14, 37–38  
 brain cancer in, **XIV**:5, 14, 37  
 bronchitis and asthma in, **X**:35  
 lung cancer in, **IX**:9, **X**:45–46, **XIV**:14, 36  
 metal fume fever in, **XIV**:13  
 pulmonary function testing, **X**:31, **XI**:3, 9  
 welding safety regulations, **VIII**:22  
 Cancer. *See also* Carcinogenicity, specific types of cancer  
 carcinogenicity of compounds, **I**:xxi–xxii, **VI**:13  
 case-control studies, **VIII**:30  
 children of welders, **VIII**:6, 32–33, **X**:1, 4, 57–58  
 cohort studies, **VIII**:30  
 cross-sectional studies, **VIII**:29–30  
 current research on, **X**:4  
 electromagnetic fields (EMFs) and, **IX**:38, **X**:12, 47–48  
 ELF exposure studies, **VIII**:16  
 epidemiologic studies, **III**:xv, **VI**:7–8, 32–34, **VII**:3–4, 8–9, 13, 30–34, **VIII**:6, 29–34, **IX**:3–4, 9–10, 33–39, **X**:11–12, 40–48, **XI**:4, 10–11, 36–41, **XII**:5, 15–17, 45–53, **XIII**:6–9, 22–24, 75–87, **XIV**:5, 14, 35–38  
 summary, **XIV**:83  
 extraneous exposures, **X**:45–46  
 study design, **I**:xviii  
 thoriated electrodes, **X**:12, 44–45  
 fume exposure studies, **VI**:7–8, 32–34  
 HETAB cluster studies, **VIII**:20  
 incidence of, in welders, **V**:1–2  
 metal carcinogens, **VII**:33–34, **VIII**:33–34  
 mortality studies, **I**:22, **XIII**:7–9  
 non-stationarity conditions, **VIII**:30  
 PACs combined with welding emissions, incidence of, **VI**:14  
 pulmonary fibrosis studies, **IV**:13  
 reproductive disorders in welder parents, **VIII**:32–33



- risk multipliers, **VIII**:30  
 screening techniques for, **VII**:9, 34  
 thoriated electrodes and, **X**:12, 44–45  
 ultraviolet (UV) radiation and, **IX**:38–39  
 unresolved hazard studies, **VIII**:9  
 welders' demographics, **VIII**:30–32
- Capillary gas chromatography, production coating exposure studies, **VIII**:18
- Capnovolumetry, pulmonary function in welders, **XIV**:81
- Carbon arc cutting (CAC-A)  
 fume emission rates (FER), **VI**:5  
 lead exposure studies, **X**:22–23
- Carbonate combustion, gas emission studies, **VI**:23
- Carbon dioxide  
 accidents and injuries, **X**:24–25  
 exposure studies of, **X**:23–25  
 radiation and chemical hazards analysis, **X**:8  
 electrode composition, **VIII**:12  
 eye injuries with, **VIII**:37  
 flux-cored arc welding, fume generation, **XIV**:11  
 as fume component, **IX**:19–21  
 fume exposure studies, **VI**:6, 23–24, **VIII**:5  
 composition analysis, **XIII**:14, 34–37  
 rat studies, **I**:46  
 fume generation rate, **X**:19–20  
 of shielding gas, **V**:6  
 gas metal arc welding (GMAW), **IX**:7  
 ventilation systems, **XIV**:12, 25–26  
 hyperbaric pressure studies, **VI**:40  
 laser welding with, **VIII**:1–16, **IX**:8  
 nickel compounds, **VII**:16  
 noise exposure studies, **VIII**:34–36  
 oxidative stress and inflammation and, **XIV**:50–52  
 particle size distribution of welding fumes, **I**:71  
 production of, during welding, **I**:74–75  
 protective gear and equipment, **XI**:23  
 radiation line spectra, **I**:76  
 shielded flux cored electrodes, **I**:61  
 ultraviolet radiation exposure, **XIII**:15  
 welding arc production of, **I**:4
- Carbon monoxide  
 animal exposure studies, **VI**:10–11, 45–46  
 blood studies of welders, **I**:43  
 cardiovascular effects of, **I**:xix, 31–34  
 combined exposure measurements, **VI**:14  
 fume exposure studies, **II**:3, **IV**:xv, 1, **VI**:6, 23–24, **VIII**:5, 14, **XIII**:34–37  
 animal studies, **VI**:10–11, 45–46  
 nickel compounds, **VII**:16  
 fume generation studies, **IV**:7  
 hemoglobin effects, **I**:xvi, **VIII**:5  
 hyperbaric pressure studies, **VI**:40  
 lung diffusion capacity studies, **VI**:28–32  
 lung function testing, **X**:30–32  
 lung transfer factor studies, **X**:3  
 production of, during welding, **I**:74–75  
 in protective coatings, **IV**:7  
 pulmonary function and, **IV**:11  
 teeth and oral cavity effected by, **IV**:23  
 transport tests, in welders, **V**:2–3, 13, 19  
 welding arc production of, **I**:4  
 workplace exposure limits, **IX**:23
- Carbon steel welding  
 core wires, electrodes with, **III**:2  
 oxidative stress and inflammation and, **XIV**:50–52  
 particle emissions analysis, **XIV**:12, 25  
 ventilation practices for, **XIII**:19, 54–59
- Carbon tetrachloride, degreasing agents, exposure studies, **VI**:26
- Carboxyhemoglobin levels  
 carbon monoxide exposure, **VIII**:5, 14  
 effects of welding on, **IV**:xvii, 21  
 ELF exposure studies, **VIII**:16  
 fume particulates, **II**:14
- Carcinogenicity of welding fumes and gases. *See also* Mutagenicity  
 animal studies, **I**:48, 101–102, **II**:29–30, **V**:37, **VI**:32–34  
 chromium compounds, **III**:2–3, **IV**:5  
 current research on, **X**:1  
 epidemiologic studies of risk potential, **I**:xxi–xxii  
 fume condensate studies, **I**:xxii, **III**:xv, 15–16  
 fume exposure studies, **I**:xvi  
 fume generation, **II**:xxi, 17–19  
 IARC multinational studies, **IX**:3–4, 9, 33–39  
 incidence of, **IV**:xix  
 limits of research on, **III**:19  
 lung cancer epidemiology, **XI**:36–40, **XII**:49–50  
 respiratory tract disease, **I**:22–25  
*in vitro* studies, **II**:31–33, **III**:18–19  
 fume condensates, **I**:xxii  
 techniques used in, **VI**:13–14
- Cardiac defibrillators, electromagnetic field exposure, **X**:26, **XI**:8, 22–23
- Cardiac pacemakers, electromagnetic field (EMF) exposure, **X**:8, 26
- Cardiovascular system. *See also* Heart rate  
 epidemiologic studies, **IV**:xvii, 21, **X**:13, 55, **XI**:13, 48–50, **XII**:18, 61, **XIII**:28, 101–103, **XIV**:52  
 screening protocols, **XIV**:18  
 study design and, **I**:xix  
 summary of, **XIV**:87  
 fume exposure studies, **I**:31–34, **II**:xx, **III**:13, **V**:3, 12, 20, **VI**:38  
 fume generation studies, **II**:14  
 gas shielded arc welding (GSAW), **I**:xvi  
 metal fume fever pathogenesis, **VII**:35  
 pulmonary function and, **VII**:27–28
- Carpal tunnel syndrome, epidemiologic studies, **IX**:12, 45–46, **XI**:12, 46
- Cartridge filters, design requirements, **IX**:27
- Case-control epidemiologic studies, **VIII**:30  
 cancer epidemiology, **VII**:31–32  
 lung cancer in welders, **IX**:33, 35
- Catalase levels  
 current research, **X**:5, 61  
 oxidative stress and, **XIV**:50–52  
 pulmonary function testing, **XIV**:13, 29
- Catalytic converters, hyperbaric welding, **VIII**:11

- Cataracts  
 case studies, **I**:27  
 epidemiologic studies, **XI**:44  
 epidemiology, **I**:26  
 infrared (IR) radiation and, **IX**:10, 40  
 lens accommodation and visual acuity, **I**:27  
 pathogenesis, **I**:26–27  
 radiation exposure and, **II**:xx, **VI**:35–37, **VII**:35–36  
 ultraviolet exposure in welders and, **VI**:8
- Cats, fume inhalation studies, **I**:47, 94–95
- cDNA microarray analysis, inflammation and oxidative stress in welders, **XIV**:50–52
- CEA tumor antigen, **XI**:54
- Cell cultures  
 infectivity and inflammation, **XIV**:20  
 metal fume fever, **XII**:20–21, 71–72
- Cell-mediated immunity, effects of welding on, **VIII**:7
- Cellular immune response, oxidative stress and inflammation in welders and, **XIV**:88
- Cellulose filter, chromium analysis, **X**:20
- Central nervous system. *See* Nervous system
- Central serous chorioretinopathy (CSCR), epidemiology, **XII**:54–56
- Ceruloplasmin  
 current research, **X**:5, 16, 61  
 levels analysis, **VIII**:6  
 respiratory tract exposure studies, **VIII**:25–26
- Chelation therapy  
 lead exposure, **X**:60–61, **XIII**:31–32, 113–114  
 manganese poisoning, **XI**:52  
 mercury exposure, **X**:59, **XIII**:113
- Chemical absorbers, hyperbaric welding, **VIII**:11
- Chemical hazards, carbon dioxide lasers, **X**:23–25
- Chemical industry workers, as cohorts in welding morbidity studies, **V**:24
- Chemical pneumonia, zinc oxide exposure, **XIV**:15
- Chemical pneumonitis, cadmium exposure, **X**:38
- Chemiluminescent monitoring  
 lipid peroxidation assays, **IX**:57  
 ozone generation, **IX**:24–25, **X**:20
- Chest radiography  
 metal fume fever, **VIII**:34 (*See also* X-rays)  
 pneumoconiosis epidemiology, **XII**:44–45, **XIII**:64–68
- Chibro-Uvelin eyedrops, **VII**:36
- Children of welders  
 brain tumor incidence in, **XIII**:9, 23, 85  
 cancer epidemiology, **XII**:53  
 cancer risk in, **IX**:10, 37–38, **X**:1, 4, 57–58  
 childhood cancers, epidemiologic studies, **VIII**:32–33  
 newborn health effects, **XII**:19, 65–66
- Chinese hamster ovary (CHO) cells  
 cytogenetic assays, **V**:41–42  
 mammalian cell studies, **VIII**:41–43  
*in vitro* studies of, **V**:4
- Chinese welders  
 genotoxicity studies, **XIII**:30–31, 110–111  
 laryngeal cancer in, **IX**:37  
 manganese exposure in, **XIV**:7–8, 57  
 neurophysiological effects, **XIV**:43–44  
 oxidative stress and inflammation in, **XIV**:50–52  
 pneumoconiosis in, **XIV**:82  
 sino-nasal cancer in welders in, **X**:12, 46  
 women welders, lung cancer epidemiology, **X**:4, 42–43
- Chiseling, noise exposure studies, **VII**:21–22
- Chi-squared analysis, respiratory tract studies, **VIII**:28–29
- Chloramine-T  
 as allergen in welders, **IX**:14  
 incidental exposure in welders, **IX**:54
- Chlorendic anhydride, asthma epidemiology, **XIII**:4–5, 21, 64
- Chlorinated hydrocarbons  
 decomposition, gas production, **I**:75–76  
 fume exposure studies, **VI**:6, 26–27  
 welding emissions combined with, **VI**:14  
 incidental exposure studies, **XIII**:16, 42–43
- Chlorine exposure, asthma and, **XIV**:30
- Cholecystitis, epidemiological studies, **I**:35
- Chorioretinal burns, ultraviolet radiation from welding and, **I**:xviii
- Chromate  
 gastrointestinal effects of, **I**:xix  
 respiratory tract cancer and, **I**:xxi–xxii
- Chromium exposure. *See also* Hexavalent chromium, Trivalent chromium  
 aerosol measurements, **IX**:22, **XI**:16–17  
 allergic reactions, **VII**:9, 37–38  
 animal studies, **VII**:12  
 contact sensitivity, **VI**:37–38  
 alveolar macrophage studies, **VIII**:6, 25  
 analytic techniques, **V**:1, **X**:7, 20–21, **XII**:11, 23–24  
 animal studies  
 allergic reactions, **VII**:12  
 carcinogenicity studies, **V**:4, 37  
 fertility, **X**:69–70  
 fume exposure studies, **VI**:11, 45–46, **IX**:54–55  
 fume inhalation in rats, **I**:83–85  
 infectivity and inflammation, **XIV**:20  
 pulmonary retention and clearance, **V**:40, **VII**:42–44  
 toxicology studies, **IV**:25–27, **VII**:44–45  
 whole-body effects, **V**:39–40  
 asthma and, **III**:8, **XIV**:4  
 biochemical effects, **III**:15, **IV**:24–25  
 biological monitoring, **IX**:13, 51–52, **X**:16, 21, 63, **XI**:14, **XII**:20, 67–68, **XIII**:32, 114–115, **XIV**:19, 55, 89  
 analytical methods, **VII**:4, 7, 10–11, 40–42  
 welding-related diseases, **V**:3, 21–23  
 biomarkers, **IX**:22, 50–51  
 blood level studies, **II**:xv–xvi, xx  
 carcinogenicity studies, **IV**:xix, **VI**:32–34, **VII**:4, 33–34, **VIII**:33–34, **X**:1  
 cardiovascular effects of, **V**:3, 20  
 cell transformation assays, **V**:41  
 chromatographic analysis, **XIII**:14–15  
 clastogenesis and, **VIII**:39  
 contact sensitivity studies, **IV**:23–24  
 dermatitis, **VI**:8, 37  
 DNA biomarkers, **X**:68  
 DNA damage, **VIII**:33–34  
 DNA-protein cross-links, **XI**:56

- electrode composition, **VIII**:12  
 epidemiologic studies, **IX**:4–5  
 fertility and welding, **IX**:4, **X**:4, 56–58  
 flux cored arc welding (FCAW), fume generation, **X**:19, **XIV**:11  
 fume component analysis, **I**:69–70, **X**:7, **XI**:7, **XII**:25, **XIII**:34–37, **XIV**:22  
 fume exposure studies, **IV**:xv, 4–5, **V**:7–9, **VI**:20–21, **IX**:7, **XIII**:37–38  
     analytic techniques, **VII**:17  
     animal studies, **VI**:11  
     biological monitoring techniques, **VI**:9–10, 41–43  
     cancer incidence and, **VI**:7–8  
     comparison of, in various welding techniques, **VI**:15  
     pulmonary function testing, **VI**:29–32  
     research techniques for, **VII**:5  
 fume generation studies, **IV**:4–5, **IX**:20  
     electrode composition, **V**:6  
     fume generation rates (FGR), **II**:2, **III**:xiii, **VII**:16  
     measurement techniques, **VI**:5–6  
     voltage and current effects, **V**:5–6  
 gas metal arc welding (GMAW), **X**:19  
 genotoxicity studies and, **X**:17, **XIV**:57–59  
 health surveys, **XIII**:31  
 hyperbaric pressure studies, **VII**:48  
 kidney function and, **V**:3, 21, **VII**:10, 39, **X**:14, 54–55, **XI**:12–13, 47–48  
 lung cancer, **II**:18, **IV**:15–19, **VII**:31, **X**:11, 43–44  
 metal fume fever and, **VIII**:34  
 mutagenicity and carcinogenicity studies, **III**:2–3, 15–16  
 nasal sinus effects, **II**:18, **XIII**:111–112  
 particle generation studies, **IV**:4  
 plasma arc welding, **IX**:32  
 pulmonary function testing, **IV**:14–15, **VI**:13, 28–32, **VII**:27–28, **IX**:31, **XI**:29–30, **XIV**:28  
 pulmonary irritation from, **II**:11  
     particle retention estimation, **IV**:12–13  
 reproductive system disorders, **X**:14–15, **XIV**:9–10, 18–19  
 respiratory tract exposure, **IV**:xiii–xiv, **V**:12–13, **VII**:13  
 skin conditions and, **I**:xvi  
 soluble chromium, SMAW, pulmonary defense suppression, **XIV**:1  
 sources of, in welding, **I**:2–3  
 tissue biopsy studies, **X**:38  
 urine analysis for, **I**:43–44, **II**:xiv, xvi, xviii  
 urogenital tract effects, **VIII**:7, 39–40  
*in vitro* studies, **II**:32–33  
     sister chromatid exchange (SCE), **VII**:46–47  
 workplace exposure studies, **X**:8, 22–23, **XIII**:49–51  
 X-ray fluorescence spectrometry, **VIII**:14  
 Chromium-molybdenum electrode, fume composition studies, **XIII**:34–37  
 Chromosome studies  
     biological monitoring techniques, nickel and chromium compounds, **VI**:41–43  
     clastogenesis studies, **VIII**:39  
     cytogenetic assays, **V**:41–42  
     fume exposure studies, **VI**:10  
     fume mutagenicity and carcinogenicity and, **III**:xv, 15–16  
     genotoxicity studies, **X**:17, 67–68, **XIII**:31, 110–111  
     nickel carcinogenicity, **VI**:14  
     *in vitro* carcinogenicity studies, **III**:18–19  
     *in vitro* studies of welding and, **V**:4  
 Chronic actinic dermatitis, epidemiologic studies, **X**:13, 50–51  
 Chronic beryllium disease (CBD), epidemiology, **XI**:52  
 Chronic fluorosis, welding and, **I**:xix  
 Chronic gastritis, welding and, **I**:34–35  
 Chronic interstitial lung disease, gas metal arc welding and, **X**:3  
 Chronic myeloid leukemia, epidemiologic studies, **VIII**:31  
 Chronic obstructive pulmonary disease (COPD) in welders, **X**:33  
     absenteeism from, **XIII**:69–70  
     automotive assembly operations, **XIV**:4  
     epidemiologic studies, **XIV**:32  
     pulmonary function testing, **XIV**:13, 29–30  
 Chronic renal failure (CRF)  
     incidence of, in welders, **VII**:39  
     renal tubular dysfunction, cadmium exposure and, **V**:3  
     in welders, **XI**:48–49  
 Chronic respiratory disease. *See also* Acute respiratory disease, bronchitis, e.g., specific conditions  
     age-related studies, **I**:17–19  
     assessment procedures, **I**:81–82  
     Chilean welders, **I**:21–22  
     epidemiologic studies, **I**:xvii–xviii, xxi, 12–23, **IX**:9, 29–32  
     Finnish welders, **I**:13, 15  
     fluorosis, **I**:xix  
     iron compounds, **I**:xv–xvi, xxi–xxii, 13  
     ozone and, **I**:xxi, 13  
     pulmonary function testing, **I**:13–22, 81–82  
     shipyard welders, **I**:12–15  
     smoking and, **I**:12–22  
     Swedish welders, **I**:18–19  
     welding fume particles, **I**:xv–xvi, **III**:xiv, 6–8  
     working conditions and, **I**:17–18  
 Chronic toxicity studies. *See also* Acute toxicity studies  
     epidemiologic study design, **VII**:13  
 Chrysolite, fume screening studies for fibrogenic potential, **I**:xxii  
 Circumferential burn, **II**:13  
 Clastogenesis in welders, **VIII**:39  
 Clearance function in lungs. *See* Pulmonary retention and clearance  
 Clinical conditions, in fume exposure studies, **II**:xiii  
 Closing volume, respiratory tract studies, **V**:18–19  
 Coatings  
     fume exposure studies, **IV**:xv, 7–9, **VI**:6, **VII**:6, 8, **VIII**:5–6, 18–20, 25–26  
     incidental exposure studies, **IX**:8, 14, 26, 53–54  
     laser welding, **IX**:7–8  
     lead, incidental exposure studies, **XIII**:42  
     respiratory tract effects, **VII**:30  
 Cobalt exposure  
     animal studies, **II**:27  
     infectivity and inflammation, **XIV**:62–63  
     biological monitoring, **X**:16, 63–65  
     blood studies, **II**:xx

- hard metal coatings with, **X**:39–40  
 local exhaust ventilation systems and exposure to, **XIII**:19  
 pulmonary function testing, **XI**:29–30  
 radiation exposure studies, **IX**:26–27  
 ventilation systems analysis, **XIII**:55–59  
 Co-carcinogenicity studies, **VI**:11, 48–49  
 Cognitive function  
   aluminum exposure, **XII**:17, **XIV**:7, 42–43, 85  
   manganese exposure, **XII**:18, 59–61, **XIV**:7–9, 85–87  
 Cohort epidemiologic studies, **VIII**:30  
   lung cancer in welders, **IX**:33–34  
 Cold vapor atomic absorption spectrometry, urine analysis with, **X**:7  
 Collagen levels  
   fibrosis in welders, **IX**:14, 55  
   pneumoconiosis and, **V**:38–39  
 Collection, storage and analysis techniques, chromium compound exposure studies, **V**:8  
 Color blindness, welding-related eye injury and, **I**:28  
 Colorectal cancer, incidence of, in welders, **V**:25  
 Colorimetric analysis  
   ozone exposure studies, **V**:10  
   *in vitro* studies, **VII**:12  
 COMECON countries, welding safety regulations, **VIII**:21  
 Comet assay  
   animal studies  
     fibrosis, **XIV**:64–66  
     genotoxicity studies, **XIV**:20, 58–59  
 Compensation claims, as epidemiologic indices, **XI**:5, 10  
 Compliance analysis, health and safety regulations, **XIII**:19, 57–59  
 Computed tomography (CT), pneumoconiosis epidemiology, **XI**:36, **XII**:44–45, **XIII**:21, 65–68  
 Condensation particle counter, ultrafine particle analysis, **XIV**:11, 23–24  
 Confidence intervals (CI)  
   biological monitoring, **XIV**:55–57  
   lung cancer studies, **X**:40–41  
 Conjunctival injury, welding and, **I**:25–26  
 Conjunctivitis  
   arc welding and, **XI**:12  
   electromagnetic radiation, **IX**:25  
   radiation-related eye injury, **VI**:37  
   ultraviolet radiation and, **II**:xix, 13  
   in welders, **IX**:11, 41  
 Connective tissue effects in welders, **XIV**:15, 41  
 Construction industry workers, cancer incidence among, **X**:42, 46  
 Contact dermatitis. *See also* Allergic reactions  
   chromium sensitivity, **IV**:23–24  
   fume exposure studies, **VI**:8, 37  
   ultraviolet (UV) radiation and, **IV**:xvii, 20, **IX**:11, 42  
 Contact lenses  
   eye injuries in welders, **IX**:41–42  
   safety of, in welders, **VI**:37  
   welding fumes and, **III**:xiv, 12–13, **VII**:36–37  
 Convective-interaction media (CIM) chromatography, chromium analysis, **XIII**:14–15, 38  
 Copper  
   animal fume inhalation studies, **I**:86–88  
   biological monitoring, **XIV**:55–57, 89  
   blood analysis, **II**:xv–xvi  
   braze welding fume composition, **X**:20  
   carbon electrodes, lead exposure studies, **X**:8, 22  
   electrode composition, **III**:13, **IV**:2  
   ELF exposure studies, **VIII**:16  
   epidemiologic study design, **II**:19  
   as fume constituent, **I**:69  
   fume generation studies, **II**:1, **III**:xiii, 3i  
     electrode composition, **V**:6  
   gas exposure studies, **VI**:6  
   inflammation and oxidative stress and, **XIV**:88  
   liver damage from, **II**:14  
   metal fume fever epidemiology and, **XIII**:9–10, 24, 88–89  
   ozone exposure studies, **V**:10  
   in paints, fume exposure studies, **VI**:25–26  
   plasma arc welding, **IX**:32  
   production coatings, **X**:26–27  
   sources of, in welding, **I**:2  
   workplace exposure analysis, **XIII**:17–18, 48–51  
 Coproporphyrin (CPU), levels of, in urine, **II**:16  
 Corneal injury  
   cicatrices, in welders, **IX**:41  
   contact lenses in welders and, **III**:13  
   epidemiological studies, **XIII**:25, 93, **XIV**:15, 39–40, 84  
   radiation damage to, **VI**:8, 35–37, **VII**:19–20  
   thermal burns, **I**:25–26  
 Corneal touch threshold (CTT) measurements, radiation-related eye injuries, **VI**:35–37  
 Corrosive substances, asthma and, **XIV**:30  
 Cough  
   incidence of, in welders, **V**:12  
   lung toxicity studies, **II**:9  
   oxidative stress biomarkers, **XIV**:6  
   pulmonary function testing, **XIV**:3  
   respiratory disease studies of, **V**:16–17  
 Covered electrode welding. *See* Shielded metal arc welding (SMAW)  
 C-reactive protein  
   cardiovascular effects of welding, **XIV**:87  
   oxidative stress and inflammation, **XIV**:6, 17–18, 50–52  
 Creatinine levels in urine, cadmium exposure, **X**:62–63  
 CREST syndrome, **XII**:15, 44–45  
 Crocidolite asbestos, epidemiologic studies, **VIII**:31  
 Cross-sectional epidemiologic studies, **VIII**:29–30  
   respiratory disease in welders, **V**:15  
 Cross-linked DNA, genotoxicity studies and, **XIV**:20  
 Cumulative exposure index (CEI), manganese exposure, **XII**:59–61  
 Cumulative radiation dose, cancer incidence and, **XIV**:5  
 Cumulative welding experience, respiratory symptoms, **XIV**:3  
 Curtains, radiation protection with, **III**:5, **IV**:xvi, 9–10  
 CYP2D6L gene, manganism susceptibility, **XII**:7–8  
 Cytogenetic assays, *in vitro* fume exposure studies, **V**:41–42  
 Cytokines  
   animal studies  
     fibrosis, **XIV**:64–66  
     gene expression, **X**:72–74

infectivity and inflammation, **XIV**:20, 60–63  
 asthma in welders and, **XIV**:82  
 cardiovascular disease in welders and, **XI**:50, **XIV**:87  
 duration of exposure and presence of, **XI**:5–6  
 fume exposure and lung disease, **XI**:58–59  
 inflammation in welders and, **XIV**:6, 49–52, 88  
 metal fume fever and, **IX**:10, **X**:1, 5, 12, 48–49, **XII**:5–6, 17, 53–54  
 Cytoskeletal analysis, hyperbaric pressure studies, **VII**:48  
 Cytotoxicity assays  
   alveolar macrophages, **VIII**:6  
   *in vitro* studies, **VII**:47, **VIII**:7  
 Czech Republic, welders in  
   genotoxicity studies, **XIII**:111  
   neuromuscular disease in, **X**:54  
   pulmonary function and respiratory disease, **IX**:31  
   ventilation and air cleaning equipment, **IX**:27  
   workplace exposure analysis, **XIII**:48–51

## D

Danish welders  
   cancer epidemiology, **XI**:4, **XII**:45–46  
   chromium exposure studies, **IX**:51  
   eye injuries, **IX**:11  
   fertility studies of, **IX**:12, 46, 48, **X**:57–58  
   genotoxicity in, **X**:17  
   ischemic heart disease epidemiology in, **XIII**:102–103  
   laryngeal cancer epidemiology, **V**:26  
   lung cancer epidemiology, **XI**:10–11, 37–40, **XIV**:83  
   nasal cancer epidemiologic studies, **V**:24–25  
   neurodegenerative disease in, **XIV**:8–9, 17, 47–48  
   reproductive function studies, **XII**:64–65, **XIV**:10, 54  
   respiratory disease studies of, **V**:17  
 Darkness adaptability, welding-related eye injury and, **I**:28  
 Death certificates, inaccuracy of, in epidemiological studies, **V**:33–34  
 Degreasing agents  
   accidents with, **VII**:6–7, 21, 23  
   fume exposure studies, **VI**:6, 26–27  
   gas emission studies, **VI**:23–24  
   incidental exposure in welders, **IX**:13–14, 53  
   welding emissions combined with, hazards of, **VI**:14  
 Dental amalgams  
   ELF exposure studies, **VIII**:16  
   fume exposure studies, **VI**:9, 40  
   underwater welding and, **VII**:10, 39–40  
 Depression, in welders, **IX**:11  
 Derived air concentration (DAC), thorium exposure studies, **XII**:30–31  
 Dermatitis. *See* Contact dermatitis  
   epidemiologic studies, **XI**:14, **XII**:16–17  
 Dermatitis, epidemiologic studies, **XI**:12, 44–45  
 Dichloroacetyl chloride, welders' incidental exposure to, **IX**:53  
 Dichlorodifluoromethane, degreasing agents, fume exposure studies, **VI**:26  
 Difluorochloromethane refrigerant  
   hydrochloric acid/hydrogen fluoride exposure, **XIV**:11–12  
   incidental exposure studies, **XIV**:11–12, 25  
 Digestive tract. *See* Gastrointestinal tract  
 Digit span tests, metallic compound exposure studies, **XIV**:85–86  
 Dilution ventilation, analysis of, **XIII**:51–57  
 Dimercaptosuccinic acid (DMSA), manganese poisoning, **XI**:52  
 Diode Array Rapiduse Scan Spectrometer, **V**:10  
 Dioxins, exposure studies, **XII**:12, 28–29  
 Dipalmitoyl phosphatidylcholine (DPPC), *in vitro* exposure studies, **V**:42  
 Diphenyl carbazide techniques, fume exposure studies, **VII**:17  
 Direct current welding, thoriated electrodes, exposure studies, **XIV**:11, 24  
 Direct fume transfer, **IX**:19–20  
 Displacement ventilation systems, analysis of, **XIII**:56–59  
 Divalent metal transporter 1 (DMT1), manganese and iron bioavailability and, **XIV**:49  
 Divers. *See also* Underwater electric arc welding  
   ELF exposure studies, **VIII**:16  
   fume exposure studies, **VI**:9, 40  
 DNA  
   animal toxicology studies, **IV**:27  
   chromium biomarkers, **IX**:50–51  
   chromium damage to, **VIII**:33–34  
   damage  
   fibrosis, **XIV**:21, 64–66  
   genotoxicity studies, **XIV**:20, 57–59  
   oxidative stress and, **XIV**:18, 52  
   sperm damage in welders, **XIV**:53–54  
   gene expression, **X**:72  
   genotoxicity studies, **X**:67–68, **XI**:55–56, **XIII**:30–31, 110–111, **XIV**:20, 57–59  
   mammalian cell studies, **VIII**:42–43  
   mutagenicity tests, **IV**:xix–xx  
   protein cross-links, **X**:68–69  
   chromium exposure, **XI**:56  
   epidemiologic studies, **XI**:14  
   genotoxicity studies, **XII**:20, 70–71  
   radiation exposure, **IV**:xvi, 9–10  
   reproductive function in welders and, **XIV**:10, 18–19  
   sperm damage in welders, **XIV**:53–54  
   synthesis, hyperbaric pressure studies, **VII**:48  
   *in vitro* toxicity studies, **IV**:29  
 Dopamine oxidation, **XII**:21  
   fume component studies, **XII**:75  
 Dose-effect relationships, risk assessment with, **VIII**:9  
 Dose-response curve  
   biological monitoring of welding-related diseases, **V**:21–23  
   cancer incidence in welders and, **V**:2  
   pulmonary retention and clearance studies, **V**:19  
 Driving while intoxicated, as risk index, **VIII**:9  
 Duodenal ulcers, epidemiological studies, **I**:35  
 Duplex steel welding, asthma and, **XIV**:4  
 Duration of employment, absenteeism and sick leave rates, **XII**:34–35  
 Duration of exposure  
   health effects of welding and, **XI**:4–6  
   pulmonary retention and clearance studies, **V**:3–4

respiratory disease in welders, **V**:12

Dust exposure studies, **X**:8, 22–23

  bronchitis and asthma incidence, **X**:33

  eye injuries and, **IV**:20

  magnetopneumography, **XII**:42–43

  workplace exposure analysis, **XI**:17–20, **XIV**:12

Dyspnea

  epidemiologic studies, **IX**:3, 9

  incidental exposure to degreasing agents, **IX**:53

  lung nodules in studies of, **XIV**:13–14

  metal fume fever and, **II**:15

  pneumoconiosis in welders and, **XIII**:65–68, **XIV**:34

  prevalence of, in welders, **I**:16, **V**:2–3, 12, 18

  pulmonary fibrosis studies, **IV**:13

  pulmonary function testing, **VI**:31–32, **XIV**:3

    Romanian welders, **I**:16

**E**

Ear injuries. *See also* Hearing loss

  acoustic trauma, **I**:39

  burns, **I**:39, **VII**:35

  epidemiologic studies, **IX**:10, 39–40, **X**:13, 49–50, **XIV**:15, 41, 84

  middle ear spark injuries, **XIII**:10, 24, 90

  noise exposure studies, **II**:13, **VI**:8, 14, 35

  protective devices for reduction of, **IV**:xvii

  welding and, **II**:xx, **III**:xiv, 12, **IV**:19

Earmuffs

  noise exposure studies, **VII**:21

  as protective devices, **IV**:xviii, 19

Eclipse burn. *See* Photoretinitis

Eczema, in welders, **III**:xiv, 13–14

Electric arc welding

  degreasing agents, fume exposure studies, **VI**:26

  effects on teeth, **IX**:49

  ELF exposure studies, **VIII**:16

  pulmonary function and respiratory disease, **IX**:30

  time and duration of arcing periods, **VII**:17

Electric current

  fume composition and, **V**:1, **VI**:15

  fume generation rates (FGR), **I**:67–69, **IV**:2, **V**:1, 5–6, **VII**:15–19

    intensity linked with, **II**:1

  ozone production and, **I**:73–74

  radiation, **I**:77

    ultraviolet (UV) radiation, **VII**:19–20

Electric particle counting

  fume exposure studies, **IX**:7

  laser welding, **IX**:25–26

Electrical low pressure impactor, ultrafine particle analysis, **XIV**:11, 23–24

Electrocardiogram (EKG), cardiovascular, effects of welding, **I**:xix, 31–34

Electrocution

  forensic diagnosis, **XII**:13, 36

  hygiene and work practices, **XI**:8–9, 24, **XII**:13, 35–36

  mortality rates, **X**:29

  portable arc-welding equipment, **X**:9

risks of, with welders, **IV**:11

Electrode melting rates (EMRs), fume generation, studies, **V**:5–6

Electrodes. *See also* specific types of electrodes, e.g., Thoriated electrodes

  animal studies

    fume inhalation studies

      guinea pigs, **I**:92–93

      rabbits, **I**:91

      rats, **I**:83–85

    infectivity and inflammation, **XIV**:62–63

    inflammation and fibrosis, animal studies, **VII**:11, 41–42

    toxicology studies, **IV**:xviii–xix

  carbon dioxide electrodes, **I**:2, 61

    flux and slag compositions, **VIII**:12

  chromium compounds in, **I**:70, **III**:3

  classification of, **III**:2

  coating composition, **I**:58–60, **IV**:2–3

    analysis of, **II**:2

  barium coatings, **VI**:21–22, 43

  chromium emission studies, **VI**:20

  copper coatings, **I**:69

  fluoride compounds, **I**:69, **IV**:3

    absorption, distribution and biotransformation, **II**:19

    fume exposure studies, **II**:19

  fluorine compounds, **V**:6

  flux cored arc welding, **I**:2, 62–64, 66, **VII**:15, **VIII**:12

    pneumoconiosis, animal studies, **V**:37–39

  flux fume formation, **V**:6

  fume-to-weight ratios, **I**:61–62

  gas tungsten arc welding, **I**:65–67

  kidney effects, **XIV**:52–53

  plasma arc welding, **I**:67

  shielded metal arc (SMA) welding, **I**:1–2, 59–60

  ultraviolet radiation variations, **I**:77, **XIV**:11, 24

  voltage and current linked with, **IV**:2

  fibrogenic potential of, **I**:xxii

  filler and core materials, composition of, **I**:1

  fluorspar (calcium fluoride) in, **I**:2

  fume conversion factor, **VIII**:12

  fume exposure studies, **II**:xix, **VI**:19–20, **VIII**:11–12

  fume generation rates (FGR), **II**:1, **III**:2, **V**:6, **VI**:5, **VII**:5, 16, **IX**:19–22

    gas shielded vs. no gas shield, **VII**:5

  fume reduction in, **III**:4

  hardfacing electrodes, **VII**:16

  innershield vs. covered electrodes, **X**:20

  lipid peroxidation assays, **IX**:57

  manganese compounds on, **I**:70

  particle analysis, **VI**:21–23

  respiratory disease in welders and, **VII**:3

  shielded metal arc welding, ventilation systems and manganese exposure, **XIV**:26

*in vitro* exposure studies, toxicity assays, **V**:42

  workplace exposure limits, **IX**:23

Electroencephalograms

  manganese exposure studies, **XIV**:7–9, 16

  neurophysiological effects, **XIV**:43–44

Electromagnetic fields (EMFs)

- animal studies, **X**:17, 69  
cancer epidemiology, **IX**:10, 38, **X**:47–48, **XI**:11, 40, **XIII**:23–24, 85–87  
cardiovascular effects of welding and, **XIV**:18, 52  
central nervous system cancer, **XI**:40  
endocrine gland tumors, **XIV**:38  
epidemiologic studies, **XI**:8, 22–23  
exposure studies, **IX**:8, 25–26, **X**:8, 12, 25–26, **XII**:13, 32–33  
fertility effects, **XII**:19  
inflammation and oxidative stress and, **XIV**:88  
leukemia epidemiology and, **XI**:4, **XII**:52  
neuroblastoma risk and, **XII**:16–17  
neurodegenerative disease and, **XIV**:16, 41–49  
reproductive function studies, **XII**:8
- Electromagnetic radiation  
blue light, **XIII**:2, 12, 15, 39–40  
epidemiologic studies, **XI**:8, 21–22  
exposure studies, **XII**:12–13, 31–32  
ultraviolet light, **XIII**:2–3, 40–41  
workplace exposure studies, **XII**:3
- Electromyography  
musculoskeletal effects of welding, **IX**:11–12, 44–45  
shoulder pain in welders and, **IV**:22
- Electron beam welding  
ELF exposure studies, **VIII**:16  
fume composition studies, **XI**:7, 15–17
- Electron microscopy, workplace exposure analysis, **XI**:20–21
- Electron spectroscopy for chemical analysis (ESCA)  
fume exposure studies, **XI**:16–17  
particle studies, **IV**:3–4
- Electrophysiological indices, animal studies, **I**:88
- Electroretinography, eye and vision injuries, **VII**:36
- Electrostatic particle charge, particle deposition, studies, **VI**:22
- Electrostatic precipitators, design requirements, **IX**:27
- Electrothermal atomic absorption spectrometry  
chromium analysis, **XIII**:37–38  
chromium exposure studies, **XII**:11
- Elimination pathways  
animal toxicity studies, **III**:17–18  
chromium compound biological monitoring, **V**:3
- Embryogenesis, welding and impact on, **XIII**:108–109
- Embryonal fibroblast cell cultures, mammalian, cell studies, **VIII**:42–43
- Emotional status, manganese exposure studies, **XIV**:8–9
- Emphysema  
animal studies, **V**:4, **VI**:10–11, 45–46  
case reports, **IX**:9  
fume exposure studies, **V**:4, **VI**:27–32, **VII**:3  
chronic fume exposure, **IV**:11  
ozone exposure, **I**:xv–xvi  
pathogenesis, **I**:81  
pulmonary function testing, **VII**:26–29, **XIV**:29
- Employee records  
demographics analysis, **II**:xix  
epidemiologic studies, records design for, **I**:xxii
- Encephalopathy, welding and, **VIII**:37
- Enclosed environment studies, workplace exposure analysis, **XIII**:17–18, 47–51
- Endocrine system in welders  
epidemiological studies, **I**:35–37, **VI**:9, 39–40, **XIII**:29, 104  
fume exposure studies, **I**:xix, **II**:15, **III**:14
- Endocrine gland tumors  
epidemiologic studies, **XIV**:14, 38  
summary, **XIV**:88  
incidence in welders, **XIV**:5
- End-stage renal failure, in welders, **XI**:13, 48–49
- Endothelin-1, cardiovascular effects of welding, **XIV**:87
- Energy Dispersive X-ray Analysis (EDXA)  
particle studies, **IV**:3–4, **V**:7, **VII**:17  
pneumoconiosis epidemiology, **XIII**:66–68  
protective gear analysis, **VII**:23  
respiratory disease in welders and, **III**:7
- Environmental hazards, accident rates and, **IX**:28
- Enzyme-linked immunosorbent assay (ELISA), **IX**:55
- Eosinophilia, in welders, **I**:31
- Epicondylitis, epidemiologic studies, **XI**:12, 46
- Epidemiologic studies. *See also* Fatality studies, Mortality studies, specific study areas  
allergic sensitivity reactions, **VII**:9, 37–38  
analytic techniques, **XI**:7  
biological monitoring techniques, **VII**:4, 10–11, 17, 40–41  
blood studies, design of, **I**:xix  
brain cancer, diagnostic sensitivity bias in, **V**:32  
cancer in welders, **VI**:7–8, 32–34, **VII**:3–4, 8–9, 13, 30–34, **VIII**:6, 29–34, **XI**:4, 10–11  
carcinogenicity risk assessment, **I**:xxi–xxii  
study design, **I**:xviii  
cardiovascular system, **I**:xix, **XI**:13  
case-control studies, **VIII**:30  
cohort studies, **VIII**:30  
cross-sectional studies, **VIII**:29–30  
duration of exposure, **XI**:4–6  
ear injuries and hearing loss, **VII**:35, **XI**:11–12  
electromagnetic radiation, **XI**:8  
employee records forms, design of, **I**:xxii  
endocrine system and welding effects, **I**:xix  
eye injuries, **I**:xviii–xix, xxii, **VII**:9, 35–37, **XI**:12  
fume composition, **VII**:15–19, **XI**:7  
allergic sensitivity, **VII**:37–38  
analytic techniques, **VII**:16–17  
biological monitoring, **VII**:17  
chromium compounds, **VII**:16  
electrode composition and, **VII**:16  
nickel compounds, **VII**:16  
particle analysis, **VII**:17–19  
screening for fibrinogenic potential, **I**:xxii  
fume exposure study design, **II**:19–22  
combined fume exposure measurements, **VI**:14  
fume generation study design, **VII**:15  
gastrointestinal tract, study design, **I**:xix  
hygiene and work practices, **XI**:8–9  
kidney function, **I**:xix, **XI**:13  
laryngeal cancer, study design, **V**:26–27  
magnetopneumography, **XI**:11  
metal exposure, **XI**:13–14  
metal fume fever, **VII**:9, 34–35  
mortality and carcinogenicity studies, **III**:xv, 16, 19

- musculoskeletal system, **VII**:10, 38, **XI**:12–13  
 mutagenicity studies, **I**:xxi  
 nervous system, **I**:xix, **VII**:37, **XI**:12  
 noise exposure, **VII**:20–21  
 non-stationarity in, **VIII**:30  
 occupational asthma, **XI**:30–35  
 ozone exposure, **VII**:19  
 parameters of, **VIII**:30  
 production coatings, **VII**:20  
     limits of study design, **VI**:26  
 radiation exposure, **VII**:19–20  
 reproductive function, **XI**:13  
 research methodology, **II**:xxiii  
 respiratory tract, **IV**:xiii–xiv, **VII**:7–8, 13, 24–30, **XI**:3–4, 9–10  
     alveolar macrophages, **VII**:7  
     case studies, **VII**:8  
     chronic disease, study biases in, **I**:xvii–xviii, xxi, 12  
     prospective studies, **I**:xxi  
     pulmonary function and bronchitis, **VII**:7–8  
     pulmonary retention and clearance, **VII**:7  
 risk multipliers, **VIII**:30  
 skin injuries, **VII**:9, 37, **XI**:12  
 study designs for respiratory disease, **V**:12–14  
 teeth and oral cavity, **VII**:10, 39–40  
 toxicity studies, **II**:xxi  
 unresolved hazard studies and, **VIII**:9–10  
 urogenital tract, **VII**:4, 10, 38–39  
 vocal damage, **VII**:11, 40  
 welders' demographics, role of, **VIII**:30–33  
 working conditions, **VII**:21–24, **XI**:7–8  
     accidents, **VII**:21, 23  
     protective equipment, **VII**:23–24  
 Epidermoid cancer, epidemiology, **XII**:16  
 Epoxy resin exposure, scleroderma incidence, **XIV**:41  
 Equivalent mobility diameter (DME), particle analysis, **VII**:6, 18–19  
 ER70S-3 electrodes, lead exposure studies, **VIII**:12  
 Ergonomics  
     welding safety and health and, **IV**:xx  
     “welding table” design, **IX**:27  
 E-rosette-forming cells (E-RFC), immune system studies, **VIII**:40  
 Erythema  
     epidemiologic studies, **II**:21, **IV**:xvii  
     photosensitivity in welders and, **XIII**:13  
     radiation exposure and, **VI**:8, 37, **VII**:19–20  
     ultraviolet radiation exposure, **IV**:20, **XIII**:2–3, 40–41, 94–95  
 Erythrocytes  
     biological monitoring studies, **VII**:4, 10–11  
     erythrocytosis in welders, **I**:31  
     nickel exposure, animal studies, **II**:28–29  
 Esophageal cancer, epidemiology, **XII**:16  
 Ethanol, incidental exposure studies, **IX**:26  
 Ethylenediaminetetraacetic acid (EDTA)  
     chromium emission studies, **VI**:21  
     lead exposure and, **X**:15–16, 60–61  
     manganese poisoning, **XI**:52, **XII**:58–61  
 European Community (EC)  
     protection of workers, directives, **VIII**:21  
     workplace exposure limits for welders, **IX**:22–23  
 European/International Standard (ISOprEN 10882-1),  
     workplace sampling, **XII**:27  
 Exercise  
     musculoskeletal effects of welding and, **IV**:xvii  
     shoulder pain in welders and, **IV**:22  
 Exhaled breath condensate (EBC), biological monitoring of  
     welders, **XIV**:89  
 Exhaust equipment. *See also* Local exhaust ventilation  
     design requirements, **IX**:27  
     hygiene and work practices, **XIII**:18–19  
     training systems for use of, **X**:9  
     ventilation systems, workplace analysis, **XIII**:53–59  
 Explosions  
     accident analysis, **X**:29, **XIII**:20, 58–59  
     hygiene and work practices, **XII**:13, 36  
 Exposure estimation techniques, **XII**:36–37  
 Exposure pathways, animal toxicology research, **II**:23–24  
 Exposure potential of welding materials. *See* Fume exposure  
     studies, Fume generation studies  
 Extinction values, aerosol analysis, **VIII**:13  
 Extremely low frequency (ELF) magnetic fields  
     cancer in welders and, **VII**:32, **IX**:38, **XIII**:9, 85–87, **XIV**:5  
     endocrine gland tumors, **XIV**:38  
     exposure studies, **VIII**:5, 15–17, **XII**:32–33  
     fertility rates and, **XII**:19  
     inflammation and oxidative stress and, **XIV**:88  
     neurodegenerative disease and, **XIV**:16, 41–49  
     reproductive function studies, **XII**:64–65  
     retinal damage and, **III**:12  
 Eye drop protection solution, **XII**:17, 55–56  
 Eye filters, specification studies, **X**:9, 28–29  
 Eye injury and disease. *See also* Ocular melanoma, Uveal  
     melanoma, Visual acuity and loss  
     accident and injury studies, **I**:25, **XIII**:20, 57–59, **XIV**:27, 39–40  
     arc welding, **XI**:3  
     burn injuries, **XIII**:93–95  
     cancer epidemiology, **XI**:40, **XIII**:84, **XIV**:5, 14, 37  
     cataract and lenticular effects, **I**:26–27, **IX**:40  
     contact lenses, **IX**:41–42  
     corneal and conjunctival injuries, **I**:25–26  
     electromagnetic radiation, **IX**:25, **XI**:22  
     epidemiologic studies, **V**:13, **VIII**:6, 35–37, **IX**:10–11, **X**:13, 40–42, 50, **XI**:12, 43–44, **XII**:17, 54–56, **XIII**:25, 90–93, **XIV**:15, 55, 84  
     fume exposure studies, **II**:xx, 12–13, **IV**:11  
     laser welding, **X**:8, 24–25  
     long-term effects, **IX**:41  
     photokeratitis, **IX**:40–41  
     protective gear and equipment, **XII**:17  
     radiation exposure, **VI**:6, 8  
     infrared radiation exposure, **IV**:xiv, xvii, 9, 19–20  
     radio frequency radiation, **VIII**:17  
     retinal injury (*See* Retinal injury)  
     unresolved hazards, **VIII**:9  
     UV radiation and uveal melanoma, **IX**:39



vision impairment (*See* Visual acuity and loss)  
welding arc radiation, **I**:xvi

## F

F-actin filaments, hyperbaric pressure studies, **VII**:48  
Falls

fatalities due to, **X**:9  
mortality rates, **X**:29

Fanconi-like syndrome, kidney effects of welding and, **XIV**:53

Farm workers

asthma incidence, **XIV**:32  
eye injury and disease in, **XIV**:84

Fast protein liquid chromatography (FPLC), chromium analysis, **XIII**:14–15, 37–38

Fatality studies. *See also* Morbidity studies, health effects of welding

cadmium fume exposure, **IV**:xviii, 25, **IX**:13, 50  
cancer in welders, **IX**:9  
electromagnetic fields (EMF) and cancer in welders, **IX**:38  
fault tree analysis, **VIII**:19–20  
health effects of welding and, **II**:8, 22  
ironworkers, studies of, **X**:9  
lung cancer in welders, **IX**:33–37  
welding apparatus and, **II**:xxii, **IX**:8  
workplace design and, **IX**:28–29

Fault tree analysis, accident/safety research, **VIII**:19–20

FCAW. *See* Flux-cored arc welding

Febrile episodes, incidence of, in welders, **II**:15. *See also* Metal fume fever

Fecal analysis

animal studies  
toxicology of nickel compounds, **IV**:27–28  
whole-body effects of welding, **V**:39–40  
biological monitoring of welding-related disease, **V**:23  
manganese levels, **II**:xviii, **XIV**:57  
metallic compound levels, **II**:xxiii  
plutonium exposure, **X**:17, 66

Ferritin levels

bronchoalveolar lavage fluid studies, **XIII**:21  
pneumoconiosis epidemiology and, **XIII**:67–68

Ferromagnetic particles

lung retention, **V**:3–4, 19–20  
manganese exposure, **XIV**:19, 57  
magnetopneumographic measurement, **XI**:41–43  
pneumoconiosis, **XIV**:33–34  
systemic iron overload, **XIV**:4, 13–14

Ferrous alloys. *See* Iron alloys

Fertility in welders. *See also* Reproductive function

animal studies, **IX**:14, 54–55, **X**:17, 69–70  
chromium exposure and, **IX**:4–5  
epidemiologic studies, **I**:31, **IV**:23, **IX**:4, 12, 46, 48–49, **X**:4, 14–15, 56–58, **XI**:13, 51, **XII**:18–19, 62–65, **XIII**:12, 30, 106–109, **XIV**:9–10, 53–54

Fetotoxicity studies, cadmium exposure in animal studies, **II**:27

Fiber glass exposure

chronic interstitial lung disease, **X**:10–11  
lung disease and, **X**:3, 39

respiratory disease and exposure to, **X**:33

Fibrinogens, cardiovascular disease in welders and, **XI**:50

Fibrogenicity of welding fumes

animal studies, **VI**:46, **VII**:11, 41–42  
collagen evaluation in welders, **IX**:14  
epidemiological studies of, **I**:xxii, **VII**:13  
particle accumulation studies, **VI**:27–28

Fibrosis

aluminum arc welding and, **IV**:xvi, 13  
animal studies, **VII**:11, 41–42, **IX**:55, **XIII**:33, 116–117, **XIV**:20–21, 63–66  
case studies of, **IX**:9  
chronic fume exposure and, **IV**:11  
epidemiologic studies, **V**:12  
fume exposure studies, **I**:xxii, 81, **VI**:7, **VI**:11  
hard metal coatings exposure, **X**:39–40  
lung cancer in welders, **XI**:11  
pneumoconiosis and, **XIII**:21, 66–68, **XIV**:4, 13–14, 33–34  
pulmonary function testing, **VI**:31–32, **VII**:26–29, **IX**:29  
rat studies, **I**:46  
respiratory disease studies, **VI**:28–32, **XIII**:21  
siderosis in welders and, **IX**:32  
summary of studies, **XIV**:82  
welding fumes and, **III**:6–7

Fibrous tissue formation (lungs), ozone exposure and, **I**:xv–xvi

Filter wire composition, fume generation studies, **V**:6

Filter devices, design requirements, **IX**:27

Filtering devices, cardiovascular effects of, **VI**:38

Filter leaching techniques, chromium compound exposure studies, **V**:7–8

Filter plates

prevention of eye injuries with, **II**:13  
protective coatings and, **IV**:7  
radiation protection with, **IV**:xvi, 9

Fingernail analysis

biochemical effects of welding compounds, **IV**:25  
genotoxicity studies, **X**:17, 69

Finnish Biological Action Limits, chromium/nickel levels in urine, **X**:8, 23–24

Finnish Occupational Exposure Limits, **X**:8, 23–24

Finnish welders

aluminum exposure in, **X**:52, **XIII**:97–98, **XIV**:3, 13, 30, 82  
asthma in, **XI**:33–35, **XIII**:4–5, 20–21, 61–64  
cancer in, **XII**:45–46  
central nervous system function in, **X**:14  
compensation claims, **XI**:5  
incidental exposure to production coatings, **IX**:26  
isocyanate incidental exposure, **XIII**:44–45  
leukemia and central nervous system tumors in, **IX**:38  
liver cancer among, **X**:4, 12, 47  
lung cancer in, **IX**:9, 37, 42, **XIV**:83  
manganese exposure in, **X**:65  
nasal cancer epidemiologic studies, **V**:24–25  
psychological stress among, **IX**:88  
reproductive function in, **XIV**:88  
ventilation systems analysis, **XIII**:56–59  
workplace exposure studies, **X**:8, 22–24

Flame atomic absorption spectroscopy (FAS)  
chromium exposure studies, **XII**:11

- nickel analysis, **X**:21
- Flame cutters  
 cancer in, **XIV**:5  
 neurodegenerative disease and, **XIV**:9  
 nickel exposure in, **X**:38
- Flame size, noise exposure studies and, **IV**:10
- Flash burns, incidence of, in welders, **IV**:19–20
- Flow-volume curves, respiratory tract studies, **V**:18
- Fluoride compounds  
 allergic reactions to, **IV**:24  
 analytical techniques for, **X**:7  
 animal studies, distribution and excretion, **I**:97–98  
 biochemical effects of, **III**:15  
 biological monitoring of, **V**:21–23  
 blood studies, **I**:31  
 nickel and chromium compounds, **VI**:41–43  
 urine studies, **I**:43–44, **II**:xvi  
 electrode composition, **I**:69, **IV**:3, **VI**:19–20  
 absorption, distribution and biotransformation, **II**:19  
 fume exposure studies, **II**:19  
 epidemiologic study design, **II**:19  
 fume composition studies  
 analytical techniques for, **X**:21  
 workplace exposure studies, **X**:8  
 fume exposure studies, **VIII**:5, **IX**:7  
 toxicokinesis, **II**:xxi  
 fume generation rates (FGR), **III**:xiii, 3, **VII**:5  
 as fume constituent, **I**:2, 68–69  
 particle studies, **V**:7  
 readaptation time of, **III**:13  
 sources of, **I**:2  
 teeth and oral cavity effects, **II**:15  
*in vitro* studies, sister chromatid exchange (SCE), **VII**:46–47  
 workplace exposure limits, **IX**:23, **X**:22–23, **XIV**:12
- Fluorine  
 biochemical effects, **IV**:24–25  
 biological monitoring of, **IV**:xiv  
 fume generation studies  
 electrode composition, **V**:6  
 potassium silicate electrodes, **VI**:5  
 metal fume fever, **IV**:xviii  
 teeth and oral cavity effected by, **IV**:23  
 urine analysis, **IV**:xviii
- Fluoroborate fluxes, fume emission studies, **VI**:5, 20
- Fluorocarbons, “ozone-destroying theory” of, **II**:3
- Fluorosis, welding and, **I**:xix, 37
- Fluorspar (calcium fluoride), electrodes as source of, **I**:2
- Fluphenazine, retinal injuries and, **IX**:10, 40–41
- Flux-cored arc welding (FCAW)  
 animal studies  
 pneumoconiosis, **V**:37–39  
 toxicology research, **II**:25  
 asthma and, **XIV**:31  
 barium electrode coatings, **VI**:21–22, 43, **X**:61–62  
 chromium emission studies, **VI**:20, **XIV**:11, 19  
 biological monitoring techniques, **XIV**:55  
 chronic fluorosis and, **I**:xix  
 chronic respiratory disease and, **I**:xxi, 13  
 fume composition models, **IX**:19, **X**:19, **XIII**:14, **XIII**:36–37, **XIV**:11, 22  
 fume exposure studies, **IV**:xv, 1, **VII**:15, **IX**:7  
 fume generation rates, **I**:62–64, **III**:2, **VI**:5, 15, **IX**:19, **X**:19  
 fume sampling, **XII**:3  
 gas emission studies, **VI**:23  
 manganese fume constituents, **I**:3, 70  
 nickel monitoring, **XIV**:19, 55  
 nitrogen oxide production, **I**:74–75  
 noise production, **I**:77–78  
 ozone production, **I**:3, 72, **IV**:6–7, **VII**:19, **VIII**:14, **IX**:24–25  
 particle analysis, **VII**:6, 18  
 particle size distribution, **I**:3, 71  
 protective equipment for, **VI**:16  
 screening studies for fibrogenic potential, **I**:xxii  
 respiratory disease with, **V**:15  
 sampling procedures, **XII**:27  
 silicon compounds and, **III**:2  
 skin injuries during, **IV**:20  
 ultraviolet radiation exposure, **I**:77, **XIII**:2–3, 15, 40–41  
 ventilation systems for, **XIII**:19, 54–59  
*in vitro* studies, carcinogenicity studies, **II**:32–33  
 welding wires, exposure studies, **XIV**:12
- Flux-cored electrodes  
 fume composition studies, **X**:19, **XIII**:34–37  
 metal component concentration in fumes, **X**:7
- Flux fume formation  
 electrode composition, **V**:6  
 flux production and, **VI**:5  
 voltage and current, effects of, **V**:5–6
- Foam insulation, accident/safety analysis of, **VIII**:20
- Follicle stimulating hormone (FSH) levels  
 animal studies of, **X**:17, 69–70  
 chromium exposure and levels of, **X**:14–15  
 fertility studies of welders, **IX**:4, 48–49, **X**:4, 56–58
- Forced expiratory flow (FEF) measurements  
 asbestos workers vs. welders, **X**:9  
 bronchitis and, **IX**:29–32  
 oxidative stress biomarkers, **XIV**:6  
 pulmonary function testing, **VII**:26–29, **XIII**:60–61  
 respiratory changes in welders, **XIV**:27–30, 81  
 respiratory disease studies, **V**:13, 16–17, **IX**:9
- Forced expiratory volume (FEV1) measurements  
 asbestos workers vs. welders, **X**:9  
 assessment of welding effects with, **III**:10  
 asthma in welders and, **X**:10, **XII**:41–42, **XIV**:3–4  
 bronchitis studies, **X**:10  
 chronic respiratory disease, **I**:13–20, 82  
 degreasing agents, fume exposure studies, **VI**:26–27  
 metal fume fever studies, **II**:15  
 oxidative stress biomarkers, **XIV**:6  
 oxygen welders, **X**:3  
 pneumoconiosis, **XIV**:33–34  
 pre-employment vs. adult values, **X**:29–30  
 pulmonary function testing, **VII**:26–29, **IX**:9, **X**:31–32, **XI**:25–30, **XIV**:3, 12  
 respiratory changes in welders, **XII**:4, 14

- respiratory disease studies, **IV**:14–15, **V**:13–18, **VI**:28–32, **IX**:3, 29–32, **XIV**:27–30  
 shipyard welders, **X**:9
- Forced vital capacity (FVC) measurements  
 arc welders, **X**:3  
 asthma in welders and, **XIV**:3  
 assessment of welding effects with, **III**:10  
 metal fume fever studies, **II**:15  
 oxidative stress biomarkers, **XIV**:6  
 oxygas welders, **X**:3  
 pneumoconiosis, **XIV**:33–34  
 pre-employment vs. adult values, **X**:29–30  
 pulmonary function testing, **VIII**:27, 29, **IX**:9, **X**:31–32, **XI**:26–30, **XIV**:12, 81  
 respiratory changes in welders, **XII**:14, 38–40, **XIV**:27–30  
 respiratory disease studies, **V**:13, 16–17, **VI**:28–32, **IX**:3, 29–32  
   chronic disease, **I**:13–14, 17–18  
   fume exposure studies, **IV**:14–15  
 shipyard welders, **X**:9
- Forensic diagnosis, electrocutions, **XII**:13, 36
- Fowler nitrogen test, respiratory tract studies, **V**:19
- Fractional uptake of carbon monoxide (FuCO), lung function testing, **X**:30
- Fractionated fume transfer, **IX**:19–20
- French welders  
 electromagnetic fields (EMF) exposure among, **X**:47  
 genotoxicity studies, **XIV**:58–59  
 lead exposure in, **XIII**:31–32, 113–114  
 lung cancer in, **X**:40, **XIV**:83  
 pulmonary function testing, **XI**:3, 9  
 scleroderma incidence in, **XIV**:41  
 sino-nasal cancer in, **X**:46  
 visual acuity testing in, **XIII**:25
- Fume aging, chromium emission studies, **VI**:21
- Fume box measurements, fume emission rates (FER), **VI**:5, 16
- Fume collection devices, design analysis, **IX**:27
- Fume component studies, **VIII**:5, **XI**:7  
 air monitoring, **X**:22  
 allergic contact sensitivity, **VI**:37–38  
 analytic techniques, **VI**:15–19, **IX**:7, 19–22, **X**:20–22, **XII**:24–25  
 animal toxicology studies, **II**:24–26  
 barium levels in, **VI**:21–22  
 biological monitoring, **X**:21  
 carcinogenicity analysis, **II**:xxi  
 chromium exposure, **VI**:20–21, **X**:20–21, **XIV**:11  
 electrode composition and, **VI**:19–20  
 exposure studies, **X**:19–20, **XIII**:34–37  
 fluoride exposure, **X**:21  
 fume generation and, **III**:2  
 health effects of welding and, **II**:7  
 inductively-coupled plasma mass spectroscopy, **XII**:11  
 metal compounds, **XIV**:22  
 nickel exposure, **X**:21  
 particle analysis, **VI**:21–22  
 pulmonary inflammation, **XII**:72–75  
 research methodology, **XIII**:14  
 role of, in epidemiologic studies, **II**:xxiii  
 technical summary, **X**:7  
 voltage and current levels and, **VI**:15  
 workplace exposures, **XI**:15–17, **XII**:3
- Fume conversion factor, electrode composition, **VIII**:12
- Fume emission rates (FER)  
 fume box measurements, **VI**:5, 16  
 by various welding processes, **VI**:16–17  
 ventilation systems and, **XIII**:52–59
- Fume exposure studies. *See also* Gases  
 aerosol analysis, **VIII**:13–14  
 aluminum, **VIII**:12  
 analytic techniques, **X**:20  
 animal studies, **VI**:10–11, 45–46, **IX**:14–15, 56  
   human comparisons, **XIV**:32  
   infectivity and inflammation, **XIV**:20, 60–63  
   inhalation studies, **I**:45–54  
   techniques for, **II**:23–24  
 arc welding radiation, **I**:76–77  
 biological monitoring techniques, **VI**:9–10, 41–44, **X**:21–22  
 cancer incidence and, **VI**:7–8, 32–34  
 carbon monoxide, **VIII**:14  
 cardiovascular system effects, **XIV**:87  
 chromium exposure, **I**:69–70, **X**:20–21  
 combined exposure studies, **VI**:14  
 component sensitivity, **IV**:23–24  
 composition properties, **I**:1–2, 59–75, **XIII**:34–37  
   constituents concentration and exposure duration, **I**:68–71  
   copper constituents, **I**:69  
 contact dermatitis, **VI**:8  
 distribution and excretion studies, **I**:48  
 duration of exposure and lung cancer incidence, **X**:12  
 electrode composition, **VIII**:11–12  
 electromagnetic field (EMF) exposure, **X**:8, 25–26  
 elimination pathways and, **III**:6–7  
 endocrine system effects, **VI**:9, 39–40, **XIV**:5  
 epidemiologic studies, **I**:1–3, 69–71, **II**:19–22, 24–25, **VIII**:5, 11–14, **IX**:7, 19–14  
 exposure estimation techniques, **I**:1–3, **XII**:36–37  
 fluoride exposure, **I**:68–69, **X**:21  
 flux cored arc welding, **I**:62–64  
 formation mechanisms, **I**:57–62  
 fume generation rates, **I**:57–62, **II**:xix, 1–3, **IV**:1–5  
 fume stability measurements, **VII**:4  
 gas exposure studies, **I**:3–4, 71–76  
 gas generation rates, **II**:xix, 2–3  
 gas metal arc welding, **I**:64–65  
 gas tungsten arc welding, **I**:65–67  
 heat and stress exposure studies, **I**:4, 78  
 hyperbaric pressure, **VI**:9  
 incidental exposure studies, **IX**:8, **X**:26–27  
 influenza and tuberculosis, **I**:103–104  
   animal studies, **I**:49  
 inhalation studies  
   animal studies, **I**:45–54, 83–95  
   blood and urine studies, **I**:41–42  
   carcinogenicity, **I**:101–102  
   cats, **I**:94–95  
   distribution and excretion studies, **I**:97–101  
   guinea pigs, **I**:92–94

mice, **I**:94  
 rabbit studies, **I**:89–92  
 rat studies, **I**:83–89  
 intraperitoneal effects, **I**:102  
 intratracheal administration of suspensions, **I**:47–48, 54, 94–97  
     carcinogenicity, **I**:101–102  
 laser welding, **X**:8, 23–25  
 lead exposure, **VIII**:12  
 lipid peroxidation assays, **IX**:57  
 lung cancer incidence and, **XIV**:5, 14  
 lung disease, **XI**:57–59  
 manganese constituents, **I**:70  
 measurement techniques, **II**:xix–xx, 5  
 metal fume fever, **VI**:8, 34–35  
 mutagenicity studies, **I**:55  
 nickel exposure, **I**:70, **X**:21  
 nitrogen oxides, **VIII**:14  
 noise exposure studies, **I**:4, 77–78  
 obstruction of radiation with, **I**:77  
 occupational asthma, **XI**:30–35  
 OSHA airborne contaminants standard, **I**:79  
 oxidative stress and inflammation biomarkers and, **XIV**:6, 50–52, 88  
 oxygas welding, **I**:67–68  
 ozone, **VIII**:14  
 particle size distribution, **I**:3, 70–71  
 plasma arc welding, **I**:67  
 pneumoconiosis epidemiology, **XIII**:21, 64–68  
 pneumonia risk and, **XIV**:6–7, 34–35  
 posture and, **IV**:22  
 pulmonary function testing, **VI**:13, **XIV**:27–30  
 radiation exposure, **I**:4, **II**:xix–xx, 3–4  
 reproductive function in welders and, **XIV**:9–10, 88  
 research methodology, **IV**:xv, **V**:1, **VII**:5, 15–19  
 respiratory disease, **VI**:7, 27–32, **XIV**:14  
 risk assessment techniques, **III**:1, **VIII**:9  
 scleroderma incidence, **XIV**:41  
 screening studies  
     fibrogenic potential, **I**:xxii  
     mutagenicity and *in vitro* carcinogenicity potentials, **I**:xxii  
 silica constituents, **I**:68  
 skin sensitization to, **I**:40–41  
 subcutaneous effects, **I**:102–103  
 submerged arc welding, **I**:67  
 teeth and oral cavity effects, **VI**:9, 40  
 transfer mechanisms, **IX**:19  
 urogenital tract, **VI**:9, 38–39  
 ventilation and air cleaning equipment, **IX**:27, **XIII**:54–59, **XIV**:25–26  
     *in vitro* studies, **VI**:11  
     workplace exposure, **X**:22–23, **XIII**:17–18, 45–51  
 Fume extraction guns, ventilation systems analysis, **XIII**:54–59  
 Fume formation rate (FFR)  
     epidemiologic studies, **V**:1, **XI**:16–17  
     fume composition analysis, **XII**:25  
     voltage and current effects, **V**:5–6  
 Fume generation rate (FGR). *See also* Gases

analytical techniques, **IX**:22  
 animal studies of, **III**:xv  
     toxicologic effects, **III**:16–18  
 AWS standard laboratory method, **VI**:16  
 biochemical effects of, **III**:xiv  
 chromium compounds, **V**:7–9, **XIV**:22  
 comparison of, by welding technique, **IX**:19–22  
 current intensity and, **II**:1, **IX**:20  
 electrode composition, **IV**:2–3, **V**:6, **VI**:19–20, **VII**:16  
 epidemiologic studies, **VII**:5, 15–19  
 eye injuries, **II**:12, **III**:xiv  
 flux cored arc welding, **I**:62–64, **X**:19–20, **XIV**:11  
 fume composition, effect of, **VI**:5  
 fume exposure studies, **II**:xix, 1–3, **IV**:1–5, **IX**:7  
 gas metal arc welding, **I**:64–66, **X**:19  
 gas tungsten arc welding, **I**:65–67  
 laser welding, **IX**:7–8, **X**:23–24  
 measurement techniques, **II**:2, **III**:3–4, **VI**:5–6  
 mechanics of, **III**:xiii  
 oxygas welding, **I**:67  
 ozone production, **I**:72–74  
 particle size distribution, **V**:7  
 plasma arc welding, **I**:67  
 pulmonary irritation, **II**:11  
 risk factors, **III**:1–4  
 rutile or slag content, **X**:7  
 shielding gas, effects of, **V**:6  
 various types of welding, **I**:2, 61–62, 68–69  
 voltage and current linked with, **IV**:2, **V**:5–6  
 workplace exposure limits, **IX**:23–34  
 Fume-to-weight ratios, electrode composition, **I**:61–62  
 Furocoumarins  
     skin conditions linked with, **I**:40  
     UV exposure and, **II**:4  
 Fuzzy logic controllers and filters, welding robotics, **VIII**:19

## G

Galactosuria, welding and, **I**:35–36  
 Gall bladder cancer, epidemiologic studies, **XII**:5, 16  
 Gallium scanning, asbestosis epidemiologic studies, **X**:10, 37  
 Galvanized steel welding  
     challenge test results, **XII**:41  
     metal fume fever and, **IX**:10, **XIV**:15  
 Gamma globulin, liver function in welders and, **I**:35–36  
 Gamma spectrometry, thorium exposure studies, **XII**:29–31  
 Gas chromatography/mass spectroscopy, incidental exposure studies, **IX**:26, 54  
 Gas inhalation, illness and, **XIV**:3  
 Gases. *See also* Argon, e.g., Ozone, specific gas compounds, specific gases  
     analytic techniques used on, **V**:1  
     animal exposure studies, **IV**:xviii, 27, **VI**:45–46  
     bacterial assays, **VI**:46–47  
     chlorinated hydrocarbon decomposition, **I**:75–76  
     chronic respiratory disease and, **III**:6–7  
     combined exposure measurements, **VI**:14  
     concentration, **III**:xiii  
     electrode composition, **VII**:16, **VIII**:12

- exposure studies, **II**:xix, 2–3, **III**:xiii, **V**:9–10, **VI**:6, 23–24, **VIII**:5  
 generation studies, **IV**:5–7  
 health risks of welding and, **III**:1, 4  
 hyperbaric pressure studies, **VI**:9, 40  
 production of, during welding, **I**:3–4, 71–76  
 protective coatings and, **IV**:7  
 pulmonary irritation from, **II**:10–11  
 research methodology, **IV**:xv  
 respiratory disease incidence, **VI**:27–32, **VII**:5–6, 24  
 respiratory toxicity studies, **II**:8–9  
 Gas metal arc welding (GMAW)  
   acute poisoning, etiology, **I**:xv  
   aerosol analysis, **VIII**:13, **IX**:22  
   aluminum exposure, **VII**:40, **IX**:52–53, **X**:52, **XII**:17  
     biological monitoring techniques, **VI**:43  
     nervous system effects, **XIII**:10–11, 97–98  
     ozone generation, **VI**:15  
   alveolar macrophages, **VIII**:6  
   amyotrophic lateral sclerosis (ALS) incidence and, **XI**:45–46  
   animal studies, **V**:4, **X**:18, 71  
     fibrosis, **VII**:11, 41–42  
     infectivity and inflammation, **XIV**:20, 60–63  
     inflammation and fibrosis, **VII**:11, 41–42  
     pulmonary retention and clearance, **VII**:11, 42–44  
     toxicity effects, **II**:25, **III**:17–18, **VII**:44–45  
     whole-body effects, **V**:40  
   anti-oxidant exposure, **X**:61  
   asthma epidemiology, **XI**:10, **XII**:42, **XIII**:20–21, 64, **XIV**:31  
   atomic absorption analysis, **VIII**:14  
   biological monitoring, **VII**:10–11, **XI**:55, **XII**:20, 67–68  
     chromium exposure, **VII**:40–42  
     nickel and chromium compounds, **VI**:41–43  
   blue light exposure studies, **XIII**:2, 12, 39–40  
   carbon monoxide generation, **IV**:7  
   cardiovascular disease, **XI**:49–50  
   case report, **XI**:14, 54–55  
   cell culture studies, **VI**:47–49  
   central nervous system function and, **X**:14  
   chromium exposure  
     emission studies, **IV**:4–5, **VI**:20, **IX**:51  
     fume constituents, **I**:70, **V**:7–9, **X**:20–21  
     measurement techniques, **VI**:5–6, 15  
     production measurements, **I**:3  
   chronic fluorosis and, **I**:xix  
   chronic lung disease and, **I**:xxi  
   clastogenesis and, **VIII**:39  
   cobalt exposure and, **X**:63–65  
   degreasing agents  
     exposure studies, **VI**:26–27  
     incidental exposure, **IX**:53  
     photochemical decomposition from UV radiation, **VI**:6, 14  
   dopamine oxidation, **XII**:75  
   electrode composition, **I**:2, 64–65, **VIII**:12  
   electromagnetic field exposure, **IX**:25, **X**:25–26, **XII**:13, 33  
   electromagnetic radiation, **XI**:21–22, **XII**:31–32, **XIII**:15  
   exposure estimation techniques, **XII**:37  
   eye injuries, **VIII**:37, **X**:50  
   fertility studies, **IX**:48–49, **X**:4, 14–15, 56–58  
   fume components, **IX**:19, **X**:7, 19, **XI**:7, 15–17, **XII**:24–25, **XIII**:14, 34–37  
   fume composition models, **XIV**:22  
   fume exposure studies, **II**:xix, **IV**:1, **VIII**:41, **IX**:7  
     analytic techniques, **VII**:17  
     animal studies, **VI**:11  
     biological monitoring techniques, **VI**:10  
     carcinogenicity, animal studies, **V**:37  
     cell studies, **VI**:11  
     emission rates (FER), **VI**:16  
   fume generation rate, **I**:64–66, **VI**:5, 15, **VII**:16, **IX**:19–21  
     electrode composition, **V**:6  
     shielding gases, **V**:6  
     voltage and current effects, **V**:5–6  
   fume sampling procedures, **XII**:3  
   fume stability, **VII**:4  
   gas exposure studies, **IV**:xv, **VII**:6, 15  
     carbon dioxide-shielded GMAW, **VI**:23–24  
   genotoxicity studies, **XI**:14, 55–56  
   health and safety regulatory compliance and, **XIII**:57–59  
   immune system effects, **IX**:43, **XII**:8–9, 19, 66–67  
   inductively-coupled plasma mass spectroscopy analysis, **XII**:23  
   isocyanate incidental exposure, **XIII**:43–45  
   lead exposure studies, **VIII**:12  
   local exhaust ventilation systems, **XIII**:3–4  
   lung cancer epidemiology, **IX**:36, **X**:41, **XI**:38–40, **XIII**:7, 76–79  
   lung disease and, **XI**:57–59  
   magnetopneumography (MPG), **XII**:43  
   mammalian cell studies, **VIII**:41–43  
   manganese exposure, **VII**:40  
   musculoskeletal system and, **X**:53–54  
   mutagenesis assays, **V**:40–41  
   nickel exposure, **VII**:16, **IX**:52  
   nitrogen oxide production, **I**:74–75  
   noise exposure studies, **IV**:10, 19, **V**:1, 10, **VI**:6, **VII**:21–22, **VIII**:34–36  
   occupational asthma, **XI**:34–35  
   oculomotor studies, **VIII**:37–38  
   oxidative stress and inflammation and, **XIV**:50–52  
   ozone exposure studies, **I**:3, 72–74, **V**:10, **XI**:17  
     generation rates, **IX**:23–24  
     particle analysis, **V**:7, **VI**:22, **VII**:6, 18  
       animal studies, **VII**:42–44  
     particle size distribution, **I**:3, 70–71, **IV**:3–4  
     pneumonitis, **I**:6  
     pulmonary retention and clearance studies, **IV**:12–13, **VII**:7, 25–26, 42–44  
   phosgene incidental exposure, **XIII**:42–43  
   pneumonia risk and, **XIV**:7  
   pneumoconiosis, animal studies, **V**:37–39  
   protective coatings and equipment, **IV**:7, 9, **IX**:28  
   pulmonary function testing, **IV**:15, **VI**:28–32, **VII**:28–29, **X**:9–10, 30–31, **XII**:38–40  
   pulmonary inflammation, **XII**:6, 21, 72–75

- radiation exposure studies, **IV**:xvi, 9–10, **VI**:6, 24–25  
 respiratory changes in welders, **XII**:4, 14  
 respiratory disease with, **V**:15  
 sampling procedures, **XII**:27  
 shielding gases, **I**:2, 65–66  
 skin cancer, **XII**:53  
 skin conditions and injuries, **IV**:20, **XIII**:26, 94–95  
 small bowel cancer epidemiology, **XIII**:82–83  
 ultrafine particle analysis, **XIII**:74, **XIV**:23–24  
 ultraviolet radiation exposure, **I**:77, **V**:10, **VI**:24, **VII**:6, 19–20, **XIII**:2–3, 15, 40–41  
 ventilation systems for, **XIII**:19  
   push-pull systems, **XIV**:12, 25–26  
   workplace analysis, **XIII**:52–59  
 visual acuity loss and, **XIII**:91  
*in vitro* studies  
   carcinogenicity studies, **III**:18–19  
   cytotoxicity, **VII**:47  
   fume exposure studies, **V**:4  
     cell transformation assays, **V**:41  
     mammalian cell cultures, **VII**:12  
     toxicity studies, **IV**:29  
 voltage and current with, **IV**:2  
 workplace exposure analysis, **IX**:22–23, **X**:22–23, **XI**:18–20, **XIII**:17–18, 45–51  
 zinc exposure studies, **X**:39
- Gas shielded flux-cored arc welding (FCAW-G), pulmonary function testing, **X**:32
- Gas-shielded wires, electrode composition, **VIII**:11
- Gastroduodenitis, welding and, epidemiological studies, **I**:35
- Gastrointestinal tract  
 cancer, incidence of, in welders, **I**:24, **VII**:3–4, 9, 33  
 carcinogenicity studies, **VI**:34  
 disease, incidence of, in welders, **V**:14  
 epidemiological study design, **I**:xix, 34–35  
 fume generation effects on, **II**:13–14  
 metal fume fever and, **II**:15  
 welding exposure studies, **II**:xx, **III**:13
- Gas tungsten arc welding (GTAW)  
 aluminum exposure, **VII**:40, **IX**:52–53  
 animal studies, **IX**:55  
 arc distance, ozone production and, **I**:73  
 asthma and, **XIV**:31  
 biological monitoring, **VII**:10–11, **XI**:55, **XII**:20, 67–68  
   nickel and chromium compounds, **VI**:41–43  
 cardiovascular disease, **XI**:49–50  
 chromium emission studies, **VI**:20  
   exposure measurements, **VI**:15, **IX**:51, **X**:63  
 chronic bronchitis and, **IX**:9  
 degreasing agents, incidental exposure, **IX**:53  
 electrode composition and, **IV**:2, **VIII**:12  
   fertility studies, **IX**:4, 14, 48–49  
   fume generation rate, **I**:2, 65–67  
 electromagnetic radiation, **XI**:21–22  
 exposure estimation techniques, **XII**:37  
 fume composition analysis, **XII**:24–25  
 fume exposure studies, **I**:10–11, **IV**:xv, **VII**:5, 15, **IX**:7, **XIII**:37–38  
   analytic techniques, **VII**:17  
   animal studies, **VI**:11, 46–47  
   pulmonary function testing, **VI**:7  
 fume generation rates, **VI**:5, 15–16, **VII**:15, **IX**:19–20  
   electrode composition, **I**:2, 65–67, **V**:6  
 gas exposure studies, **IV**:xv, **VI**:6  
 genotoxicity studies, **X**:26, 67, **XI**:14, 55–56  
 health and safety regulatory compliance and, **XIII**:57–59  
 hyperbaric pressure studies, **VI**:40  
 immune system effects, **XII**:8–9, 19, 66–67  
 local exhaust ventilation, **XII**:4  
 lung cancer epidemiology, **X**:41, **XI**:38–40, **XIII**:7, 76–79  
 nervous system effects, **VII**:37  
 nickel compounds, **VII**:16  
 nitrogen oxide generation, **I**:74–75, **V**:9, **VIII**:5, 14  
 noise exposure studies, **I**:77–78, **IV**:10, **V**:10, **VIII**:34–36  
 oxidative stress and inflammation and, **XIV**:50–52  
 ozone exposure studies, **I**:6, 72–74, **IV**:6–7, **V**:9–10, **VI**:24, **IX**:23–24, 56  
 particle retention estimation in lungs and, **IV**:12–13  
 particle size distribution, **IV**:3–4  
 phosgene incidental exposure, **XIII**:42–43  
 protective coatings and equipment, **IV**:7–9, **IX**:28  
 pulmonary function testing, **IV**:xvi, **VI**:7, 28–32, **IX**:31, **X**:31, **XII**:38–40  
 radiant heat exposure studies, **VI**:25  
 radiation exposure studies, **III**:xiii, 5, **IV**:xvi, 9–10  
 reproductive system disorders, **X**:14–15  
 respiratory changes in welders, **II**:xx, 17, **XII**:14  
 small bowel cancer epidemiology, **XIII**:82–83  
 thoriated electrodes  
   exposure studies, **XIV**:11, 24  
   lung cancer incidence, **X**:44–45  
 thorium exposure studies, **XII**:30–31  
 ultrafine particle analysis, **XIII**:74  
 ultraviolet radiation exposure, **VI**:24, **VIII**:15  
 ventilation systems for, **XIII**:19, 54–59  
 visual acuity loss and, **XIII**:91  
*in vitro* studies of, **IX**:14  
 voltage and current with, **IV**:2  
 welding emissions, **VI**:13  
 workplace exposure limits, **IX**:22–23, **XIII**:18, 45–51
- Gene expression  
 animal studies, **X**:18, 72–74  
 fume exposure studies, **XIV**:6  
 inflammation and oxidative stress and, **XIV**:17–18, 50–52
- General dilution ventilation, studies of, **XIV**:26
- Genetics studies  
 manganese toxicity, **XII**:18, 61  
 manganism, **XII**:7–8
- Genitourinary system. *See* Urogenital tract
- Genotoxicity studies  
 animal studies, **VI**:46–47  
 biomarkers, **XI**:14, 55–56  
 carcinogens, **VIII**:33  
 exposure studies and, **X**:17, 66–68  
 international surveys, **XIII**:30–31, 110–111  
 techniques for, **XII**:20, 70–71, **XIV**:20, 57–59  
*in vitro* studies, **IV**:29
- German welders

consumable warning labels, **VIII**:11  
 eye injuries in, **IX**:40  
 fertility problems in, **XIII**:106–109  
 industrial hygiene studies, **VIII**:11  
 laryngeal cancer in, **IX**:37  
 laser welding, **IX**:25–26  
 lung cancer in, **IX**:9, 36, **X**:42  
 metal levels in dust, **X**:8  
 nickel exposure, **IX**:52  
 pneumoconiosis in, **XIII**:21  
 pulmonary edema in, **XIII**:88  
 renal cell carcinoma in, **XIII**:79–80  
 respiratory disease studies of, **V**:13–14  
 workplace exposure limits, **IX**:23

Gingivitis in welders, **IV**:23, **IX**:49  
 Glare test, radiation-related eye injury, **VI**:37  
 Glass beads, alveolar macrophage studies, **VIII**:25  
 Glass filters, chromium analysis, **X**:20  
 Glass-metal welding, radio frequency radiation, **VIII**:17  
 Glomerular dysfunction  
   cadmium exposure studies, **VI**:9, 39  
   epidemiologic studies of in welders, **VII**:10  
 Glomerulonephritis, incidence of, in welders, **VII**:38–39  
 Glomerular nephropathy, **XIV**:52–53  
 Glutathione  
   oxidative stress and, **XIV**:6, 50–52, 88  
   pulmonary function testing and, **XIV**:13, 29  
 Glutathione peroxidase, current research, **X**:5, 61  
 Glycoprotein regulation, hexavalent chromium exposure, **XIV**:89  
 Goggles  
   eye protection with, **VIII**:36–37  
   radiation protection with, **VI**:24–25, **VII**:19–20  
 Gold eye filters, specification studies, **X**:28–29  
 Granulocytopenia  
   fume particulates, **II**:14  
   metallic compounds, **II**:xx  
 Graphite furnace atomic absorption spectrometry, aluminum exposure, **XII**:23  
 Greenberg-Smith impingers, chromium analysis, **X**:21  
 Greyscale ultrasonography, metallic exposure analysis, **II**:xv–xviii  
 Grinding operations  
   asthma and, **XIV**:4  
   biological monitoring, **XIV**:89  
   noise exposure studies, **VII**:21–22  
   oxidative stress and inflammation and, **XIV**:50–52  
   thoriated electrodes, exposure studies, **XIV**:11, 24  
   ventilation systems analysis, **XIII**:55–59  
 Guinea pigs  
   distribution and excretion of inhaled fumes, **I**:98–99  
   fume inhalation studies, **I**:47, 92–94  
     manganese content, **I**:98–100  
     silica content, **I**:99–100  
   fume particle studies, **III**:17  
   intraperitoneal effects, studies of, **I**:102  
   iron compound exposure studies, **II**:27  
   tuberculosis from fume inhalation in, **I**:104

## H

Hair analysis  
   biochemical effects of welding compounds, **IV**:25, **V**:23  
   cardiovascular effects of welding, **V**:20  
   epidemiologic studies, **XI**:14  
   fume exposure studies and, **III**:14  
     genotoxicity studies, **X**:17, 69  
     in newborns, **VI**:10, 44  
   heavy metal monitoring, **VI**:44  
   manganese levels, pulmonary function, correlated with, **VII**:27–28  
   metallic compound exposure, **II**:xvi, xvii, 16–17, **XI**:56  
 Halogenated refrigerants, exposure studies, **XIV**:11–12, 25  
 Hamsters  
   cobalt exposure studies, **II**:27  
   iron compound exposure studies, **II**:27  
   mammalian cell studies, **VIII**:41–43  
   nickel compound exposure studies, **II**:28  
 Hand-arm vibration syndrome, epidemiologic studies, **XII**:18, 61–62, **XIII**:28, 103–104  
 Hard cascade impaction, particle analysis, **VI**:23  
 Hard metal coatings, exposure studies, **X**:39, **XI**:8  
 Hazard analysis  
   factors included in, **I**:1  
   hazard index, **II**:7  
     laser welding, **X**:8  
   hygiene and workplace design, **XI**:9  
   risk assessment with, **VIII**:9  
 Hazard Evaluations and Technical Assistance Branch (HETAB) (NIOSH), fume exposure studies, **VIII**:20–21  
 Headache, epidemiologic studies, **XIV**:55  
 Health screenings  
   effects of welding assessed with, **III**:8–9  
   occupational disease surveys, **XIII**:30, 109–110  
   recommendations for, in risk assessment, **III**:20  
 Healthy worker effect  
   lung cancer in welders, **IX**:36  
   pulmonary function and respiratory disease, **IX**:32  
 Hearing loss. *See also* Ear injuries  
   burn-related, **VII**:35  
   epidemiologic studies, **XI**:43  
   middle ear studies, **XIII**:10, 24  
   noise exposure studies, **II**:13, **VI**:8, 21, **VIII**:6, 14, 34–36  
   noise level monitoring, **XI**:11–12  
   protective devices for reduction of, **IV**:xvii  
   in welders, **III**:xiv, 12, **IV**:19, 25, **X**:49  
   welding exposure studies, **II**:xx  
 Heart failure, welding and, **I**:32  
 Heart rate variability (HRV)  
   effects of welding on, **IV**:xvii, 21  
   fume exposure studies, **XIV**:87  
   manganese exposure, **XII**:18, 59–61  
 Heat  
   radiation exposure studies, **VI**:25  
   reproductive dysfunction, **VIII**:38–39  
   during welding process, **I**:4, 78  
 Heavy metals  
   electrode composition analysis, **VI**:19–20  
   in welding fumes, **III**:14–15

- Helium  
 fume generation rates, **IX**:20–21  
 gas metal arc welding (GMAW), fume exposure studies, **IX**:7  
 hyperbaric pressure studies, GTAW, **VI**:40  
 ozone exposure studies, **IV**:xv, 6, **V**:9–10  
 ventilation equipment monitoring with, **IX**:27  
 Helium shielded arc welding, ozone generation, **I**:6  
 Helmets  
 ear injuries and, **IX**:10, 40  
 electromagnetic radiation, **IX**:25  
 fume exposure studies, **VI**:16  
 metal fume fever and, **IX**:10  
 workplace exposure limits, **IX**:23  
 Hematocrit levels in welders, **XIII**:29, 105–106  
 Heme oxygenase  
 animal studies, **X**:72–74  
 protein synthesis induction and, **X**:5  
 Heme synthesis, lead exposure studies, **IV**:24  
 Hemochromatosis  
 epidemiologic studies, **XI**:5  
 magnetopneumographic measurement, **XI**:42–43  
 siderosis and, **XIV**:4  
 Hemoglobin levels  
 epidemiological studies of, **I**:xix, 30–31  
 lead exposure studies, **IV**:24  
 Hemolysis  
 fume particulates and, **II**:14  
*in vitro* assays, **IV**:29  
 Hemoptysis, incidence of, in welders, **V**:12  
 Hemostatic protein concentrations, cardiovascular effects of welding, **XIV**:87  
 Hepatic cirrhosis, carcinogenicity studies of welding compounds, **VI**:33  
 HETacid anhydride, incidental exposure studies, **IX**:54  
 Hexavalent chromium (CrVI). *See also* Chromium exposure, Trivalent chromium  
 aerosol measurements, **IX**:22, **XI**:16–17  
 aging effects of, **V**:8  
 alveolar macrophage studies, **VIII**:25  
 analytic techniques for, **V**:1, **X**:7, 20–21  
 animal studies of, **V**:4, **IX**:54–55, **X**:17, 69–70, 72–73  
   infectivity and inflammation, **XIV**:62–63  
 atomic absorption analysis, **VIII**:13–14  
 biological monitoring, **V**:3, **VII**:4, 40–41, **VIII**:7, 40–41, **X**:16, 63, **XI**:55, **XIV**:19, 55, 89  
 biomarkers, **IX**:50–51  
 cancer incidence and, **VIII**:6  
 carcinogenicity studies, **VI**:32–34, **VII**:4, 33–34, **VIII**:13, 33, **IX**:33  
 cell culture studies, **VI**:48–49  
 cell transformation assays, **V**:41  
 chromatographic analysis, **XIII**:14–15  
 component analysis, **V**:9  
 DNA-protein cross-links, **XI**:56  
 electrode composition studies, **VI**:19–20, **VIII**:11–12  
 epidemiologic studies, **VI**:13, **IX**:4  
 exposure analysis, **XII**:21, 23–24  
 fertility and welding, **IX**:4, 14, **X**:17, 69–70, 72  
 flux cored arc welding (FCAW) fume generation, **X**:20, **XIV**:11  
 fume composition studies, **XII**:11, 25, **XIII**:14, 34–37, **XIV**:22  
 fume exposure studies, **V**:7–9, **VI**:20–21, **VIII**:5, **IX**:7, **XIII**:37–38, 110–111  
   analytic techniques, **VII**:16–17  
   biological monitoring techniques, **VI**:41–43  
 fume generation rates (FGR), **VII**:5, 15–16  
   measurement techniques, **VI**:5–6  
 genotoxicity studies, **XI**:56, 71, **XIV**:58–59  
 health surveys, **XIII**:31  
 immunomodulation, **XII**:75  
 kidney disease and, **X**:14, 54–55  
 laser welding hazards, **X**:23–24  
 lung cancer epidemiology, **V**:29, **X**:43–44, **XI**:37–40, **XII**:16, 48–50, **XIV**:35–36  
 oxidation reduction, **V**:8  
 ozone measurements, **XI**:17  
 particle studies, **V**:7  
 relative fume formation rate (RFFR) and, **IX**:20  
 respiratory effects of, **V**:12–13  
 urogenital tract effects, **VIII**:7  
 ventilation studies, **X**:28, **XIII**:56–59  
*in vitro* studies, **V**:4, **VI**:13–14  
   sister chromatid exchange (SCE), **VII**:46–47  
   toxicity assays, **V**:42  
 whole-body effects of welding, animal studies, **V**:39–40  
 workplace exposure analysis, **IX**:22–23, **X**:8, 22–23, **XI**:18–20, **XIII**:49–51  
 X-ray fluorescence spectrometry, **VIII**:14  
 High-pressure liquid chromatography (HPLC)  
 asbestosis epidemiology, **X**:10  
 incidental exposure studies, **IX**:26  
 High-resolution computed tomography (HRCT)  
 asbestosis epidemiologic studies, **X**:37  
 magnetopneumographic analysis vs., **XI**:42–43  
 High-voltage (HV) welding, workplace exposure analysis, **XI**:20–21  
 Histamine, metal fume fever pathogenesis, **VI**:34–35  
 Histopathologic stain, forensic diagnosis of electrocution, **XII**:36  
 Hodgkin's disease, incidence in welders, **V**:2, 33–34, **IX**:9, 37, **X**:4, 12  
 Human health studies, accidents vs. fume exposure as cause, **II**:xx  
 Human immunodeficiency virus (HIV), cancer risk and, **XII**:16  
 Humoral immune system, oxidative stress and inflammation in welders and, **XIV**:51–52, 88  
 Hungarian welders, workplace exposure studies, **X**:8, 22–23  
 Hydrocarbons  
 aliphatic, effects, **VIII**:7  
 Hydrocephalus, in children of welders, **X**:15  
 Hydrochloric acid (HCl), incidental exposure studies, **IX**:54, **XIV**:11–12, 25  
 17-Hydrocorticosteroids, levels of, in welders, **VI**:39–40  
 Hydrogen, ozone exposure studies, **IV**:6, **V**:9–10  
 Hydrogen chloride, respiratory tract effects of, **VII**:24  
 Hydrogen cyanide (HCN), in protective coatings, **IV**:7



- Hydrogen fluoride (HF)  
 electrode coatings, **VI**:5, 19–20  
 gas emission studies, **VI**:23  
 incidental exposure studies, **XIV**:11–12, 25  
 workplace exposure limits, **IX**:23
- Hydrogen sulfide, nervous system effects, **VIII**:7, 37
- 4-Hydroxyalkenals, animal studies, infectivity and inflammation, **XIV**:60–63
- 8-Hydroxy-2'-deoxyguanosine (8-OHdG)  
 animal studies  
 fibrosis, **XIV**:64–66  
 oxidative DNA damage in welders and, **XIV**:18, 52
- 5-Hydroxyindolacetic acid, manganese exposure studies, **XIV**:85–86
- 4-Hydroxymethyl-uracil (HMdU), DNA biomarkers, **X**:68
- 1-Hydroxypyrene (1-OHP) biomarker  
 biological monitoring techniques, **XIII**:32, 115  
 polycyclic aromatic hydrocarbon exposure, **XIV**:19, 55–57
- Hygiene practices  
 accident and sick leave rates, **XII**:13, 33–35  
 air requirements  
 exposure studies and, **X**:9, 27–29  
 fume generation rates and, **III**:2, 4  
 analysis of, **XI**:8–9, **XIII**:18–20, 51–59  
 protective gear and equipment, **XI**:23–25
- Hyperbaric pressure  
 control devices, **VIII**:11  
 fume exposure studies, **VI**:9, 40–41  
 fume generation rates (FGR), **VII**:15  
 ventilation experiments, **VII**:23  
*in vitro* studies, **VII**:48, **VIII**:7, 43, **IX**:14, 55–56  
 welding emissions combined with, hazards of, **VI**:14
- Hyperopia in welders, epidemiologic studies, **XIII**:91
- Hyperpigmentation, welding and, **III**:13  
 photosensitivity mechanisms, **XIII**:13  
 treatment and epidemiology, **XIII**:26, 94–95
- Hypersensitivity pneumonitis, **X**:10, **XI**:35, **XIV**:83
- Hypertension, welding and, epidemiological studies, **I**:35
- Hypochlorous acid (HOCl), *in vitro* studies of welders, **IX**:14, 56
- Hypoxemia, in respiratory disease, **V**:18
- I**
- Ignition hazard studies, **VIII**:20
- ILO Profusion Grade, pulmonary function testing, **VIII**:27
- IMIS database  
 iron oxide exposure studies, **XII**:12  
 lead exposure studies, **XII**:12, 28
- Immune system. *See also* Central nervous system, specific disorders  
 animal studies of metallic compounds and, **II**:29  
 effects of welding on, **VIII**:7, 40, **IX**:43, **XIII**:29, 105–106  
 foam insulation exposure studies, **VIII**:20  
 hexavalent chromium exposure, **XII**:75  
 metal fume fever pathogenesis, **VI**:34–35  
 mutagenicity tests, **IV**:xix–xx  
 oxidative stress and inflammation in welders and, **XIV**:18, 50–52, 88  
 to toxicity, **II**:xiii  
 unresolved hazard studies, **VIII**:9  
 welding effects, **XII**:8–9, 19, 66–67
- Immunoglobulin A (IgA) levels  
 kidney effects of welding and, **XIV**:53  
 mesangial glomerulonephritis, **XIV**:18  
 welding and, **IX**:43, **XIII**:29, 105–106
- Immunoglobulin E (IgE)  
 asthma in welders, **XII**:40–42, **XIV**:30–31  
 occupational asthma, **XI**:30–35
- Immunoglobulin G (IgG) levels,  
 asthma incidence, **XIV**:30  
 welding and, **IX**:11, 43, **XIII**:29, 105–106
- Immunoglobulin levels  
 effects of welding on, **VIII**:7  
 immune system in welders, **VIII**:40, **XIII**:105–106  
 pulmonary function testing, **X**:31
- Immunoglobulin M (IgM) levels, welding and, **IX**:11, 43, **XIII**:29, 105–106
- Impingement techniques, chromium analysis, **X**:21
- Implantable cardioverter defibrillator (ICD)  
 cardiovascular effects of welding and, **XIV**:52  
 EMF interactions with, **XIV**:18
- Implantation techniques, animal studies of welding effects, **V**:4
- Impotence, welding and, **I**:31
- Impulse oscillometry, pulmonary function in welders, **XIV**:81
- Incidental exposure studies, **XIII**:16, 42–45  
 allergens, **IX**:14, 54  
 cancer in welders and, **IX**:33, 53–54, **X**:9  
 degreasing agents, **IX**:13–14, 53  
 fume exposure, **IX**:8, 53–54  
 laser welding, **IX**:25  
 production coatings, **IX**:14, 26, 53–54  
 radiation, **IX**:8, 26–27
- Inconel alloy, workplace exposure analysis, **XI**:7–8, 18–20
- INCO techniques, chromium compound exposure studies, **V**:7–8
- Indian welders  
 genotoxicity studies, **XIV**:58–59  
 health surveys of, **XIII**:30, 109–110  
 ventilation system studies, **XIV**:26
- Inductively-coupled plasma mass spectroscopy (ICP-MS), **XII**:11  
 applications, **XII**:23  
 thorium analysis, **XIII**:15, 38–39
- Industrial hygiene  
 accidents/personal safety research, **VIII**:19–23, **IX**:28–29  
 fume exposure studies, **IX**:8  
 HETAB surveys, **VIII**:20–21  
 international comparisons, **VIII**:11  
 NIOSH survey, **VIII**:21  
 protective gear, **IX**:27–28  
 risk reduction with, **VIII**:9–10  
 robots, **VIII**:19  
 stress, **IX**:29  
 ventilation and air cleaning equipment, **IX**:27
- Industrial respirators, impact of, on cardiovascular system, **VI**:38
- Inert gas welding. *See* Gas-metal arc welding (GMAW)

- Infection  
 animal studies, **XIV**:20, 60–63  
 incidence in welders, **XIV**:6–7  
 respiratory tract, epidemiology, **XIV**:34–35
- Inflammation  
 alveolar macrophages and, **VII**:24–25  
 animal studies, **VII**:11, 41–42, **XIV**:20, 60–63  
 epidemiologic studies, **XIV**:6, 17–18, 49–52  
 summary, **XIV**:88  
 respiratory system, fume exposure studies, **VI**:27–32
- Influenza  
 animal fume inhalation studies, **I**:103–104  
 welding fume inhalation and, **I**:49
- Infrared (IR) radiation  
 exposure studies, **II**:4, **III**:xiii, **IV**:9–10, **VI**:24–25, **VII**:19–20  
 measurement techniques, **VIII**:14–16  
 eye and vision effects, **I**:26, **II**:13, **VI**:35–37, **VIII**:35–36, **IX**:10, 40  
 laser welding, **IX**:25–26, **X**:23–25  
 protective gear and equipment, **X**:9, 28  
 retinal damage from, **III**:12, **IV**:19
- Infrared spectrometry  
 carbon monoxide analysis, **X**:20  
 chromium compound studies, **III**:3
- Inhalable particulate mass  
 defined, **XI**:17  
 sampling procedures, **XII**:27
- Inhalation studies  
 animal studies, **I**:45–51, **III**:17–18, **XIII**:116–120  
 illness and irritant gas inhalation, **XIV**:3  
 toxicology studies, **IV**:27–28  
 workplace exposure analysis, **XI**:17–20
- Inhaled iron distribution, **XII**:21, 75
- Inhibin B, endocrine system effects in welders, **XIV**:88
- Injuries. *See also* Accidents, Fatalities, specific body parts  
 burns, **I**:39  
 cross-sectional surveys, **XIV**:27  
 ear injuries, **I**:39, **III**:12  
 epidemiologic studies, **IV**:xiv  
 eye injuries, **I**:xvi, xviii–xix, xxii, 25–28, 39–40, **IV**:xvii, 19  
 general statistics, **I**:41  
 incidence of, in welders, **III**:1, **IV**:11  
 infrared radiation exposure, **IV**:9  
 Pakistani welders, **XIV**:12  
 prevalence studies of, **XIII**:57–59  
 skin injuries, epidemiologic studies, **II**:21  
 statistical analysis of, **I**:41, **II**:xix
- Inorganic chemicals, fume exposure studies, **VIII**:18–19
- Interferon, experimental studies with, **II**:xxiv
- Interlaboratory/intermethod round-robin experiments,  
 chromium emissions, **V**:1, 7–9, **VI**:5–6, 20
- Interleukin-1  
 duration of exposure and presence of, **XI**:5–6  
 fume exposure and lung disease, **XI**:57–59  
 metal fume fever and, **IX**:10, 39, **XII**:5–6, 17, 53–54
- Interleukin-6  
 cardiovascular disease in welders and, **XI**:50  
 duration of exposure and presence of, **XI**:5–6  
 metal fume fever and, **X**:5, 49, **XII**:5–6, 17, 53–54
- Interleukin-8  
 animal studies and cell cultures, **XII**:71–72  
 metal fume fever and, **X**:5, 49
- International Agency for Research on Cancer (IARC)  
 cancer in welders, **IX**:3–4, 9, 33–39  
 epidemiologic studies, **XII**:50–51
- International Commission on Radiological Protection (ICRP),  
 thorium exposure studies, **XII**:30–31
- International Institute of Welding Commission VIII, lung  
 cancer study, **X**:4
- Interstitial pulmonary fibrosis  
 case studies of, **IX**:9  
 hard metal coatings exposure, **X**:39–40  
 pneumoconiosis and, **XIII**:21, 66–68  
 welding fumes and, **III**:6–7
- Intracellular penetration, lung toxicity studies, **II**:9, 29
- Intramuscular pressure measurements, musculoskeletal effects  
 of welding, **IX**:11–12, 44–45
- Intraoral electrical activity, underwater welding, **VII**:10, 39–40
- Intraperitoneal effects of welding, animal studies, **I**:102
- Intraperitoneal injection, fertility and welding studies, **IX**:4
- Intratracheal administration (instillation) techniques  
 animal studies, **VI**:45–46, **VII**:7  
 biochemical effects, **VII**:45  
 fume carcinogenicity, **V**:37  
 fume exposure studies, **VI**:11  
 inflammation and fibrosis, **VII**:42  
 pneumoconiosis, **V**:38–39  
 toxicity studies, **III**:17–18, **IV**:27–28
- Intratracheal effects, welding fume suspensions, **I**:47–48, 54
- In vitro* fertilization, reproductive function in welders and,  
**XIII**:12, **XIII**:108–109, **XIV**:54
- In vitro* welding studies, **VII**:12, **IX**:14, 55–56  
 allergic reactions, **IV**:xviii, 24  
 animal research, **IV**:xix  
 fume exposure, **X**:18, 71  
 bacterial assays, **VII**:46  
 carcinogenicity and mutagenicity of welding components,  
**III**:15–16, 18–19  
 cell transformation assays, **V**:41  
 cytogenetic assays, **V**:41–42  
 fume condensate carcinogenicity, **I**:xxii  
 fume exposure, **VI**:11, 46–49  
 bacterial assay, **VI**:46–47  
 carcinogenicity and mutagenicity, **VI**:13–14  
 mammalian cell studies, **VI**:47–48  
 fume-gas-vapor interactions and, **IV**:xx  
 health effects of welding, **V**:4, 40–42  
 hyperbaric pressure, **VII**:48  
 mammalian cell cultures, **VII**:46–47  
 metal carcinogenicity, **II**:31–33  
 mutagenesis assays, **V**:40–41  
 overview, **VIII**:7, 41–43  
 study design, **VII**:13  
 teeth and oral cavity, **VII**:39–40  
 toxicity assays, **II**:xxii, **III**:xv, **IV**:29, **V**:42
- In vivo* studies, overview, **VIII**:7
- Ion chromatography, fluoride analysis, **X**:21

Ionizing radiation. *See* Infrared radiation, Radiation, Ultraviolet radiation

Ion sputtering techniques, particle studies, **V**:7

Iranian welders, pulmonary function testing in, **XIV**:12, 28, 81

Iron alloys and oxides

- animal studies of, **III**:xv, **IX**:14, 56
- epidemiologic studies, **IX**:13, 50
- fume exposure studies, **II**:27–28
- fume inhalation studies
  - in rabbits, **I**:91
  - in rats, **I**:85
- bioavailability studies, **XIV**:49
- biological monitoring, **XIV**:57
- blood levels, in welders, **I**:42–43, **II**:xx
  - manganese exposure, **XIV**:19
- blood pressure studies, **I**:34
- braze welding fume composition, **X**:19
- carcinogenicity studies, **VI**:32–34
- chronic respiratory disease and, **I**:13
- electrode composition, **IV**:2
- ferrous alloys
  - aerosol analysis, **VIII**:13
  - chronic lung disease and, **I**:xv–xvi, xxi–xxii
- Fe/S ratios, pulmonary function testing, **VIII**:27–28
- fibrosis and, **II**:10
- fume generation studies
  - electrode composition, **V**:6
  - voltage and current effects, **V**:5–6
- gas metal arc welding (GMAW), **X**:19
- immune system effects, **IX**:43
- nervous system effects, **VIII**:37–38
- oxidative stress and inflammation and, **XIV**:88–89
- particle generation studies, **IV**:4, **V**:7
  - mycobacterial infection in welders and, **XIII**:6
- plasma arc welding, **IX**:32
- pneumoconiosis and, **II**:xx, 10, **IV**:11, **XIII**:64–68
- pneumonia risk and, **XIV**:6–7
- production coatings, **X**:26–27
- pulmonary retention and clearance, **V**:40
- siderosis epidemiology and, **X**:37, **XIII**:64–68
- workplace exposure limits, **IX**:23, **X**:22–23

Iron overload

- epidemiology, **XIV**:4, 13–14
- pneumoconiosis and, **XIV**:33–34

Iron oxide, workplace exposure studies, **XII**:12, 27–28

Ischemic heart disease, in welders, **XI**:49–50, **XIII**:28, 101–103

Isocyanates

- asthma epidemiology, **XIII**:4–5
- fume exposure studies, in lacquers, **VIII**:18
- incidental exposure to, **XIII**:16, 44–45

Isotope dilution mass spectrometry (IDMS)

- biochemical effects of metallic compounds and, **II**:16
- chromium exposure analysis, **XII**:11, 24
- fume composition analysis, **XII**:24–25

Israeli welders

- bladder cancer in, **XIV**:14
- fertility problems in, **XIII**:106–109

Italian welders

aluminum exposure and neurodegenerative disease in, **XIV**:42–43

cancer incidence in, **XIII**:7–8, **XIII**:75

electromagnetic fields (EMF) exposure among, **X**:47

lung cancer in, **X**:11, 42, **XIII**:7, 23, **XIV**:5, 14, 35

mesothelioma in, **XIV**:14, 36–37

pulmonary function testing, **X**:31

sinonasal cancer in, **XIV**:83

workplace exposure studies, **X**:23

## J

Japanese welders

- mycoplasma infection in, **XIV**:14
- nervous system effects, manganese exposure, **XIII**:100–101
- pneumoconiosis studies, **XIII**:66–68
- pulmonary function testing, **X**:31
- thoriated electrode exposure studies, **XIV**:11, 24

Job-exposure matrix

- lung cancer incidence and, **X**:12, 43–44
- stainless steel/mild steel fumes, **XII**:37–38

## K

Kendall rank correlation, clastagenesis studies, **VIII**:39

Keratitis, ultraviolet radiation and, **II**:13

Keratoconjunctivitis

- epidemiologic studies, **I**:xviii–xix, 25–26, **IV**:xvii, **VIII**:36–37, **IX**:10, 40–41, **X**:50, **XI**:43–44
- radiation effects, **I**:xvi, **II**:xix, **VI**:6, 8, 35–37, **VII**:9, 35–36
- ultraviolet radiation, **II**:4, **III**:16, **IV**:19, **VI**:24–25, 35–37

Keratosis, epidemiologic studies, **XII**:16–17

Keratosis, welding and, **I**:24–25

Kidney function. *See also* Renal system

- aluminum exposure, **IX**:42
- animal toxicology studies, **IV**:28
- biopsy immunofluorescence studies, **V**:20–21
- cadmium exposure, **VI**:9, 34, 38–39, **VII**:4, **IX**:46–48
- cancer epidemiology and, **V**:2, 31, **V**:21, **VII**:3–4, **VII**:9, **IX**:12, **XIII**:23–24, 79–80
- chromium exposure, **IX**:4–5, 46, **XI**:47–49
- epidemiologic studies, **I**:xix, 31, 48, **IV**:xvii, 23, **V**:3, 20–21, **VII**:10, 38–39, **X**:14, 54, **XIV**:18, 52–53
- fume exposure studies, **VIII**:7, 39–40
- lead exposure and, **XIII**:31–32
- in welders, **XI**:13

Knee injuries, in welders, **III**:14, **IX**:43–45

Kratschmer reflex, lung toxicity studies, **II**:9

## L

Laboratory reference values, immune system effects, **XII**:67

Lacquers, isocyanate release, **VIII**:18

Lactate dehydrogenase (LDH)

- animal studies, infectivity and inflammation, **XIV**:60–63
- pulmonary inflammation, **XII**:72–75
- in vitro* studies
  - cytotoxicity, **VII**:47

- mammalian cell cultures, **VII**:12
- Lanthanum, measurement of, **X**:20
- Laryngeal cancer  
 carcinogenicity studies of welding compounds, **VI**:33  
 epidemiologic studies, **XII**:5  
 epidemiology, **XII**:16  
 incidence of, in welders, **V**:2, 25–26, **IX**:9, 36–37
- Laryngitis, incidence in welders, **XIV**:82
- Laser cutting systems, electrode composition, **VIII**:11
- Laser therapy, skin conditions and injuries, **XIII**:26
- Laser welding  
 electromagnetic radiation, **IX**:25–26  
 exposure studies, **IX**:7–8  
 eye injuries in, **IX**:40  
 hazards analysis of, **X**:23–25  
 radiation exposure studies, **VIII**:5, **X**:8
- Laundromat operators, mesothelioma in, **X**:11
- LD50 values, animal studies, **VII**:11–12
- Leaching techniques, fume exposure studies, **VII**:5
- Lead  
 biochemical effects of, **II**:16–17, **III**:14  
 biological monitoring, **VI**:10, 43–44, **VIII**:41–42, **X**:17, 65, **XII**:20, 68–69, **XIV**:19, 55–57, 57  
 blood level studies, **I**:31, **II**:xv, xvi, **IV**:xviii, 24–25  
 bone lead measurements, **X**:59–61  
 cardiovascular disease and, **XI**:50  
 case reports, **X**:38  
 epidemiologic studies, **X**:15–16, 59–61, **XI**:14, 53, **XIII**:31–32  
 exposure studies, **XII**:12, 28, **XIII**:113–114  
 fume exposure studies, **II**:16, **VIII**:12, **IX**:7  
 fume generation studies, electrode composition, **I**:70, **V**:6  
 gastrointestinal effects, **I**:30, 34  
 hair analysis, **II**:xvi, xviii, **VI**:44  
 incidental exposure studies, **XIII**:16, 42  
 lead poisoning treatment, **X**:60–61  
 metal fume fever and, **VIII**:34  
 metallothionein analysis, **X**:60  
 nervous system disorders, **I**:xvi, xix, **IX**:11, 42–43, **XIV**:85–86  
 production coating exposure studies, **VIII**:18–19  
 protective coatings, **IV**:7  
 pulmonary function testing, **XIV**:28  
 radiation exposure studies, **VI**:25  
 reproductive dysfunction, **VIII**:38–39  
 urinary analysis, **I**:44, **II**:xiv, 14  
 whole-body effects of welding, animal studies, **V**:39–40  
 workplace exposure limits, **IX**:23, **X**:8, 22–23, **XIII**:17–18
- Lead-acid batteries, fume exposure studies, **VI**:10
- Lens implants, welding effects on, **VII**:36
- Lenticular cataracts  
 epidemiology, **I**:26  
 pathogenesis, **I**:26–27  
 ultraviolet radiation from welding and, **I**:xviii
- Leukemia. *See also* specific types of leukemia  
 carcinogenicity studies, **VI**:34  
 electromagnetic field exposure, **IX**:10, 38, **X**:4, 12, 47–48, **XI**:4, **XIII**:23–24, 85–87  
 epidemiologic studies, **VII**:3–4, 8–9, **VIII**:32–33, **XII**:51–52, **XIV**:5, 14, 36
- Leukocytes  
 cardiovascular disease in welders and, **XI**:50  
 migration, animal studies, **IV**:25
- Leukocytosis  
 metal fume fever and, **I**:xix, **XIII**:89  
 welding and, **I**:30–31
- Leukopenia  
 fume particulates, **II**:14  
 in welders, **I**:31
- Levodopa (L-dopa)  
 manganese intoxication and, **I**:29  
 manganese-induced parkinsonism, **XIV**:16, 45, 86–87
- Lichen sclerosus et atrophicus, **XIII**:26, 94–95
- Life-style factors. *See also* e.g., Smoking, specific factors  
 as risk index, **VIII**:9–10  
 role of, in epidemiologic studies, **II**:xxiii, **III**:19  
 welding hygiene and, **II**:xiii
- Ligament disorders, welding and, **I**:xix
- Light. *See* radiation, visible light
- Line spectra, in welding arc, **I**:76
- Lipid peroxidation, **XII**:21  
 animal studies, **VII**:45, **IX**:15, 56–57  
 current research, **X**:5  
 genotoxicity studies, **XIV**:59  
 oxidative stress and, **XIV**:50–52
- Lipoid pneumonia, incidental exposure to surface coatings, **IX**:54
- Listeria monocytogenes  
 animal studies, **XIV**:20, 60–63  
 pneumonia risk in welders and, **XIV**:7
- Lithium  
 animal toxicology studies, **IV**:28  
 electrode composition, **V**:6
- Litigation bias, manganese exposure studies, **XIV**:44–46
- Liver cancer  
 epidemiologic studies, **VIII**:33, **X**:4, 47  
 in Finnish welders, **X**:12
- Liver damage  
 animal studies, **I**:88–89, **IX**:14–15  
 cancer epidemiologic studies, **VIII**:6  
 childhood cancer mortality rates, **VIII**:33  
 effects of welding on, **III**:14  
 epidemiologic studies, **I**:35–36, **IV**:xviii, 21  
 fume exposure studies, **II**:14  
 fume inhalation studies, rat studies, **I**:46  
 metallic compound exposure studies, **II**:xv, xx–xxi
- Lobar pneumonia  
 classification as occupational disease, **X**:10  
 epidemiologic studies, **XIV**:6–7, 14, 34–35  
 as occupational disease, **X**:3
- Local exhaust ventilation (LEV)  
 exposure studies, **XII**:12, 29  
 hygiene and work practices, **XIII**:3–4, 18–19, 51–59  
 magnetopneumographic analysis, **XII**:43  
 pulmonary function testing and, **XI**:3, 9, 28–30  
 thorium exposure, **XII**:12  
 workplace exposure studies, **XII**:3–4

Logistic regression, epidemiologic studies, **VIII**:32

Lower back pain, epidemiologic studies, **XI**:12–14, 47

Low molecular weight (LMW) proteins  
cadmium and chromium exposure, **IX**:46  
proteinuria, in kidney disease, **V**:21

Lumbosacral radiculitis, **IV**:22

Lung cancer. *See also* Respiratory disease  
asbestos exposure and, **VII**:8–9, **VIII**:29  
duration of exposure and risk of, **XI**:5  
epidemiologic studies, **I**:xviii, xxi, **IV**:xvi–xvii, **VI**:32–34, **VII**:3–4, 30–31, **VIII**:31–33, **IX**:3–4, 9, 33–37, **X**:1, 4, 11–12, 40–48, **XI**:4, 10–11, 36–40, **XII**:5, 15–16, 46–50, **XIII**:6–7, 22, 75–79, **XIV**:14, 35–36, 83  
fume carcinogenicity studies, **II**:xxi, 18, **VI**:13  
fume exposure studies and, **IV**:15–19  
incidence in welders, **IV**:xiii–xiv, **V**:2, 27–30  
metal analysis in welders and, **IX**:22  
mortality studies, **I**:22–24  
pneumoconiosis epidemiology and, **XIII**:69  
screening procedures, **VII**:34  
welding and, **XIII**:6–7, **XIV**:5

Lung function test. *See* Pulmonary function testing

Lungs. *See also* Pulmonary function testing, Pulmonary retention and clearance, Respiratory system  
animal fume inhalation studies  
in rabbits, **I**:90–91  
in rats, **I**:83–86  
chronic disease, assessment procedures, **I**:81–82  
ciliary movements, **II**:9  
collagen content, rat fume inhalation studies, **I**:46, 86, 95–97  
diffusion capacity research, **VI**:29–32  
inflammation, metal fume fever and, **X**:48–49  
intratracheal administration of fume suspensions, in rats, **I**:94–97  
particle burden, magnetopneumographic measurement, **XI**:42–43  
pathogenesis of disease, **I**:81  
retention and clearance functions (*See* Pulmonary retention and clearance.)  
restriction, incidence in welders, **X**:31  
tissue biopsies, asbestos bodies, **X**:37–38  
toxicity studies, **II**:9  
welding fume distribution in, **I**:48

Lung transfer factor  
carbon monoxide testing, **X**:30  
shipyard welders, **X**:9  
single-shift tests, **X**:3, 32

Lung weight/body weight ratio, animal studies  
fume exposure studies, **VI**:10–11  
pneumoconiosis, **V**:38–39

Lupus erythematosus (LE), in welders, **I**:40

Luteinizing hormone (LH)  
animal studies of, **X**:17, 69–70  
chromium exposure and levels of, **X**:14–15  
fertility in welders, **IX**:48–49, **X**:4, 56–58

Lymphatic system  
clearance capabilities, iron exposure, **II**:28  
drainage, lung toxicity studies, **II**:9

Lymphocyte proliferation test (LPT), chronic beryllium disease (CBD), **XI**:52

Lymphocytes  
chromium exposure studies, **IX**:5, 13, 51  
chromosomes, fume exposure studies, **VI**:10

Lymphocytosis, in welders, **I**:31

Lymphoma, epidemiologic studies, **XI**:41

Lymphosarcoma  
fume exposure studies, **II**:20  
incidence in welders, **IX**:36

Lysozyme levels, periodontal disease in welders and, **IX**:12, 49

## M

alpha-2-Macroglobulin  
animal gene expression studies, **X**:73–74  
protein synthesis induction and, **X**:5

Macromolecules, anti-oxidant effect on, **X**:5

Macular hyperpigmentation, pathogenesis, **I**:28

Maculopathy  
arc welding, **XI**:3, 12  
epidemiologic studies, **IX**:10, 40–41, **X**:50, **XI**:44, **XIII**:25, 92–93  
retinal injury rates, **XII**:17

Magnesium  
animal fume inhalation studies, **I**:86–88  
fume exposure studies, **IX**:7  
fume generation studies, electrode composition, **V**:6  
ozone generation and, **IV**:xv, 6  
radiation exposure studies, **III**:5, **VI**:25

Magnesium oxide, metal fume fever, **XII**:54

Magnetic field dosimetry, radio frequency radiation, **VIII**:17

Magnetic flux density  
electromagnetic field exposure, **XII**:32–33  
ELF exposure studies, **VIII**:16

Magnetic fume components, stability studies, **VII**:4, 26  
Magnetic resonance imaging (MRI), manganese exposure, **X**:58, **XII**:6–8, 17–18, 57–61, **XIV**:44–45

Magnetic-susceptibility plethysmography (MSPG), hemochromatosis analysis, **XI**:43

Magnetite  
chromium compound exposure studies, **V**:8  
particle analysis, **VI**:21–23  
pulmonary retention and clearance, **VII**:26  
shielded metal arc welding (SMAW), **VII**:4

Magnetophosphenes, retinal damage and, **III**:12

Magnetopneumography (MPG)  
biological monitoring with, **IV**:xiv, **V**:22–23  
epidemiologic studies and, **XI**:11, 41–43  
particle retention studies, **IV**:11–12, **VII**:7, 25–26, **VIII**:6  
respiratory assessment in welders, **IV**:xiii, xvi, **V**:19, **XII**:14–15, 42–43

MAK (maximum safe workplace concentration) values, in protective coatings, **IV**:7–8

Male welders, reproductive disorders in, **X**:1, **XIII**:12, 30

Malondialdehyde  
animal studies  
anti-oxidants, **X**:70–71  
infectivity and inflammation, **XIV**:60–63

- biochemical studies, **VII**:45  
 genotoxicity studies, **XIV**:59  
 oxidative stress and inflammation, **XIV**:50–52, 88
- Mammalian cell cultures. *See also* specific types of cells  
 fume exposure studies, **VI**:11, 47–48, **VII**:12, 46–47  
 toxicological research, **IV**:xviii–xix  
*in vitro* studies, **II**:32–33, **IV**:29, **VIII**:41–43  
 transformation assays, **V**:4, 41
- Mammalian spot tests, fume particle mutagenicity, **III**:xv, 19
- Manganese  
 aerosol analysis, **VIII**:13  
 allergic reactions to, **IV**:24  
 animal studies, **II**:28–29, **VI**:45–46, **XIV**:66  
   distribution and excretion studies, **I**:98–100  
   infectivity and inflammation, **XIV**:20, 62–63  
   pulmonary retention and clearance, **VII**:11, 43  
   toxicity effects, **VII**:44–45  
   whole-body effects of, **V**:40  
 bioavailability studies, **XIV**:9, 17, 49  
 biochemical effects, **III**:xiv, 14  
 biological monitoring, **V**:3, 21–23, **VI**:43, **VII**:10–11, 40, **X**:16–17, 65, **XII**:20, 68, **XIII**:32, 114–115, **XIV**:19, 55–57, 57, 89  
 cardiovascular effects of, **V**:3, 20  
 central nervous system effects, **II**:xx, 14  
 chronic managanism, **I**:29–30  
 clastogenesis and, **VIII**:39  
 cognitive effects, **XII**:59–61  
 combined exposure measurements, **VI**:14  
 DNA biomarkers, **X**:68  
 dust, levels in, **X**:7  
 electrode composition, **VIII**:12  
 epidemiologic studies, **XI**:13, 52, **XII**:6–8, 17–18, **XIV**:1  
 fecal analysis, **II**:xviii  
 fertility and, **XI**:13, 51  
 flux cored arc welding  
   fume generation, **X**:19  
   workplace exposure studies, **XIV**:12  
 fume composition studies, **X**:7, **XIII**:14, **XIII**:34–37  
 fume exposure studies, **IV**:xv, **IX**:7, **X**:15, 58  
   animal studies, **VI**:10–11  
   hair analysis, **VI**:10  
 fume generation studies, **I**:70, **III**:xiii, 3, **IX**:20  
   electrode composition, **V**:6  
   voltage and current effects, **V**:5–6  
 gas metal arc welding, **X**:19  
 genotoxicity studies and, **X**:17  
 hair analysis of, **VI**:44  
 immune system effects, **IX**:43  
 local exhaust ventilation systems, **XIII**:3–4  
 metal fume fever, **IV**:xviii, **VIII**:34  
 nervous system effects, **I**:xvi, xix, **IV**:xvii, 21–22, **VII**:37, **VIII**:37–38, **IX**:11, 42–43, **XI**:12, 46, **XII**:57–61, **XIII**:11, 27–28, 98–101, **XIV**:1, 7–9, 16, 43–49, 85–86  
 oxidative stress and inflammation, **XIV**:88  
 Parkinson's disease and, **XIV**:1, 8–9, 16–17, 44–45, 86  
 particle analysis, **IV**:4, **V**:7, **VI**:23  
 plasma arc welding, **IX**:32  
 pulmonary function testing, **VII**:27–28  
 pulmonary retention and clearance rates  
   animal studies, **V**:40  
   particle analysis, **VIII**:26–27  
 relative fume formation rate (RFFR) and, **IX**:20  
 sources of, in welding, **I**:3  
 teeth and oral cavity effected by, **IV**:23  
 urine studies of we and, **I**:44  
*in vitro* studies  
   sister chromatid exchange (SCE), **VII**:46–47  
   toxicity studies, **IV**:29  
 ventilation studies and exposure to, **XIV**:12  
   general dilution ventilation, **XIV**:26  
 workplace exposure studies, **IX**:23, **X**:7, 22–23, **XIII**:17–18, 49–51
- Manganese-copper alloys, electrode composition, **IV**:2
- Manganism, **XII**:6–8  
 biological monitoring, **XIV**:89  
 diagnosis and pathogenesis, **I**:29–30  
 endocrine system effects, **XIV**:88  
 epidemiology of, **XIII**:11, 27–28, 98–101, **XIV**:8–9  
 genetics studies, **XII**:7–8, 61  
 neuropsychological function and, **XIV**:44–45, 87
- Mangjet electrodes, ventilation systems and exposure to, **XIV**:26
- Mantel Haenszel odds ratio  
 epidemiologic studies, **VIII**:32  
 leukemia epidemiology, **VII**:32  
 multiple sclerosis epidemiology, **VIII**:37
- Manual metal arc (MMA) welding. *See* Shielded metal arc welding (SMAW)
- Mass median aerodynamic diameter (MMAD)  
 particle analysis, **VII**:6, 18–19  
 workplace exposure analysis, **XI**:20–21
- Material safety data sheet (MSDS)  
 OSHA regulations, **VIII**:21  
 sampling procedures, **XII**:27
- Maternal occupational exposure, fume studies, **V**:33
- Maximal mid-expiratory flow volume (MMFV)  
 pulmonary function testing, **I**:82  
 respiratory tract exposure studies, **IV**:14–15
- Maximal voluntary ventilation (MVV) measurements  
 pulmonary function testing, **XIV**:12  
 respiratory changes in welders, **XIV**:27–30
- Maximum admissible limits (MALs), workplace exposure analysis, **XIII**:18, 49–51
- Maximum allowable concentration (MAC) values, phosgene incidental exposure, **XIII**:43
- Maximum expiratory flow (MEF)  
 pulmonary function testing, **VII**:26–29, **X**:31, **XI**:26–30, **XII**:39–40, **XIV**:29  
 respiratory tract exposure studies, **IV**:14–15, **V**:15, **VI**:28–32
- Maximum permissible exposure (MPE) limit  
 electromagnetic radiation, **XII**:12–13, 31–32  
 radiation-induced skin effects, **VII**:37  
 workplace exposure studies, **XII**:3
- Maximum voluntary contraction (MVC) measurements, welding studies with, **X**:53–54

- MDI-based PUR-insulated district heating pipes, isocyanate exposure for welders of, **XIII**:16, 44–45
- Mean respirable dust concentration, workplace exposure studies, **X**:8
- Medical history  
 epidemiological studies with, **I**:xxi, **II**:xxiii  
 health effects of welding and, **IV**:25  
 respiratory effects of welding assessed with, **III**:8–9  
 surveillance procedures, toxicity assessment, **III**:19
- MEF fume extractor, ventilation systems analysis, **XIII**:53–59
- Memory function  
 aluminum exposure and, **XIV**:7, 16, 42–43, 85  
 manganese exposure studies, **XIV**:8–9, 87  
 thorium exposure, **XIII**:38–39
- Meningiomas, epidemiology, **VII**:33
- Mercury  
 ELF exposure studies, **VIII**:16  
 epidemiologic studies, **X**:15, 59–61, 65–66, **XIII**:31, 112–113  
 nervous system effects, **IX**:42  
 in paints, fume exposure studies, **VI**:25–26
- Mercury/hydride atomic absorption spectrometry, urine analysis, **X**:7, 21
- Mesothelioma  
 asbestos exposure and, **IV**:18–19, **X**:39–44  
 carcinogenicity studies, **VI**:33–34  
 epidemiologic studies, **VIII**:31, **IX**:4, 36, **XII**:15–16, **XIV**:14, 36–37  
 incidence of, in welders, **V**:2, 12, 30–31  
 shipyard welding and, **X**:3, 11–12
- Messenger RNA (mRNA), animal gene expression studies, **X**:72–74
- Metal active gas (MAG) welding  
 clastogenesis and, **VIII**:39  
 electrode composition, **VIII**:12  
 infrared radiation exposure studies, **VIII**:14  
 oculomotor studies, **VIII**:37–38
- Metal fume fever, **X**:3  
 animal studies, **I**:48–49, 103, **X**:18, 70, **XII**:20–21, 71–72, **XIII**:33, **XIII**:118–120  
 in apprentice welders, **XIV**:13  
 asthma and, **XIV**:31  
 cadmium exposure, **IX**:50  
 in Canadian welders, **XIV**:13  
 case reports, **XIII**:88–89  
 cell cultures, **XII**:20–21, 71–72  
 epidemiologic studies, **I**:38–39, **III**:14, **IV**:xviii, 23, **V**:3, 13, 20, **VII**:9, **VIII**:6, 34–35, **IX**:10, 39, **X**:5, 12, 48–49, **XII**:5–6, 17, 53–54, **XIII**:9–10, 24, 87–89, **XIV**:15, 38–39  
 fume exposure studies, **II**:15–16, **VI**:8, 34–35  
 gastrointestinal effects, **I**:xix, 34  
 metallic compound exposure studies, **II**:xxi  
 metallothionein levels and, **X**:5  
 pathogenesis, **I**:37–38  
 production coatings, fume exposure studies, **VI**:26  
 symptoms, **I**:xv  
 zinc fumes, **I**:xv, 38–39, **III**:11
- Metal-glass welding, ELF exposure studies, **VIII**:16
- Metal inert gas (MIG) welding. *See* Gas metal arc welding (GMAW)
- Metallic compounds. *See also* Specific metals  
 animal studies, **II**:29–30  
 asthma and exposure to, **X**:33, **XIV**:3  
 biochemical testing for, **II**:xiii–xviii  
 biological monitoring, **IX**:22, **XII**:20, 67–70, **XIV**:19  
 bladder cancer and, **XIV**:5  
 blood analysis, **II**:xiv–xv  
 bronchitis and exposure to, **X**:33  
 carcinogenicity studies, **II**:29–30, **VII**:33–34  
 fume generation rates, **I**:70, **III**:xiii  
 genotoxicity studies, **XIV**:58–59  
 hair analysis for, **XI**:56  
 immune system effects, **XII**:67  
 inductively-coupled plasma mass spectroscopy (ICP-MS), **XII**:11  
 inflammation and oxidative stress and, **XIV**:88  
 lipid peroxidation techniques, **IX**:56–57  
 local exhaust ventilation, **XII**:29  
 metal fume fever and, **II**:15  
 nervous system effects, **XII**:56, **XIV**:85–86  
 pneumoconiosis epidemiology and, **XIII**:64–68  
 pneumonia incidence and, **X**:3  
 pulmonary retention and clearance studies, **IV**:12–13  
 urine analysis studies, **II**:xiv  
*in vitro* studies, **II**:31–33  
 in welders, **IX**:12–13, 49–50, **XI**:13–14, 52–53  
 workplace exposure limits, **XIV**:12
- Metallothioneins  
 animal studies, **X**:73–74  
 lead exposure studies, **X**:15, 60  
 protein synthesis induction and, **X**:5
- Metal oxides  
 fume exposure studies, **VI**:6  
 lung injury and, **X**:1  
 ozone emission studies, **VI**:23
- Methacholine  
 asthma in welders, **XIV**:31  
 pulmonary function testing with, **X**:9, 29–31, **XIV**:3
- Methemoglobin, animal fume inhalation studies  
 guinea pig studies, **I**:92–93  
 in rabbits, **I**:91  
 in rats, **I**:84–85
- Methyl chloroform, as degreasing solvent, **I**:76
- Mice  
 arc welding radiation studies, **I**:105  
 fume inhalation studies, **I**:47, 94, 99–101  
 intraperitoneal effects, studies of, **I**:102  
 iron compound exposure studies, **II**:27  
 nickel exposure, biochemical effects, **II**:29  
 tuberculosis from fume inhalation in, **I**:104
- “Microciliary escalator,” metal compound exposure and, **II**:29
- beta-2-Microglobulin  
 cadmium exposure studies, **VI**:9, 38–39, **IX**:46  
 chromium exposure, kidney disease and, **X**:54–55  
 epidemiologic studies of kidney damage, **VII**:10, 38–39  
 urogenital tract studies, **VIII**:39–40

- Micronucleus assay, genotoxicity studies, **XII:20**, **XIV:20**, 58–59
- Micro-Orifice Uniform Deposit Impactor (MOUDI), workplace exposure studies, **XII:26–27**
- Mild steel (MS) welding, **XIII:75–79**  
 aluminum exposure, nervous system effects, **XIII:10–11**, 97–98  
 alveolar macrophages, **VIII:6**  
 animal studies  
   fume exposure, **XI:14**  
   infectivity and inflammation, **XIV:20**, 60–63  
   inflammation and fibrosis, **VII:11**  
   pneumoconiosis, **V:37–39**  
 asthma and, **XIV:31**  
 bronchitis and asthma incidence and, **X:10**, 33–34  
 cancer incidence and, **VIII:6**, **IX:4**  
 challenge test results, **XII:41**  
 chromium exposure studies, **IX:51**  
 fertility rates and, **IX:4**, 12, 48–49, **X:4**, 57–58  
 fume exposure and lung disease, **XI:57–59**  
 fume generation rates, **IX:20–21**  
 job-exposure matrix, **XII:37–38**  
 lung cancer incidence and epidemiology, **V:28–30**, **VII:33**, **IX:9**, 36–37, **X:41**, **XII:15–16**, **XIV:35**, 83  
 manganese exposure, **X:16–17**  
 neurodegenerative disease and, **XIV:9**  
 occupational asthma, **XI:32–35**  
 particle analysis, **VII:6**  
 pneumonia risk and, **XIV:7**  
 pulmonary function testing, **V:3**, **VI:29–32**  
 pulmonary retention and clearance studies, **V:40**, **VII:7**, 43–44  
 reproductive function and, **XIV:10**  
 respiratory disease and, **V:15**, 19, **XII:21**, 72–75  
 skin effects, **VII:37**, 53  
 ultraviolet radiation exposure studies, **VI:24**  
*in vitro* studies  
   bacterial assays, **VII:46**  
   cytotoxicity, **VII:47**  
   mammalian cell cultures, **VII:12**  
   workplace exposure analysis, **XIII:18**, 46–51
- Mild steel-pulse (MS-PULSE) welding, fume exposure and lung disease, **XI:57–59**
- Mild steel-spray (MS-SPRAY) welding, fume exposure and lung disease, **XI:57–59**
- Millwrights, carcinogenicity studies of, **VI:34**
- Mineral glass filters, specification studies, **X:9**, 28
- Mining, injury rates and, **II:7**
- Minnesota Multiphasic Personality Inventory (MMPI), manganese intoxication assessment, **I:29–30**
- Mison gas, nitrogen oxide generation, **VIII:14**  
 fume generation studies and, **XIII:36–37**
- Missouri Cancer Registry, epidemiologic studies of welders, **VIII:32**
- Mitotic delay assays, *in vitro* studies, **VII:46**
- Mixed dust pneumoconiosis, x-ray studies, **I:7–11**
- Mixed pulmonary disease, prevalence of, in welders, **V:2–3**
- Molecular biology, lung cancer epidemiology, **XII:50**
- Molecular weight proteins  
 cadmium exposure studies, **VI:9**, 39  
 epidemiological studies of kidney damage, **VII:10**, 38–39
- Molybdenum  
 biological monitoring of, **XIII:32**  
 blood studies, **II:xx**  
 fume generation studies, voltage and current effects, **V:5–6**  
 liver damage from, **II:14**  
 “Monday fever.” *See* Metal fume fever
- Monkeys, arc welding radiation studies, **I:106**
- Monoamine oxidase (MAO), manganese levels, animal experiments, **II:28**
- Morbidity studies, health effects of welding, **V:23–24**
- Mortality rates. *See also* Standardized mortality ratios (SMR)  
 accidental deaths compared with fume exposure effects, **II:22**  
 bladder cancer, **II:18–19**, **V:31**  
 carcinogenicity of welding compounds, **II:xxi**, **VI:33–34**  
 epidemiologic studies, **III:16**, **VIII:32**  
   lung cancer, **VII:31**, 33  
   study design, **II:xxiii**  
 fume exposure studies, **VI:7–8**  
 lung cancer incidence and, **II:18**, **IV:xvi–xvii**, 16–17, **V:28–30**, **XIV:14**, 36  
 mesothelioma in welders, **V:2**  
 nasal sinus cancer, **II:18**  
 nasopharyngeal cancer, **V:24**  
 neurodegenerative disease in welders and, **XIV:8–9**, 17, 42–49  
 pneumonia in welders, **V:2**, **X:3–4**, **XIV:6–7**  
 respiratory disease, **V:13–15**, **VI:31–32**
- Mössbauer spectroscopy, particle retention in lungs, **VII:7**, 26
- Motor neuron disease (MND), epidemiologic studies, **X:13**, 51–52, **XIV:41–49**
- Multiple myeloma  
 epidemiologic studies, **XII:51–52**  
 incidence in welders, **V:34**
- Multiple Orifice Uniform Deposit (cascade) Impactor (MOUDI), fume composition studies, **XI:16–17**
- Multiple sclerosis, incidence of, in welders, **VIII:37**, **X:13**, 52
- Multi-regression analysis, manganese exposure studies, **XIV:43**
- Multisensor integration, welding robotics, **VIII:19**
- Muscle fatigue, welding and, **I:37**
- Muscular stress, working conditions and, **IX:8**
- Musculoskeletal system  
 effects of welding on, **II:14**, **III:xiv**, 14  
 epidemiologic studies, **I:36–37**, **IV:xvii**, 22–23, **VI:8–9**, 38, **VII:10**, 38, **IX:11–12**, 43–46, **X:14**, 53–54  
 ergonomic studies, **IV:xx**, **VIII:7**, 38  
 hand-arm vibration syndrome, **XIII:28**, 103–104  
 hygiene and work practices and, **XII:34–35**  
 metal fume fever pathogenesis, **VII:35**  
 posture, **IV:22**  
 shoulder pain, **IV:22**  
 welding effects in, **XI:12–14**, 46–47
- Mutagenicity. *See also* Carcinogenicity  
 chromium compounds, **III:2–3**  
 epidemiologic study design, **I:xxii**, 55, **IV:xix–xx**  
*in vitro* studies, **II:31–32**, **III:18–19**



assays, **IV**:29, **V**:40–41  
 bacterial assays, **VI**:11, 46–47, **VII**:46  
 techniques, **VI**:13–14  
 welding fumes and gases, **III**:xv, 15–16  
 Mycobacterial infection in welders, **IX**:9, **XIII**:22, 70–71  
 pneumoconiosis and, **XIII**:6  
 Mycoplasma infection in welders, **XIV**:14, 35  
 Myoclonic involuntary movement, manganese exposure and,  
**XIII**:11, 27–28, 100–101  
 Myopia in welders, epidemiologic studies, **XIII**:91

## N

*n*-Acetyl glucosaminidase (NAG), pulmonary inflammation,  
**XII**:72–75  
 Nail analysis  
 biochemical effects of welding compounds, **IV**:25  
 manganese levels, **XIV**:57  
 Nasal cancer  
 epidemiologic studies, **VII**:9, 32, **IX**:9, 36–37, **XII**:16,  
 50–51  
 fume carcinogenicity studies, **II**:xxi, 18  
 incidence of, in welders, **V**:2, 24–25, **VII**:3–4  
 screening procedures, **VII**:34  
 Naso-pharyngeal cancer. *See* Sino-nasal cancer  
 National Cancer Registry, nasal cancer epidemiologic studies,  
**V**:24–25  
 National Heart and Lung Institute (London), work-related  
 respiratory disease studies, **XIV**:3  
 National Institute of Occupational Safety and Health (NIOSH)  
 “criteria document” for welding standards, **VIII**:22  
 electrocutions, **XII**:13, 35–36  
 Hazard Evaluations and Technical Assistance Branch  
 (HETAB), **VIII**:20  
 industrial health survey, **VIII**:21  
 sampling technique, ozone exposure studies, **V**:10  
 National Technical Information Service (NTIS), published  
 accident/safety reports, **VIII**:19  
 Natural killer (NK) cells  
 immune system effects of welding, **XII**:8–9  
 welding effects and, **XII**:67  
 Nd:YAG lasers, accidents and injuries, **X**:24–25  
 Neck injuries, welding and, **IX**:11–12, 43–45  
 Neoplasms. *See* Cancer  
 Nephelometry, ultrafine particle analysis, **XIII**:73–74  
 Nephrolithiasis, cadmium exposure and, **XIV**:53  
 Nervous system. *See also* Brain cancer, specific disorders  
 aluminum exposure, **XI**:12, 46, **XII**:56, **XIII**:10–11, 26–27,  
 96–98, **XIV**:7, 42–43, 85–86  
 animal fume inhalation studies, **I**:88  
 barium exposure, **X**:61–62  
 cancer epidemiology, **XI**:40  
 effects of welding on, **III**:14, **X**:13–14, 51–53, **XIII**:10–11  
 ELF exposure studies, **VIII**:16  
 EMF exposure studies, **IX**:10, 38  
 epidemiologic studies, **I**:xix, xvi, 28–30, **III**:14, **IV**:xvii,  
 21–22, **VIII**:7, 37–38, **IX**:11, 42–43, **XI**:12, 45–46  
 fume exposure studies, **VI**:38, **VII**:37  
 hyperbaric pressure studies, **VI**:9, 40

lead exposure studies, **X**:60–61  
 manganese exposure, **II**:14, **VI**:43, **X**:58, **XII**:18, 57–61,  
**XIII**:10–11, **XIII**:11, 27–28, 98–101, **XIV**:7–9, 43–49,  
 85–86  
 meningioma epidemiology, **VII**:33  
 mercury exposure studies, **X**:58–59  
 metallic compound exposure, **II**:xx, **XIV**:85–86  
 vibration disorders, **IV**:21–22  
 Netherlands, welders in  
 absenteeism trends in, **XIII**:69–70  
 asthma and bronchitis in, **X**:32–35  
 fume exposure studies, **VI**:15  
 lung cancer incidence, **X**:43–44  
 prostate cancer epidemiology, **XIV**:14, 38  
 reproductive function studies, **XIV**:53–54  
 workplace exposure limits, **IX**:23  
 Net thoracic magnetic moment, lung particle retention, **V**:20  
 Neurbehavioral Core Test Battery (NCTB), manganese  
 exposure studies, **XIV**:85–86  
 Neurobehavioral testing  
 aluminum exposure, **XIV**:85  
 endocrine system effects in welders, **XIV**:88  
 manganese exposure studies, **XIV**:8–9, 43–44, 85–86  
 Neuroblastoma  
 electromagnetic field exposure and, **XII**:16–17, 53  
 incidence of, in welders, **V**:33  
 Neuropsychological testing  
 aluminum exposure in welders, **XIII**:10–11, 26–27, 97–98  
 biological monitoring studies, **XIII**:114–115  
 manganese exposure in welders, **XII**:18, 59–61, **XIII**:11,  
**XIV**:16, 43–44, 87  
 Neutron activation analysis  
 biological monitoring studies, **V**:23, **VII**:17  
 cadmium, **V**:3  
 manganese, **III**:14  
 electrode composition, **VI**:19–20, **VII**:16  
 fume composition analysis, **X**:7  
 gas metal arc welding (GMAW), fume composition, **X**:20  
 mixed fume animal studies, **I**:101  
 Neutrophil counts  
 infectivity and inflammation studies, **XIV**:20  
 metal fume fever, **VIII**:34  
 oxidative stress and inflammation in welders and, **XIV**:6  
 Nevi formation in welders, treatment and epidemiology,  
**XIII**:26, 94–95  
 New Zealand welders  
 cancer epidemiologic studies, **VII**:31  
 lung cancer incidence in, **X**:41–42  
 pulmonary function testing, **X**:32, **XIV**:12, 28  
 Nickel compounds  
 aluminum alloys with, ozone exposure studies, **V**:10  
 analysis, **X**:7, **XI**:7, 17  
 animal studies  
 allergic reactions, **VII**:12  
 biochemical effects, **IV**:24  
 carcinogenicity studies, **II**:29–30  
 fume exposure studies, **II**:28–29, **VI**:45–46  
 infectivity and inflammation, **XIV**:20, 62–63  
 pulmonary retention and clearance estimation, **VII**:42–44

- in rats, **I**:83–88  
 toxicity effects, **IV**:xviii, 27–28, **VII**:11–12, 44–45  
 whole-body effects of, **V**:40
- asthma and, **III**:8
- biochemical effects, **II**:16–17, **III**:xiv, 14, **IV**:24–25
- biological monitoring of, **V**:3, 21–23, **VIII**:41, **IX**:13, 22, 52, **X**:16, 63, **XIII**:32, 114–115, **XIV**:19, 55, 89  
 polycyclic aromatic hydrocarbons, **XIV**:55–57
- blood level studies, **II**:xv, xx, **IV**:24
- carcinogenicity studies, **I**:xxi–xxii, **IV**:xiii–xiv, xvi–xvii, xix, **VI**:32–34, **VII**:4, 13, 33–34, **IX**:33, **X**:1
- cell culture studies, **V**:41, **VI**:47–49
- clastagenesis and, **VIII**:39
- DNA biomarkers, **X**:68
- DNA damage, **VIII**:33–34
- electrode composition, **IV**:2, **VIII**:12
- epidemiologic carcinogenicity studies, **VI**:13
- fecal analysis, **II**:xviii
- fume composition studies, **X**:7, 21
- fume exposure studies  
 animal studies, **VI**:11, 45–46  
 biological monitoring techniques, **VI**:9–10, 41–43, **VII**:5, 16  
 cancer incidence and, **VI**:7–8  
 pulmonary function testing, **VI**:29–32, **IX**:7
- fume generation studies, **III**:xiii, 3, **IX**:20  
 electrode composition, **I**:70
- genotoxicity studies and, **X**:17, **XIV**:57–59
- hypersensitivity to, **X**:51
- immune system effects, **IX**:43
- inflammation and oxidative stress and, **XIV**:88
- kidney function and, **VII**:10, 39
- lung cancer epidemiology, **II**:xxi, 18, **IV**:15–19, **V**:29, **X**:11–12, 43–45, **XI**:37–40, **XII**:49–50, **XIV**:35–36
- mammalian cell studies, **VIII**:42–43
- nasal sinus cancer, **II**:xxi, 18
- nervous system effects, **IX**:42
- ozone exposure studies, **V**:10
- particle studies, **V**:7
- perspiration analysis, **II**:xv
- plasma arc welding, **IX**:32
- pulmonary function testing, **IV**:15, **VI**:13, **VII**:27–28, **IX**:31, **XIV**:28  
 voltage and current effects, **V**:5–6
- pulmonary retention and clearance studies  
 animal studies, **V**:40  
 estimation techniques, **IV**:12–13
- reproductive function in welders and, **XIV**:9–10, 18–19
- respiratory system and, **IV**:xiii–xiv, **V**:12–13, **VII**:13  
 cancer incidence, **I**:xxi–xxii
- shielded metal arc welding, fume composition, **I**:2, 59–60
- stainless steel welding and, **I**:3
- tissue biopsy studies, **X**:37–38
- urine analysis studies, **I**:44, **II**:xiv, 14, **IV**:24
- ventilation systems analysis, **XIII**:56–59
- in vitro* studies, **IV**:xix, **V**:4, **VI**:13–14  
 carcinogenicity studies, **II**:32–33  
 sister chromatid exchange (SCE), **VII**:46–47  
 toxicity studies, **IV**:29  
 workplace exposure studies, **X**:8, 22–23, **XIII**:18, 49–51
- Nigerian welders  
 accident analysis, **XIII**:20  
 eye injuries in, **XIII**:25, 91, **XIV**:84  
 morbidity studies of, **V**:24  
 pulmonary function studies, **VII**:28–29, **XIII**:20, 60–61
- Nitric oxide  
 exposure studies, **XII**:45  
 fume exposure studies, **XIII**:34–37  
 pneumonia infection and, **XIV**:7  
 ozone generation and, **IV**:6, **IX**:25, **XI**:17
- Nitrogen compounds  
 electrode composition, **IV**:2  
 fume exposure studies, **IV**:1  
 oxidative stress and, **XIV**:6  
 pulmonary function testing, **XIV**:29  
 workplace exposure limits, **IX**:23
- Nitrogen dioxide, pulmonary irritation from, **II**:10–11
- Nitrogen oxides  
 acute respiratory disease, **I**:5–7  
 gas shielded arc welding, **I**:xv  
 analytic techniques for, **V**:1  
 animal exposure studies, **VI**:10–11, 45–46  
 combined exposure measurements, **VI**:14  
 fume exposure studies, **II**:2–3, **IV**:xv, **V**:9, **VI**:6, 23–24, **VII**:15, **VIII**:5, 14  
 fume generation studies, **I**:74–75, **IV**:6, **X**:19–20, 61  
 in protective coatings, **IV**:7  
 pulmonary function testing, **VI**:13, 28–32  
 respiratory tract effects, **II**:xx, 10, **III**:6–7, **VII**:13, 24  
 teeth and oral cavity effected by, **IV**:23  
 welding arc production of, **I**:4, 75
- Nitrogen washout test  
 pulmonary function, **X**:31  
 respiratory disease studies, **V**:13
- Noise exposure studies  
 ear injuries and hearing loss, **IV**:19, **VI**:8, 14, 35, **VIII**:6, 34–36  
 hearing loss assessment, **XI**:11–12, 43  
 impulse vs. steady state studies, **V**:10, **VI**:6, 14, 27, 35, **VII**:6, 20–22  
 measurement techniques, **II**:xx, 5, **III**:5, **IV**:xvi, 10  
 procedural comparisons, **I**:4, 39, 77–78  
 voltage and current levels linked to, **III**:xiv  
 welding parameters and, **V**:1
- Nominal hazard zone (NHZ), laser radiation hazards, **VIII**:15–16
- Nominal hygienic requirement equation, fume generation studies, **II**:2
- Non-Hodgkins lymphoma, epidemiologic studies, **VIII**:32, **X**:4, 12, 46, **XI**:11, 41, **XII**:5, 16, 51–52, **XIII**:8–9, 23, 83–84
- Nonionizing radiation, exposure studies, **VIII**:5. *See also* Infrared radiation, Radiation, Ultraviolet radiation
- Non-stationarity conditions, epidemiologic studies, **VIII**:30
- Non-welding agents  
 pulmonary function comparisons with welders, **IX**:9  
 role of, in epidemiologic studies, **II**:xxiii
- Noradrenalin levels in welders, **VI**:9, 39–40

Normal hygienic air requirement, epidemiologic studies, **II**:2  
 Norwegian welders  
   aluminum exposure, asthma and, **XIV**:3  
   asthma in, **XIV**:3, 13, 30–31  
   cancer epidemiology, **XI**:4, **XII**:45–50  
   halogenated refrigerant exposure, **XIV**:25  
   lung cancer in, **X**:11, 41–44, **XIII**:22, 76–79  
   metal fume fever in, **XIII**:87–89  
   metal levels in dust, exposure studies, **X**:8  
   multiple sclerosis incidence, **X**:52  
   pneumonia incidence in, **XIII**:6  
   pulmonary function and respiratory disease in, **IX**:32  
   renal cell carcinoma in, **XIII**:80  
   respiratory disease in, **XIII**:22, 71  
   workplace exposure studies, **X**:22–23  
 “Nose-only” exposure chamber, retention and clearance of fumes, **V**:40  
 Nozzle size, role of, in exposure studies, **V**:9–10

## O

Occupational disease. *See also* Asthma; Working conditions  
   cancer epidemiology, **XIII**:22–23  
   health effects of welding and, **IV**:25  
   health surveys of, **XIII**:30  
   pneumonia as, **X**:3  
 Occupational exposure limits (OELs)  
   Finnish workplace exposure studies, **X**:23  
   isocyanate incidental exposure, **XIII**:44–45  
   pulmonary function testing, **X**:31  
 Occupational noise-induced hearing loss (OIH),  
   epidemiologic studies, **XI**:43  
 Occupational Safety and Health Administration (OSHA)  
   airborne contaminants standard, **I**:79  
   Hazard Communication Standard, **VIII**:21  
   iron oxide exposure, **XII**:28  
   lead exposure studies, **X**:22  
   permissible exposure limit (PEL), **V**:18  
 Octave band analysis, noise exposure studies, **V**:10  
 Ocular melanoma  
   epidemiologic studies, **XIV**:14, 37  
   risk factors for, **XIV**:5  
   ultraviolet exposure in welders and, **XIII**:9, 23, 84  
 Oculomotor testing, occupational exposure studies, **VIII**:7, 37–38  
 Odds ratios  
   asthma in farm workers and, **XIV**:32  
   epidemiologic cancer studies, **VII**:31  
   leukemia epidemiology in welders and, **XIII**:86–87  
   lung cancer incidence in welders and, **XIV**:35  
     asbestos exposure, **X**:42  
     latency periods and, **XIII**:78–79  
   neurodegenerative disease in welders and, **XIV**:42–49  
   pulmonary function testing, **X**:31  
   small bowel cancer epidemiology, **XIII**:81–83  
 Oil coated steel, exposure studies, **X**:26–27  
 Olfactory function, manganese exposure studies, **XIV**:86  
 OOAG tumor antigen, **XI**:54

Open-arc hardfacing and surfacing wires, electrode composition, **VIII**:11  
 Optical fibers, laser welding, **IX**:25  
 Optical techniques, aerosol analysis, **VIII**:13  
 Oral cavity cancer, **XII**:51  
   epidemiologic studies, **IV**:xiv, xvii–xviii, 23, **XII**:16  
   fume exposure studies, **VI**:9, 40  
   welding effects and, **II**:15, **III**:14, **VII**:10, 39–40  
 Organic chemicals  
   fume exposure studies, **VI**:6  
   heat release of, **VIII**:18  
   solvents, bladder cancer and, **XIV**:5  
 Organ-specific tumor antigens, **XI**:54  
 Ornithine carbamyl transferase (OCT), metallic exposure analysis, **II**:xv–xviii  
 Oxidants, genotoxicity studies, **X**:68  
 Oxidative stress  
   epidemiologic studies, **XIV**:17–18, 49–52  
   summary, **XIV**:88  
   genotoxicity studies, **XIV**:59  
   pulmonary function testing, **XIV**:28–29  
   reproductive function in welders and, **XIV**:10, 18–19  
   sperm damage in welders and, **XIV**:53–54  
   in welders, **XIV**:6  
 Oxidizing potentials, fume generation studies, **V**:6  
 8-Oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), reproductive function in welders and, **XIV**:18–19  
 Oxone levels, pulmonary function testing, **XIV**:29  
 Oxyacetylene torch welding  
   accident rates and, **IX**:28–29  
   cancer incidence and, **VIII**:6  
   cobalt exposure, **X**:63–64  
   ear injuries, **X**:49–50  
   epidemiologic studies, **VIII**:30–31, **XII**:45  
   eye injuries, **VIII**:36–37, **IX**:41  
   fume generation rates, **I**:67, **III**:2  
   gas emission studies, **VI**:23–24  
   heat release of organics, **VIII**:18  
   inorganic chemical exposures, **VIII**:19  
   lung cancer incidence and, **X**:42  
   nitrogen oxide emissions, **I**:74, **VI**:23  
   noise levels and, **I**:39, 77–78  
   pneumonitis incidence and, **XII**:15  
   pulmonary function testing, **X**:9  
   radiation exposure studies, **VI**:25  
   respiratory system effects, **II**:xx  
 Oxyfuel gas welding, ultraviolet radiation, **XIII**:15, 41  
 Oxygas cutting, pulmonary function testing, **XI**:3  
 Oxygen  
   accident rates and, **IX**:28  
   radiation from welding and, **I**:4  
 Oxypropane cutting, workplace exposure studies, **XIII**:17–18, 46–51  
 Ozone  
   acute respiratory disease, **I**:5–6  
   analytic techniques for, **V**:1  
   animal exposure studies, **VI**:10–11, 45–46  
   carcinogenicity and mutagenicity studies, **III**:15–16  
   chronic respiratory disease and, **I**:xxi, 13

combined exposure measurements, **VI**:14  
 electrode composition, **VIII**:12  
 exposure studies, **II**:3, **III**:xiii, **IV**:xv, 1, **V**:9–10, **VI**:6, 23–24, **VII**:6, 13, 15, **VIII**:5, 14, **XI**:17, **XII**:45  
 eye injuries due to, **I**:xviii–xix, **III**:12  
     animal studies, **VI**:10–11  
     fume exposure studies, **X**:19–20, 61  
 fume composition analysis, **XII**:25, **XIII**:14, **XIII**:34–37  
 fume generation studies, **IV**:6–7, **IX**:23–25  
     pneumonitis and, **I**:6  
 gas metal arc welding (GMAW), **VII**:15  
 gas shielded arc welding, acute poisoning, **I**:xv  
 hexavalent chromium exposure and, **XII**:11  
 hyperbaric pressure studies, **VI**:40  
 production of, during welding, **I**:72–74  
 pulmonary function testing, **IV**:15  
     aluminum particulates and, **VI**:13, 28–32  
 respiratory system effects, **II**:xx, 11, **III**:6–7, **VII**:24  
 ultraviolet radiation exposure studies, **II**:xix  
 variation in, with arc distance, **I**:72–73  
 ventilation systems and concentrations of, **XIII**:52–59  
*in vitro* welding studies, **IX**:14, 55–56  
 welding arc production of, **I**:3–4  
 workplace exposure analysis, **IX**:23, **XIII**:45–51  
 “Ozone-destroying theory” of fluorocarbons, **II**:3

## P

p53 gene  
     lung cancer epidemiology, **XII**:16, 50  
     skin cancer epidemiology, **XIII**:85  
 Paget’s disease, lead exposure and, **X**:16, 61  
 Pain provocation tests, epicondylitis, **XI**:47  
 Paints  
     asthma and exposure to, **XIV**:4, 30–32  
     bladder cancer incidence and, **XIV**:5  
     fume exposure studies, **VI**:6, 24–25, **VIII**:5–6  
     gas emission studies, **VI**:23–24  
     incidental exposure studies, **IX**:8, 14, 26, 53–54  
     welding emissions combined with, **I**:3, **VI**:14  
 Pakistani welders  
     accident and injury studies, **IX**:28, **XIII**:20, 57–59, **XIV**:12, 27  
     pulmonary function testing, **XIV**:12, 27  
     zinc exposure, **IX**:53  
 Pallidal index (PI), manganese exposure, **XIV**:85–86  
 Pancreatic cancer, epidemiologic studies, **VII**:3–4, 9, 32, **XII**:16, 51, **XIII**:8, 23, 80–81  
 Parathyroid gland tumors, incidence in welders, **XIV**:5, 38  
 Paresthia, radio frequency radiation, **VIII**:17  
 Parkinsonism  
     epidemiologic studies summary, **XIV**:86–87  
     manganese exposure and, **XIV**:1, 8–9, 16–17, 44–45  
 Parkinson’s disease  
     epidemiologic studies, **XIV**:16, 41–49, 86–87  
     maganism compared with, **I**:29  
     manganese exposure, **VI**:43, **VII**:37, **XII**:6–8, 17–18, 57–61, **XIII**:11, 27–28, 98–101, **XIV**:1, 8–9, 16–17, 44–45, 86

pulmonary retention and clearance studies, **VIII**:26–27  
     in welders, **IX**:11, 42–43  
 Partially chlorinated hydrocarbons, ignition hazard studies, **VIII**:20  
 Particle-Induced X-ray Emission (PIXE), **IV**:3–4  
     workplace exposure limits, **IX**:23  
 Particle removal devices, design requirements, **IX**:27  
 Particle retention studies. *See* Pulmonary retention and clearance studies  
 Particle size analysis. *See also* Aerosol analysis; Ultrafine particle analysis  
     agglomerate morphology and chemistry, **VII**:18  
     animal studies, **III**:xv, **VI**:46, **VII**:42–44  
     bacterial assays, **VI**:46–47  
     carcinogenicity studies, **VII**:33–34  
     electrostatic charge studies, **VI**:22  
     epidemiologic studies, **VII**:6, 17–18  
     fume composition analysis, **I**:3, 70–71, **X**:7, 19–20, **XI**:15–17  
     fume exposure studies, **III**:xiii, 1, 3, **IV**:3–4, **VI**:21–22, **IX**:7  
     fume generation studies, **V**:7, **VI**:21–23  
     laser welding, **IX**:25–26  
     metal fume epidemiology, **XIII**:87–89  
     pulmonary function testing, **III**:8–9, **VI**:27–32  
     respiratory tract exposure studies, **IV**:11, **XIII**:71–74  
     skin injuries from, **IV**:20  
     stability studies, **VII**:4, 26  
     workplace exposure studies, **XI**:8, **XII**:11, 25–27, **XIV**:12, 25  
 Particulate absorbers, hyperbaric welding, **VIII**:11  
 Particulate fraction analysis, cardiovascular effects of welding, **XIV**:87  
 Particulate reduction, ventilation systems, **XIII**:51–59  
 Patch skin testing, pulmonary function and respiratory disease, **IX**:32  
 Peak Expiratory Flow Rate (PEFR)  
     assessment of welding effects with, **III**:10  
     asthma in welders and, **XIV**:4  
     bronchitis and, **IX**:29  
     current studies, **X**:3  
     occupational asthma, **XI**:30–35  
     pulmonary function testing, **VII**:26–29, **IX**:32, **XI**:26–30, **XIII**:60–61, **XIV**:12, 27–30  
     respirator equipment and levels of, **X**:32  
     shift measurements of, **X**:9  
 Peak resolution techniques, X-ray fluorescence spectrometry, **VIII**:14  
 Perchloroethylene, incidental exposure in welders, **IX**:53  
 Pericardial mesothelioma, **XIV**:14  
 Periodontal disease, in welders, **IX**:12, 49  
 Peripheral vision testing, eye and vision injuries, **VII**:36  
 Permanent threshold shifts (PTS), noise exposure studies, **VIII**:34–36  
 Permissible exposure limits (PEL)  
     asthma studies, **XIV**:32  
     chromium exposure studies, **XIII**:38  
     epidemiologic studies, **XII**:45  
     fume exposure studies, **IX**:7

- iron oxide exposure, **XII**:12, 27–28  
 lead exposure, **XI**:53  
   incidental exposure studies, **XIII**:42  
 lead exposure studies, **XII**:28  
 workplace exposure analysis, **XIII**:17–18, 46–51
- Personal air sampling techniques  
 biological monitoring of chromium, **VIII**:40–41  
 fume exposure studies, **VI**:16  
 nickel levels, **V**:3
- Perspiration analysis, nickel compounds, **II**:xv
- Phagocytosis. *See also* Pulmonary function testing  
 lung toxicity studies, **II**:9  
 mammalian cell studies, **VIII**:42–43  
*in vitro* studies, **VII**:47  
 welding particulates and, **VII**:24
- Pharyngeal cancer, epidemiologic studies, **VIII**:32, **XII**:16
- Phenols  
 incidental exposure studies, **IX**:26  
 protective coatings, **IV**:7
- Phenothiazine drugs, photokeratitis and, **IX**:41
- Phlebotomy  
 iron overload and, **XIV**:4, 13–14  
 pneumoconiosis and, **XIV**:34
- Phosgene  
 fume exposure studies, **II**:3, **VI**:26  
 incidental exposure studies, **XIII**:16, 42–43, **XIV**:11–12, 25  
 pulmonary irritation from, **II**:11, **III**:6–7  
 respiratory tract effects of, **I**:5, **VII**:24  
 welders' incidental exposure to, **IX**:53
- Phosphine  
 fume exposure studies, **II**:3  
 as pulmonary irritant, **III**:6–7
- Photoc maculopathy, **VII**:36
- Photoallergy, welding and, **I**:39–40
- Photochemical decomposition, degreasing agents, **VI**:6, 26–27
- Photodermatitis, epidemiologic studies of, **VII**:9
- Photoelectric aerosol sensor, **VIII**:13
- Photoelectron spectroscopy, aerosol analysis, **VIII**:13
- Photographic dosimetry, thorium exposure studies, **XII**:29–31
- Photokeratitis. *See also* Keratoconjunctivitis  
 epidemiologic studies, **XIV**:15, 39–40, 84  
 ultraviolet radiation exposure, **IX**:40–41, **XIII**:93
- Photokeratoconjunctivitis. *See* Keratoconjunctivitis
- Photophthalmia. *See* Keratoconjunctivitis
- Photoretinitis, **VIII**:36–37  
 blue light radiation exposure, **XIII**:39–40
- Photosensitivity  
 electric welding arc exposure, **XIII**:13  
 epidemiologic studies, **XIII**:13  
 retinal injuries and, **XIII**:25, 92–93
- Photo-stress test, radiation-related eye injury, **VI**:37
- Phthalic anhydride, asthma epidemiology, **XIII**:4–5, 21, 64
- Piezoelectric detector, ozone emission studies, **VI**:24
- PIMEX system, exhaust equipment training, **X**:9, 28
- Pinguecula  
 electromagnetic radiation, **IX**:25  
 in welders, **IX**:11, 41
- Pipe fitting industry, lung cancer in welders and, **XIV**:36
- Pituitary gland, welding effects on, **XIV**:38, 88
- Plaque formation, lung cancer in welders, **XI**:11
- Plasma arc welding  
 asthma case reports, **IX**:32  
 blue light radiation exposure, **XIII**:2, 15, 39–40  
 cancer in welders in, **IX**:38  
 chromium exposure studies, **XIII**:38  
 ear injuries and hearing loss, **II**:13  
 electrode composition and fume generation, **I**:67  
 eye and vision effects, **VII**:36  
 fume exposure studies, **VII**:5  
 fume generation rates, **I**:2  
 keratoconjunctivitis incidence and, **VII**:9  
 nitrogen oxide production, **I**:74, **VI**:23–24  
 noise production, **I**:77–78  
 oxidative stress and inflammation and, **XIV**:50–52  
 particle analysis, **VI**:21–22  
 small bowel cancer epidemiology, **XIII**:82–83  
 workplace exposure limits, **IX**:23, **XIII**:18
- Plasma-cutters, nickel exposure in, **X**:38
- Plasma jet welding, noise levels and, **I**:39
- Plasma lipids, chromium exposure and, **XIII**:37–38, 112
- Plasma metal spray analysis, fume exposure studies, **VII**:17
- Plasma viscosity measurement  
 cardiovascular disease in welders, **X**:55  
 epidemiologic studies, **X**:13
- Plastic welding, radio frequency radiation, **VIII**:17
- Platform atomization, aluminum exposure, **XII**:11
- Pleural plaques, incidence of, in welders, **V**:2
- Pleurisy, incidence of, in welders, **V**:12
- Plumbing industry, lung cancer in welders in, **XIV**:36
- Plutonium exposure studies, **X**:17, 66
- Pneumoconiosis. *See also* Mixed dust pneumoconiosis;  
 Siderosis  
 agents for production of, **II**:9–10  
 alveolar macrophage, **VI**:32  
 animal studies, **V**:37–39  
 case reports, **IX**:9, 32, **XIII**:68–69  
 epidemiologic studies, **X**:10, 36–37, **XI**:10, 15, 36,  
   **XII**:43–45, **XIII**:21, 64–68, **XIV**:4, 13–14, 33–34, 82  
 fume exposure studies, **III**:7, **IV**:11, **VI**:7  
 international classification system, **VI**:28  
 iron exposure and, **IX**:13, 50  
 lung cancer risk and, **XII**:50  
 magnetopneumography and, **XI**:11  
 mycobacterial infection in welders and, **XIII**:6  
 non-collagenous pneumoconiosis, **VI**:28  
 nontuberculous mycobacterial infection and, **XIII**:70–71  
 particle accumulation studies, **III**:7–8, **VI**:28  
 pulmonary function testing, **VI**:30–32, **VII**:3, 7–8  
 respiratory toxicity studies, **II**:xx  
 welding particulates, **VII**:24
- Pneumonia  
 animal fume inhalation studies, **V**:4  
   guinea pig studies, **I**:94  
   rabbit studies, **I**:92  
   in rats, **I**:84–85, 87  
   rat studies, **I**:88  
 case reports of, **VII**:8

- epidemiologic studies of welders and, **III**:xv, 16, **XIII**:5–6, 22, 70–71, **XIV**:34–35
- incidence of, in welders, **I**:7, **V**:12–13, **VI**:30–32, **XIV**:1, 14
- metal fume fever and, **I**:38
- mortality rates, **II**:8, **V**:2, **VI**:33, **X**:3, 10, 36, **XIV**:6–7
- smoking and incidence of, **III**:10
- standard mortality ratios (SMRs), **V**:14–15
- ventilation defects and incidence of, **XIV**:89
- Pneumonitis**
- animal studies, **V**:4, **VII**:41, **IX**:14, 56
- cadmium poisoning, **IV**:25, **VI**:34–35, **XI**:52
- case reports, **XII**:15
- incidental exposure to production coatings, **IX**:14
- metal fume fever studies, **II**:15–16
- Pneumothorax**
- manganese exposure in, **XIV**:7, 16
- neurophysiological effects, **XIV**:43
- in pneumoconiosis patients, **XIII**:68–69
- pulmonary function testing, **XIV**:29
- siderosilicosis and, **XIII**:21
- Polarity, fume generation rates, IV:2**
- Polish welders**
- ear injuries in, **XIII**:90
- genotoxicity studies and, **X**:17
- manganeses exposure and nervous system effects in, **XIII**:99–101
- mercury exposure in, **XIII**:112–113
- pneumoconiosis in, **X**:10, 36
- workplace exposure studies, **X**:22–23, **XIII**:48–51
- Polychlorinated biphenyls (PCBs), analysis, XI:7, 17**
- Polychlorinated dibenzodioxins (PCDDs), exposure studies, XII:28–29**
- Polychlorinated dibenzofurans (PCDFs), exposure studies, XII:28–29**
- Polycyclic aromatic hydrocarbons (PAHs)**
- biological monitoring of, **XIII**:32, **XIV**:19, 55–57
- bladder cancer incidence and, **XIV**:5
- cancer epidemiology, **VI**:14, **VIII**:6, **XII**:47–50
- fume exposure studies, **VII**:20
- genotoxicity studies, **XIII**:11
- Polycyclic aromatic hydrocarbons (PAHs)
- lung cancer incidence and, **X**:45–46
- skin cancer and, **II**:17
- Polymorphonuclear leukocytes (PMNs)**
- hypochlorous acid (HOCl) and, **IX**:14, 56
- immune function in welders, **XIII**:29, 105–106
- inflammation and oxidative stress and, **XIV**:10, 18, 49–52
- metal fume fever, **VII**:9, **IX**:10, 39, **X**:48–49
- animal studies, **XIII**:33, **XIII**:118–120
- skin injuries and, **XIII**:94–95
- Polysulfone film dosimeters, electromagnetic radiation exposure, XI:21–22**
- Polytetrafluoroethylene (PTFE) filters, aerosol measurements, IX:22**
- Polyurethane, incidental exposure to, IX:14, 54**
- isocyanate exposure, **XIII**:16
- Polyvinyl chloride (PVC)**
- incidental exposure studies, **IX**:26
- membrane filters, fume sample collection with, **X**:20
- Population dynamics, pulmonary function testing, **IV**:15
- Porphyrin excretion, fume exposure studies, **II**:16
- Proportional mortality ratios, carcinogenicity studies, **VI**:34
- Portable sampling techniques, gas emission studies, **VI**:23
- Positron emission tomography (PET), manganese exposure studies, **XII**:7–8, 18, 57–61, 60–61
- Postural stress**
- musculoskeletal effects of welding, **VII**:10, 38
- shoulder pain in welders and, **IV**:22
- ventilation systems analysis and role of, **XIII**:54–59
- Potassium**
- aerosol analysis, **VIII**:13
- electrode composition, **V**:6, **VI**:5, 19–20, **XIV**:11, 24
- fume stability studies, **VII**:4
- Potassium dichromate, animal studies, infectivity and inflammation, XIV:20**
- Potassium fluoride, particle analysis, VI:23**
- Potential hazard studies, VIII:9**
- Prednisone therapy, cadmium exposure, IX:50**
- Pregnancy. See also Fertility in welders, Reproductive function**
- fume exposure studies and, **XIV**:88
- paternal welding exposures and, **X**:57
- welder/non-welder comparisons, **XII**:19, 62–65
- Pre-senile dementia in welders, epidemiologic studies, XIV:41–49**
- Primers, fume exposure studies of welders, VI:6**
- Profile of Mood States**
- manganese exposure studies, **XIV**:8, 44
- metallic compound exposure studies, **XIV**:85–86
- Prolactin, endocrine system effects in welders, XIV:88**
- Proportional mortality ratios (PMRs)**
- bladder cancer studies, **II**:19, 21–22
- Hodgkin's disease incidence in welders, **V**:33–34
- lung cancer incidence in welders, **V**:28–30, **IX**:33–34
- mesothelioma incidence and, **V**:2, 30–31
- multiple myeloma, **V**:34
- Prostate cancer**
- epidemiologic studies, **XI**:41, **XIV**:14, 38
- metallic compound carcinogenicity, **VI**:33, **IX**:37
- Protective clothing and equipment**
- accident rates and, **IX**:28–29, **XIII**:57–59
- burn injury rates and, **XI**:45
- chronic respiratory conditions, protection for, **III**:6–7
- clothing design, **VII**:7, 23
- coatings, **IV**:7–9
- compliance in use of, **III**:20
- curtains, **IV**:xvi
- design analysis, **IX**:27–28
- ear injuries and, **IX**:10, **X**:49, **XIV**:41
- earmuffs and earplugs, **III**:12, **IV**:xvii
- effectiveness of, **IV**:11
- electromagnetic radiation, **IX**:25
- eye protection, **I**:25–26, **III**:12, **VI**:24–25, **VII**:36, **VIII**:36–37, **IX**:11, 41, **XII**:17, 55–56, **XIII**:91, **XIV**:5, 14–15
- filter plates, **IV**:xvi
- fume exposure and, **VIII**:11, **IX**:8
- goggles, **VII**:19–20
- hazard reduction with, **III**:1

- heat- and flame-proof, design analysis, **IX**:28  
 heat protection, **I**:78  
 helmets, **VI**:16  
 hygiene and work practices, **XI**:8–9, 23–25  
 injury rates and, **XIII**:57–59  
 international regulations, **VIII**:21  
 manganese exposure, **XIV**:44  
 metal fume fever and, **IX**:10  
 mouth filtration devices, **IX**:29  
 noise exposure studies, **VII**:21  
 ozone shrouds, **V**:10  
 as protective device, **VII**:7, 23  
 radiation protection, **IV**:9–10, **VI**:24–25  
 radiation protection with, **VI**:25  
 respirators, **VII**:7, 23  
 skin injury in welders and, **III**:13  
 specification studies for, **X**:9, 29  
 ventilation and air cleaning equipment, **IX**:27  
 visual acuity preservation, **XIII**:25  
 “watchdog” devices for robots, **VII**:21  
 women welders, **XI**:24–25  
 workplace exposure analysis, **IX**:23, **XIII**:46–51
- Protein carbonyl, oxidative stress and, **XIV**:6  
 Protein-DNA crosslinks, biomarker analysis, **X**:68  
 Protein synthesis, epidemiologic studies and, **X**:5  
 Proteinuria  
 cadmium exposure, **IX**:12, 46  
 chromium exposure, **IX**:46
- Proteolytic enzymes  
 alveolar macrophages and, **VII**:24–25  
 lung disease and, **X**:1
- Proton-induced x-ray emission (PIXE) analysis, **I**:99–100  
 Provocative dose (PD), occupational asthma, **XI**:30–35  
 Psoralens  
 skin conditions linked with, **I**:40  
 UV exposure and, **II**:4
- Psychological disorders  
 manganese intoxication and, **I**:29, **VII**:37  
 welding and, **IX**:11, 29, 42–43
- PTCH gene, skin cancer epidemiology, **XIII**:85
- Pterygia  
 epidemiologic studies, **VII**:35–36, **VIII**:36–37  
 radiation exposure studies, **IV**:xvii, 20, **VI**:8, 35–37
- Pulmonary alveolar proteinosis (PAP), **I**:87
- Pulmonary disease. *See* Acute and chronic respiratory disease,  
 Mixed pulmonary disease, Respiratory disease, specific  
 respiratory diseases
- Pulmonary edema  
 aluminum exposure, **XIV**:3  
 animal studies  
 cadmium exposure, **II**:26  
 fibrosis, **XIV**:20–21, 64–66  
 fume inhalation studies, **VII**:41, 45–46  
 guinea pig studies, **I**:93–94  
 pneumoconiosis, **V**:38–39  
 in rats, **I**:45–46, 84–85  
 apprentice welders, **XIV**:3  
 asthma and, **XIV**:4  
 cadmium toxicity, **II**:26, **VI**:34  
 cardiovascular effects of welding, **XIV**:87  
 cumulative welding experience, **XIV**:3  
 current research techniques, **XIV**:12–13  
 degreasing agents  
 fume exposure studies, **VI**:26–27  
 photochemical decomposition from UV radiation, **VI**:6  
 fibrosis, **XIV**:33–34  
 fume exposure studies, **I**:5–7, **XIII**:88, **XIV**:27  
 nickel exposure, **XIV**:3  
 nitrogen oxide emissions, **II**:10–11, **VI**:23  
 oxidative stress biomarkers, **XIV**:6  
 pneumoconiosis, **XIV**:4  
 respiratory changes in welders, **XIV**:3, 27–30  
 signs and symptoms, **I**:5–7  
 summary of studies on, **XIV**:81–82  
 total fume exposure, **XIV**:3  
 toxicity studies, **I**:31–32, **II**:xx
- Pulmonary fibrosis. *See also* Interstitial pulmonary fibrosis  
 aluminum arc welding and, **IV**:xvi, 13  
 animal studies, **VII**:11, 41–42, **IX**:55, **XIII**:33,  
**XIII**:116–117  
 chronic fume exposure and, **IV**:11  
 epidemiologic studies, **V**:12  
 fume exposure studies, **I**:xxii, 81, **VI**:7, **VI**:11  
 lung cancer in welders, **XI**:11  
 pulmonary function testing, **VI**:31–32, **VII**:26–29, **IX**:29  
 rat studies, **I**:46  
 respiratory disease studies, **VI**:28–32, **XIII**:21  
 siderosis in welders and, **IX**:32
- Pulmonary function testing  
 animal studies, **IX**:14–15  
 beryllium exposure and, **IX**:12–13  
 bronchitis and, **IX**:8–9, 29–32  
 cadmium exposure, **IX**:13, 50  
 carbon monoxide transport test, **V**:3  
 current research, **X**:1  
 duration of exposure and, **XI**:4–6  
 epidemiologic studies, **V**:16–17, **VIII**:6, 27–29, **IX**:3,  
**X**:9–10, 29–32  
 fume exposure studies, **II**:11–12, **IV**:xiii, xvi, 14–15, 25,  
**VI**:13, **VII**:7–8, 26–29  
 hyperbaric pressure studies, **VI**:9  
 incidental exposure studies, **IX**:13–14, 53–54  
 limits of, **III**:19, **IV**:xix  
 metal fume fever, **VII**:34–35, **IX**:39  
 nitrogen oxide emissions, **VI**:23  
 pneumoconiosis in welders and, **VI**:7, **XIII**:65–68  
 pre-employment values for, **X**:29–32  
 pulmonary fibrosis and, **IV**:13  
 research techniques, **VII**:7–8  
 respiratory changes in welders, **I**:13–22, 81–82, **III**:9–11,  
**V**:11–20, **VI**:27–32, **VII**:3, 26–29, **XI**:3, 9, 25–30,  
**XII**:4, 14, 38–40, **XIII**:60–61  
 retention and clearance of particles (*See* Pulmonary retention  
 and clearance studies)  
 single-shift tests, **X**:3  
 toxicity studies, **II**:xx, **III**:xiv, 8–11
- Pulmonary hypertension, epidemiologic studies, **XI**:36

Pulmonary inflammation, epidemiologic studies, **XII**:5–6, 21, 72–75

Pulmonary retention and clearance studies

animal studies, **IV**:25–27, **V**:40, **VII**:11, 42–44

epidemiologic studies, **VI**:27–32, **VII**:7, 25–26, **VIII**:26–27

fume exposure studies, **VI**:11, 47

overview, **VIII**:6, 26–27

particle deposition and retention estimates, **II**:12, **IV**:11–13,

**V**:3–4, 18–19, **VI**:22–23, **VII**:7, 25–26, 42–44

respiratory disease studies, **V**:18–19

Pulmonary surfactant, *in vitro* exposure studies, **V**:42

Pulsed arc gas metal arc welding (GMAW), workplace

exposure analysis, **XIII**:17–18, 45–51

Push-pull ventilation systems, gas metal arc welding,

**XIV**:25–26

## Q

Quartz exposure

cardiovascular disease and, **XI**:50

electrode coatings, **XIV**:11, 24

Questionnaires, role of, in respiratory disease studies, **V**:3,

13–19

## R

R404 refrigerant, hydrochloric acid/hydrogen fluoride exposure, **XIV**:12

Rabbit studies

acute exposure levels, **I**:90–91

arc welding radiation studies, **I**:105

distribution and excretion of inhaled fumes, **I**:97–101

fume inhalation, **I**:46–47, 89–92, 97–98

metal fume fever studies in, **I**:103

nickel compound exposure studies, **II**:28

subcutaneous effects, studies on, **I**:102–103

Radiation. *See also* Electromagnetic radiation, Extremely low-frequency (ELF) radiation, Infrared radiation, Ultraviolet radiation, Visible light

analytic techniques used on, **V**:1

animal studies, **I**:49, **III**:18

cancer studies and, **XIV**:5

carbon dioxide lasers, **X**:8, 23–25

exposure studies, **II**:xix–xx, 3–4, **III**:xiii, **IV**:xv–xvi, 9–10,

**V**:10, **VI**:6, 24–25, **VII**:6, 17–20, **VIII**:5, 14–15,

**X**:25–26

eye injuries, **I**:xvi, **II**:12–13, **III**:12, **IV**:xvii, **VI**:24–25, 35–37, **VIII**:36–37, **X**:50

health effects of, **III**:4–5

incidental exposure studies, **IX**:8, 26–27

intensity of, linked to welding current, **I**:4, **III**:4–5

leukemia epidemiology and, **VII**:32

protective gear and equipment, **X**:29

reproductive dysfunction, **VIII**:38–39

thoriated electrodes, **X**:44–45

Radioactive materials

thoriated electrodes, exposure studies, **XIV**:11

thorium exposure studies, **XII**:12, 30–31

Radio frequency radiation, **VIII**:17

Radiography. *See also* X-rays, specific radiographic techniques

fume exposure studies and, **III**:11–12

research methodology, **III**:11–12

respiratory disease studies

chest lesions, incidence of, **VI**:30

toxicity studies, **III**:xiv

Rales, incidence of, in welders, **V**:12

Rapid scan spectrometry, ultraviolet radiation exposure studies, **VI**:24

Rat studies

cadmium exposure studies, **II**:25–27

carcinogenicity studies, **I**:101–102

chromium compounds, **V**:37

metal carcinogenicity, **II**:29–30

fibrosis, **XIII**:33, 116–117, **XIV**:4, 20–21, 64–66

fume generation studies with, **II**:xv

fume inhalation studies, **I**:45–46, 83–89, **VI**:11

acute and subacute toxicity studies, **I**:83–85

central nervous system effects, **I**:88

chronic toxicity studies, **I**:85–86

copper, nickel, aluminum and magnesium fumes, **I**:86–88

distribution and excretion studies, **I**:97–101

fluoride contents, **I**:97–98

general toxicity and lung effects, **I**:83–86

liver effects, **I**:88–89

manganese content, **I**:98–100

mixed fume studies, **I**:99–101

reproductive system effects, **I**:89

silica, **I**:99–100

tuberculosis and, **I**:104

infectivity and inflammation, **XIV**:20, 60–63

influenza from fume inhalation in, **I**:103–104

intratracheal administration of welding fumes, **I**:94–97

manganese exposure, **XIV**:9, 21, 66

metal compound exposure studies, **II**:25–27

nickel exposure, biochemical effects, **II**:29

particle analysis, **III**:17

pneumonia, **XIV**:7

respiratory disease studies of, **V**:4

respiratory function studies, **XIII**:116

Raven Progressives Matrices, aluminum exposure and cognitive function in welders and, **XIV**:42–43

Ray burns (skin), radiation exposure, **II**:xix, xxi–xxii, 13

Raynaud's phenomenon, in welders, **X**:51, 55

Reactive airways dysfunction syndrome (RADS), **X**:35

incidental exposure to surface coatings, **IX**:54

Reactive oxygen species (ROS)

animal studies, infectivity and inflammation, **XIV**:60–63

immunomodulation of hexavalent chromium, **XII**:75

metal fume fever and, **XII**:6

oxidative stress and, **XIV**:6, 49–52

pneumonia infection and, **XIV**:7

pulmonary inflammation, **XII**:72–75

Readaptation time

epidemiologic studies, **III**:xiv, 13

eye injuries and, **I**:28

Real-time analyzer, aerosol analysis, **VIII**:13

Record-keeping, role of, in epidemiologic studies, **II**:xxiii



- Redox reactions, hexavalent chromium, **V**:8
- Reed relay detection, fume exposure studies, **VII**:17
- Refrigerator repair workers, exposure studies, **XIV**:11–12, 25
- Regression analysis, biological monitoring of aluminum, **VIII**:40
- Regulatory requirements  
 compliance analysis, **XIII**:19, 57–59  
 guidelines, **VIII**:22–23  
 international comparisons, **VIII**:11, 21–22  
 standards, **VIII**:22
- Relative coefficient of variation (RCV), chromium analysis, **X**:20–21
- Relative fume formation rate (RFFR)  
 fume exposure studies, **IV**:1–5  
 study design with, **IX**:19  
 voltage and current linked with, **IV**:2, **IX**:20  
 workplace exposure limits, **IX**:23
- Relative risk (RR)  
 asthma in welders, **XIII**:63–64  
 cancer epidemiology, **VII**:30–32, **XII**:46–50  
 lung cancer epidemiology, **IX**:36, **XI**:38–40  
 neurodegenerative disease in welders, **XIV**:42
- Relaxation times, pulmonary retention and clearance estimation, **V**:19
- Remanent magnetic field (RMF) measurement, magnetopneumography, **XII**:42–43
- Renal cell carcinoma (RCC), in welders, incidence and epidemiology, **XIII**:7–8, 22–23, 79–80
- Renal system  
 aluminum exposure and, **IX**:42  
 cadmium exposure studies, **VI**:9, 39, **VII**:4  
 cancer of, in welders, **VII**:9, **IX**:36–37, **XI**:4, **XII**:5, 16, **XIII**:7–8  
 chromium exposure and, **IX**:12  
 epidemiologic studies of, in welders, **VII**:10  
 failure in welders, **XI**:13
- Reproductive function. *See also* Fertility in welders  
 animal studies  
 cadmium compound exposure, **II**:27  
 fume inhalation studies, in rats, **I**:89, **II**:25  
 cancer incidence in children and, **VIII**:32  
 ELF exposure studies, **VIII**:16  
 epidemiologic studies, **II**:xxiv, 14, **III**:14, **IV**:xiv, xvii, 23, **VIII**:7, 32, 38–39, **X**:14–15, 56–58, **XI**:13, 51, **XII**:8, 62–66, **XIII**:12, 30, 106–109, **XIV**:9–10, 18–19, 53–54, 88  
 male welders, **X**:1  
 unresolved hazard studies, **VIII**:9
- Re-radiation, exposure studies, **IV**:9
- Research methodology  
 animal studies, **II**:23–24  
 toxicology studies, **III**:17–18, **IV**:28  
 fume exposure studies, **IV**:xv  
 gas exposure studies, **IV**:xv
- Residual volume (RV), pulmonary function testing, **I**:82
- Resistance welding  
 endocrine gland tumors and, **XIV**:38  
 fume generation rate, **VII**:5
- Respirable to inhalable particulate (R/I) ratio, workplace exposure studies, **XII**:26–27
- Respirators, disposable, research on, **VII**:7, 23
- Respiratory disease. *See also* Acute and Chronic respiratory disease  
 absenteeism and, **XIII**:21–22, 69–70  
 acute obstructive  
 acute disease, **II**:9–13  
 incidence of, in welders, **I**:5–11, **V**:12  
 agents for production of, **II**:9–11  
 aging in welders and, **XI**:54  
 in apprentice welders, **XIV**:3, 14  
 asthma, **XII**:4  
 beryllium exposure and, **IX**:12–13  
 bronchitis, **XII**:4 (*See* Bronchitis)  
 cadmium poisoning, **VI**:34  
 cancer epidemiology, **XII**:46–50  
 carcinogenicity studies, **I**:22–25  
 case reports of welders, **X**:38–40  
 chromate/nickel carcinogenicity studies, **I**:xxi–xxii  
 copper fumes, **XIII**:9–10  
 degreasing agents, photochemical decomposition, **VI**:6, 26–27  
 epidemiologic studies, **IX**:3, 29–33, **X**:33–35, **XI**:10, 35–36, **XII**:15, **XIV**:34–35, 81–83  
 fume exposure studies, **II**:21, **XI**:57–59  
 inflammatory processes, **XIV**:6, 49–52  
 infectious disease, **XIII**:5–6, 22, 70–71  
 lung cancer (*See* Lung cancer)  
 metal fume fever studies, **IV**:xviii  
 nodules and granulomas, dyspnea and presence of, **XIV**:13–14  
 occupational asthma, **XI**:3–4, **XIII**:4–5, 20–21  
 pneumoconiosis and, **IV**:11, **XIII**:21  
 pulmonary fibrosis, **IV**:13  
 restrictive respiratory disease, in welders, **V**:12  
 welding effects on, **XIV**:1, 3–4, 12–14
- Respiratory minute volume, pulmonary retention and clearance studies, **VIII**:27
- Respiratory system  
 alveolar macrophages, **VII**:7, 24–25, **VIII**:25  
 animal studies, **V**:4, **VI**:45–46, **XIII**:32, **XIII**:116  
 cadmium exposure, **II**:27  
 inflammation and fibrosis, **VII**:11  
 iron exposure, **II**:27–28  
 leukocyte migration, **IV**:xviii  
 nickel exposure, **II**:28  
 anti-oxidant systems, **VIII**:25–26  
 Czech welders, x-ray abnormalities and working conditions, **I**:10–11  
 defense mechanisms of, **II**:29  
 epidemiologic studies, **III**:8–9, **IV**:xiii–xiv, xvi, 11–15, **V**:2–3, 11–20, **VIII**:6, 23–29, **X**:3, 9–11, 29–38  
 fume exposure studies, **VI**:7, 27–32, **VII**:3, 7–8, 13, 24–30  
 particle growth and agglomeration in, **VIII**:13  
 Polish shipyard welders, abnormalities in, **I**:9–10  
 production coatings exposure, studies of, **VII**:8  
 pulmonary function testing (*See* Pulmonary function testing)

pulmonary retention and clearance studies (*See* Pulmonary retention and clearance)

radiographic examination, **III**:11–12

Romanian welders, chronic abnormalities, **I**:16–17

serum enzymes in, **I**:22

toxicity studies, **II**:xx, 8–9, **III**:xiv, 6–12

welding effects on, **I**:5–22

Retention and clearance studies. *See* Pulmonary retention clearance

Reticulo-micronodules, siderosis in welders and, **IX**:32

Retinal injury. *See also* Eye injuries, Visual acuity and loss

epidemiologic studies, **I**:27–28, **VII**:9, **VIII**:6, 36–37, **XII**:17, 54–55, **XIII**:25, 92–93, **XIV**:15, 40

pathogenesis, **I**:27–28

photoretinitis, **VIII**:36–37

blue light radiation exposure, **XIII**:39–40

radiation exposure and, **III**:xiv, 12, **IV**:19, **VI**:37, **VII**:19–20

ultraviolet (UV) radiation, **VII**:36

vision loss and, **XII**:17, 54–55

Retinitis pigmentosa sine pigmento, **VII**:36

Retinoblastoma, in children of welders, **IX**:10, 37–38

Retinol-binding protein, epidemiologic studies of kidney damage, **VII**:10, 38–39

Retinopathy (arc welder's retinopathy), **X**:50, **XI**:44

Reversed-phase high pressure liquid chromatography, fume exposure studies, **VII**:17

Reynaud's disease, incidence of, in welders, **IV**:21

Rinehart's solution, chromium compound exposure studies, **V**:7–8

Risk assessment

methodology for, **VIII**:9

multipliers, in epidemiologic studies, **VIII**:30

Robotic systems

accident rates and, **IX**:28–29

fume generation and, **IX**:19

health risks of, **VII**:6–7, 21, 23

safety practices, **VIII**:6, 19, **XI**:25

Roentgen-Fluorescence techniques, pulmonary function testing, **III**:9

Rotator cuff syndrome, in welders, **VIII**:38

Round-robin experiments. *See* Interlaboratory/intermethod round-robin experiments

Russian welders

bladder cancer incidence, **X**:46

health surveys of, **XIII**:30, 110

pulmonary function and respiratory disease, **IX**:31–32

Rutile electrodes

acute respiratory disease and, **I**:10, **XIV**:11, 24

animal fume inhalation studies, **I**:46, 85–86

pneumoconiosis, **V**:37–39

copper production and, **I**:3

flux cored arc welding (FCAW) fume generation, **X**:19

fume generation rates, **I**:61–62

intratracheal fume administration, **I**:96–97

particle size distribution of welding fumes, **I**:70–71

ultraviolet radiation, **I**:77

RVD-F respirator, **VII**:7, 23

## S

SA7 adenovirus cell culture, fume exposure studies with, **VI**:11, 48–49

Safety practices

burns, **XI**:3

compliance analysis, **XIII**:19, 57–59

consensus standards, **VIII**:5, 21–23

eye injuries, **VIII**:36–37

fume exposure studies and, **II**:xxiv

health effects of welding and, **II**:7, **III**:5, **IV**:xx

hygiene and workplace design, **XI**:9, 25

risk reduction with, **VIII**:9

robots, **VIII**:19

training programs, **XI**:3

Safety shoes, slip resistance measurements, **XI**:23

Saliva testing, manganese and copper exposure studies, **XIV**:89

Sampling techniques

animal toxicology studies, **IV**:28

epidemiologic studies, **VIII**:30

fume generation studies, **VI**:5

fume sampling procedures, **XII**:3

thorium exposure studies, **XII**:30–31

ultrafine particle analysis, **XIV**:11, 23–24

workplace exposure studies, **XII**:11–12, 27

Sarcoid-like granulomatous aluminum disease, **XIV**:14

Sarcoidosis, berylliosis mistaken for, **VII**:38

Scandinavian electrode classification, **VIII**:11

Scandinavian welders, cancer epidemiology, **VII**:32

Scanning electron microscopy (SEM)

aerosol measurements, **IX**:22

animal studies of iron exposure, **II**:27–28

particle analysis, **VII**:17

pneumoconiosis studies, **II**:xx, 10, **XIII**:66–68

protective gear analysis, **VII**:23

Scanning mobility particle sizer, ultrafine particle analysis, **XIV**:11

Scanning transmission electron microscopy (STEM), welding particle studies, **V**:7

Scarring, incidence of, in welders, **IV**:20

Sciacky welding process, berylliosis and, **IX**:50

Scleroderma, in welders, **I**:41, **X**:13, 51

epidemiologic studies, **XIV**:15, 41

Scoliosis, in welders, **IX**:12

Scotoma, in welders, **XIII**:25, 39–40, 92–93

Secondary heat transmission, radiation exposure studies, **VI**:24–25

Secondary ion mass spectroscopy (SIMS), fume exposure studies, **XI**:16–17

Secondary neutral mass spectrometry (SNMS)

aerosol measurements, **IX**:22

fume exposure studies, **IX**:7

Selenium, urine analysis studies, **II**:xiv

Self-reported data

bronchitis and asthma epidemiology, **X**:33–34

lung function testing, **X**:31

Semen analysis

epidemiologic studies, **XI**:13, 51, **XII**:18–19, 62–65

- fertility in welders, **IX**:4, 12, 48–49, **X**:4, 14–15, 56–58, **XIII**:108–109
- reproductive function studies, **VIII**:7, **XIV**:53–54
- Senile keratosis, welding and, **I**:40
- Serum enzyme testing
- animal studies
    - intratracheal fume administration, **I**:95–97
    - manganese levels, **II**:28
    - toxicology studies, **IV**:26–27
  - biochemical effects of metal compounds, **II**:xv–xviii, 16, **III**:15, **IV**:xviii, 24–25
  - fume toxicity and, **III**:xiv–xv
  - immune system studies, **VIII**:40
  - lead exposure studies, **II**:xvi–xvii, **VI**:43–44
  - liver function in welders and, **IV**:22
  - manganese poisoning, **IV**:21
  - nervous system effects of welding and, **IV**:xvii
  - nickel concentrations in, **III**:xiv–xv
  - respiratory tract disease, **I**:22
  - zinc levels in, metal fume fever and, **V**:3, 20
- Serum glutamic oxaloacetic transaminase (SGOT), manganese levels, **II**:28
- Serum glutamic pyruvic transaminase (SGPT), manganese levels, **II**:28
- Sex-related epidemiological studies
- blood pressure and welding status, **I**:32–34
  - cancer in welders, **XIV**:5
  - chromium exposure, **IX**:13
- Shaver's disease, **IV**:11
- Sheet metal welding
- asthma and bronchitis, **X**:10
  - chronic respiratory disease and, **I**:13–14, **X**:33
- SHEILD survey, occupational asthma, **XI**:33–35
- Shielded metal arc welding (SMAW)
- aerosol analysis, **VIII**:13, **IX**:22
  - allergic reactions to, **IV**:24, **VII**:45
  - alveolar macrophages, **VIII**:6
  - amyotrophic lateral sclerosis (ALS) incidence and, **XI**:45–46
  - animal studies, **II**:25, **V**:4, 37–39, **IX**:14, 56, **X**:18, 71
  - allergic sensitivity, **VII**:45
  - biochemical analysis, **VII**:45
  - fibrosis, **XIV**:20–21, 63–66
  - infectivity and inflammation, **XIV**:61–63
  - inflammation and fibrosis, **VII**:11, 41–42
  - manganese distribution, **XIV**:21, 66
  - pneumoconiosis, **V**:38–39
  - pneumonia epidemiology, **XIV**:1
  - pulmonary retention and clearance, **VII**:11, 42–44
  - toxicology studies, **IV**:25–27
  - whole-body effects, **V**:40
- anti-oxidant exposure, **X**:61
- arc distance, ozone production and, **I**:73
- asthma risk, **XII**:42, **XIV**:4, 31
- case reports, **XIV**:32–33
- barium exposure, **X**:61–62
- biological monitoring, **V**:22–23, **VII**:10–11, **XI**:55, **XII**:20, **XII**:67–68, **XIV**:19
- chromium exposure, **VI**:41–43, **VII**:40–42, **XIV**:19, 55
  - nickel exposure, **VI**:41–43, **VIII**:41, **XIV**:19, 55
- blue light exposure studies, **XIII**:2, 15, 39–40
- cancer epidemiology and, **XII**:5, 16
- carbon dioxide production, **I**:74–75
- carbon monoxide generation, **I**:74–75, **IV**:7
- carcinogenicity studies, **V**:37
- cardiovascular disease, **XI**:49–50
- case reports, **XII**:45
- cell culture studies, **VI**:48–49
- cell transformation assays, **V**:41
- chromium exposure analysis, **I**:2–3, 70, **IV**:4–5, **V**:7–9, **VI**:15, 20, 41–43, **VII**:40–42, **IX**:51, **X**:16, 20, 63, **XII**:24
- soluble chromium component, pneumonia epidemiology, **XIV**:1
- chronic lung disease and, **I**:xxi
- clastogenesis and, **VIII**:39
- conjunctivitis and, **IX**:11
- degreasing agents, photochemical decomposition, **VI**:6
- DNA-protein crosslinking with, **X**:68
- electrode composition, **VI**:20, **VIII**:12
- electromagnetic field exposure, **X**:25–26, **XII**:13, 32–33
- electromagnetic radiation, **XII**:31–32
- exposure estimation techniques, **XII**:37
- eye injuries, **VI**:37, **IX**:10, 41
- fertility rates, **IX**:4, 48–49, **X**:4, 14–15, 56–58
- fume composition analysis, **I**:1–2, 58–60, 66, **IX**:19, **X**:19, **XI**:7, 15–17, **XII**:24–25, **XIV**:22
- fume emission rates (FER), **VI**:16
- fume exposure studies, **IV**:xv, 1, **VII**:5, 15, **IX**:7
- analytic techniques, **VII**:17
  - animal studies, **VI**:11, 46–47
  - cell studies, **VI**:11
  - fume buildup and decay, **VI**:16, 19
  - fume level vs. time measurements, **VI**:16, 18
  - impact of helmets on, **VI**:16
  - pulmonary function testing, **VI**:7
  - screening studies for fibrogenic potential, **I**:xxii, 10–11
  - voltage and current variations, **VI**:15
- fume generation rates (FGR), **VI**:15, **VII**:16, **IX**:19–20
- electrode composition, **V**:6
  - measurement techniques, **VI**:5
  - voltage and current effects in, **V**:5–6
- fume stability, **VII**:4
- gas emission studies, **VI**:6, 23
- genotoxicity studies, **X**:17, 66–68, **XIV**:58–59
- health and safety regulatory compliance and, **XIII**:57–59
- immune system effects, **XII**:8–9, 19, 66–67
- inductively-coupled plasma mass spectroscopy analysis, **XII**:23
- infrared radiation exposure studies, **VIII**:14
- kidney disease and, **X**:54–55
- lead exposure studies, **X**:22
- lipid peroxidation assays, **IX**:57
- lung cancer epidemiology, **IX**:36, **X**:40–44, **XI**:38–40, **XII**:48–50, **XIII**:7, 76–79
- magnetopneumographic analysis, **XI**:41–43
- mammalian cell studies, **VIII**:41–43
- manganese exposure, **I**:3, 70, **VII**:40, **X**:16–17, 65, **XIV**:9

- animal studies, **XIV**:66  
 biological monitoring, **XIV**:57  
 ventilation studies, **XIV**:12  
 metal fume fever and, **I**:38–39  
 mutagenesis assays, **V**:40–41  
 nervous system effects, **VII**:37  
 nickel exposure, **VI**:41–43, **VIII**:41, **IX**:52  
 nitrogen oxide production, **I**:74–75  
 noise exposure studies, **I**:77–78, **IV**:10, 19, **V**:1, 10  
 occupational asthma, **XI**:34–35  
 oculomotor studies, **VIII**:37–38  
 oxidative stress and inflammation and, **XIV**:50–52, 88  
 ozone production, **I**:3, 72, **IV**:6–7, **VII**:19, **VIII**:14, **IX**:24–25  
 particle analysis, **V**:7, **VI**:21–23, **VII**:6, 17–19, **XIV**:12, 25  
 particle size distribution, **I**:3, 70–71, **IV**:3–4  
 phosgene incidental exposure, **XIII**:43  
 photokeratitis, **IX**:40–41  
 pneumonia epidemiology, **XIV**:1, 7  
 pneumoconiosis, **V**:37–39, **XII**:44–45  
 pneumonitis incidence and, **XII**:15  
 protective coatings and, **IV**:7  
 protective equipment design, **IX**:28  
 pulmonary fibrosis, **XIV**:4  
   animal studies, **XIII**:33  
 pulmonary function testing, **V**:3, **VI**:28–32, **VII**:26–29, **IX**:32, **X**:9–10, **XII**:39–40, **XIV**:27, 81  
 pulmonary inflammation, **XII**:6, 21, 72–75  
 pulmonary retention and clearance studies, **IV**:xvi, 12–13, **V**:40, **VII**:7, 25–26  
   animal studies, **VII**:11, 42–44  
 radiation exposure studies, **IV**:9–10  
   underwater radiation exposure, **VIII**:18  
 respiratory changes in welders, **XII**:4, 14  
 respiratory disease and, **V**:17  
 respiratory tract cancer, **XII**:46–50  
 retinal injury, **XII**:55  
 silicon compounds and, **III**:2  
 skin cancer, **XII**:53  
 small bowel cancer epidemiology, **XIII**:82–83  
 spontaneous abortion and, **X**:15  
 toxicology studies, **IV**:25–27  
 trace metals exposure, **XII**:69–70  
 ultrafine particle analysis, **XIII**:74  
 ultraviolet radiation from, **I**:4, 77, **VI**:24, **VII**:6, 19–20, **XIII**:15, **XIV**:24  
 ventilation studies, **X**:28, **XIV**:12  
   general dilution ventilation, **XIV**:26  
 visual acuity loss and, **XIII**:91  
*in vitro* studies  
   bacterial assays, **VII**:12, 46  
   carcinogenicity studies, **II**:32–33, **III**:18–19  
   cytogenetic assays, **V**:41–42  
   cytotoxicity, **VII**:47  
   fume exposure studies, **IV**:xix, **V**:4  
   mammalian cell cultures, **VII**:12  
 voltage and current with, **IV**:2  
 welding hood configurations, **IX**:27–28  
 workplace exposure studies, **IX**:22–23, **X**:8, 22–23, **XI**:7–8, 18–20, **XIII**:17–18, 46–51  
   prevalence of abnormal chest x-rays and, **I**:8–9  
   work position and musculoskeletal injuries, **VIII**:38  
 zinc exposure studies, **X**:38–39  
 Shielding gas parameters  
   fume generation studies and, **V**:6, **XIII**:36–37  
   gas metal arc welding (GMAW), **X**:19–20  
   hazard analysis, **II**:2  
   ozone exposure studies, **I**:73–74, **V**:9–10  
 Shipyard welders  
   age-related studies, **I**:8  
   asbestos exposure, **VIII**:9, **X**:10  
   asthma in, **X**:10, **XI**:10  
   blood analysis in, **I**:30–31, 34  
   bronchitis in, **X**:10  
   cancer epidemiology, **VII**:9, 33  
   carbon dioxide/carbon monoxide production from, **I**:74–75  
   carcinogenicity studies, **VI**:33–34  
   chromium exposure in, **XIII**:31, 111–112  
   chronic respiratory abnormalities, **I**:14–15, 18–22  
   epidemiologic studies, **VIII**:30–31  
   eye injuries among, **I**:xix, 25, **XIV**:15, 40  
   fume exposure studies, cancer incidence and, **VI**:8  
   fume generation rates, **I**:67  
   gastrointestinal effects, **I**:34–35  
   hemoglobin levels, **I**:xix  
   hexavalent chromium exposure, **XIV**:89  
   leukemia incidence in, **VII**:3–4, 32–33  
   local exhaust ventilation systems, **XIII**:3–4  
   lung cancer incidence in, **V**:2, 28–30, **X**:11–12, 41, **XIII**:7, 22, 76–79, **XIV**:5, 14, 36  
   manganese exposure, **X**:23, 105–106  
   mesothelioma incidence in, **IV**:18–19, **V**:30–31, **X**:4  
   musculoskeletal effects in, **III**:xiv, **VI**:38  
   noise exposure studies, **VI**:6, **VII**:6  
   occupational exposure studies, prevalence of abnormal chest x-rays, **I**:8–9  
   oxidative stress and inflammation in, **XIV**:50–52  
   Parkinson's disease in, **XIV**:86–87  
   particle size distribution of welding fumes, **I**:70–71  
   pneumoconiosis in, **XIII**:66–68  
   pneumonia incidence among, **I**:7  
   pulmonary function testing, **IV**:14–15, **VI**:30–32, **VII**:8, 26–29, **VIII**:28, **XI**:3, 9, 26–30  
   respiratory disease in, **I**:8–9, **IV**:xvi, **V**:11–13, 19  
   skin cancer incidence, **X**:12  
   workplace exposure studies, **XIII**:17–18, 46–51  
   zinc fever in, **I**:38–39  
 Shoulder injuries, welding and, **IX**:11–12, 43–45  
   epidemiologic studies of welders, **IV**:22, **VI**:38, **VII**:38  
   tenonitis, incidence of, in welders, **VI**:8–9  
 Shrouds, protection from ozone with, **V**:10  
 Sick leave rates, hygiene and work practices, **XII**:13, 33–35  
 Siderofibrosis  
   epidemiology, **XIV**:4  
   pulmonary function studies, **VI**:31  
 Siderosilicosis  
   case reports, **XIII**:68–69

- epidemiological studies of, **XIII**:21  
 fume exposure studies, **I**:10
- Siderosis. *See also* Pneumoconiosis  
 agents for production of, **II**:10  
 animal fume inhalation studies, **I**:46, 92  
 biological monitoring of, **IV**:xiv  
 case studies of, **IX**:9, 32  
 epidemiologic studies, **X**:10, 37, **XIII**:21, 65–68, **XIV**:4, 33–34  
 fume exposure studies and, **III**:7  
 incidence of, in welders, **I**:7–11, **III**:10–11, **V**:12–13, **VI**:30–32  
 lung cancer risk and, **XII**:16, 50  
 manganese levels, **VII**:27–28  
 pneumoconiosis studies and, **XI**:36  
 pulmonary fibrosis studies, **IV**:13  
 pulmonary function testing, **I**:21–22, **VII**:7–8  
 respiratory tract studies, **IV**:xvi, 12–13, **XIV**:14  
 skin injury in welders and, **III**:13  
 x-ray studies, **I**:7–11
- Silica compounds  
 animal distribution and excretion studies, **I**:99–100  
 electrode coatings, **VI**:5, 19–20  
 fume screening studies yielding, **I**:xxii  
 pneumoconiosis and, **IV**:11  
 scleroderma incidence, **XIV**:41  
 systemic sclerosis and exposure to, **XIII**:26, **XIV**:15  
 in welding fumes, **I**:2, 68
- Silicon  
 animal toxicology studies, **IV**:27  
 fume exposure studies, **IX**:7  
 fume generation studies, **III**:xiii  
 health effects of, **III**:2  
 ozone generation and, **IV**:xv, 6  
 silicon tetrafluoride, electrode coatings, **VI**:5
- Silicosis  
 crystalline silicon as cause, **I**:2  
 pneumoconiosis incidence and, **X**:36  
 pulmonary function testing, **VIII**:27–28  
 silicon compounds linked with, **III**:2
- Silo-filler's disease, **II**:2
- Silver, study design, **II**:19
- Silver eye filters, specification studies, **X**:28–29
- SIMCA analysis, blood studies of welders, **I**:43
- Singapore, welders in  
 asthma epidemiology, **XIII**:5, **XIII**:20–21, 63–64  
 eye injury and disease in, **XIV**:84  
 respiratory disease studies, **IX**:9
- Single-shift tests, pulmonary function testing, **X**:3, 32
- Sino-nasal cancer  
 epidemiologic studies, **V**:24, **X**:4, 12, 46  
 incidence in welders, **XIV**:83
- Sinusitis, automotive assembly operations and, **XIV**:4
- Si/S ratios, pulmonary function testing, **VIII**:27–28
- Sister chromatid exchange (SCE)  
 biological monitoring techniques  
 fume exposure studies, **VI**:10  
 nickel and chromium compounds, **VI**:41–43  
 chromium exposure studies, **IX**:13, 50–51  
 cytogenetic assays, **V**:41–42  
 fume condensate carcinogenicity studies, **I**:xxii  
 genotoxicity studies, **X**:17, 66–68, **XI**:55–56, **XII**:20, 70–71  
 mammalian cell studies, **VIII**:41–43  
*in vitro* studies, **IV**:xix, 29, **V**:4, **VII**:12, **VIII**:7, 46–47  
 carcinogenicity studies, **III**:18–19
- Skin cancer  
 epidemiologic studies of welders and, **I**:24–25, **III**:xiv, 13, **IV**:xvii, 20, **XIII**:84–85  
 fume exposure studies, **II**:xxii, 17  
 photosensitivity mechanisms, **XIII**:13  
 radiation exposure and, **II**:xxii, 17, **VII**:19–20
- Skin conditions and injuries, **I**:39–41. *See also* Burn injuries  
 animal exposure studies, **II**:25  
 cancer epidemiology, **XII**:16–17, 52–53  
 contact dermatitis (*See* Contact dermatitis)  
 epidemiologic studies, **III**:xiv, 13, **IV**:xiv, xvii, 20, **IV**:11, **VII**:9, 37, **IX**:42, **X**:13, 41, 51, **XI**:12, **XI**:44–45, **XIII**:26, 93–95, **XIV**:85  
 fume exposure and, **I**:40–41, **II**:21  
 hot metal, exposure to, **II**:xx, 13  
 infrared radiation exposure, **IV**:9  
 laser welding, **X**:8, 24–25  
 nickel hypersensitivity, **X**:51  
 radiation exposure and, **II**:xix–xx, 13, **VII**:19–20  
 scleroderma, **X**:51, **XIV**:15, 41  
 ultraviolet radiation, **I**:xvi, 40, **III**:xiv, 13, 16, **VI**:24–25, **IX**:11, 38–39, 42
- Small bowel cancer, in welders, **XIII**:8, 23, 81–83
- “Smelters cataract,” epidemiology, **I**:27
- Smoking  
 acute respiratory infection and, **IV**:14  
 alveolar macrophage analysis and, **VII**:24–25  
 anti-oxidant exposure, **X**:61  
 asthma and, **IX**:9  
 bronchitis in welders and, **V**:19, **VI**:7, **VIII**:6, 28–29  
 cancer incidence in welders and, **V**:2, **VIII**:6, **IX**:4, 33–37  
 carboxyhemoglobin levels, **VIII**:5  
 cardiovascular disease in welders and, **X**:55, **XIII**:101–103  
 ceruloplasmin levels and, **X**:5  
 chromium exposure studies, **IX**:13  
 chronic bronchitis, **IX**:3, 30–32, **X**:33–34  
 chronic respiratory disease, cumulative effect of, **I**:12–22  
 ELF exposure studies, **VIII**:16  
 epidemiologic studies, role in, **I**:xviii, xxi, **II**:xxiii, **III**:8, 16, **VIII**:30–31  
 genotoxicity in welders and, **X**:17  
 kidney cancer in welders and, **V**:2  
 laryngeal cancer epidemiologic studies, **V**:26  
 lung cancer incidence in welders and, **I**:24, **IV**:17–19, **V**:29–30, **VI**:33–34, **X**:11–12, 41–44, **XII**:5, 47–50, **XIII**:6–7, 76–79  
 metal fume fever and, **I**:38  
 nasal and laryngeal cancer and, **IX**:9, 37  
 pancreatic cancer in welders and, **XIII**:80–81  
 pneumoconiosis in welders and, **XIII**:65–68  
 pulmonary function testing, **III**:10, **IV**:15, **VII**:8, 13, 26–29, **VIII**:6, 28–29, **IX**:9, **X**:31–32, **XIV**:12–13, 28–29  
 pulmonary retention and clearance studies, **V**:3–4

- respiratory disease in welders and, **III**:6, **IV**:xvi, 25, **V**:3, 12–20, **X**:35  
 acute respiratory disease and, **I**:7–8  
 bronchitis incidence with, **VI**:30–32  
 exposure studies, **IV**:12–14  
 pathogenesis of, **I**:81  
 toxicity studies, **II**:xx  
 as risk index, **VIII**:9–10  
 stainless steel welders, lung cancer epidemiology, **X**:3–4  
*in vitro* studies, cytogenetic assays, **V**:41–42
- Snowblindness. *See* Photokeratoconjunctivitis
- “Snowstorm lungs,” siderosis and mixed dust pneumoconiosis, **I**:7–8, 10
- Socioeconomic status  
 acute respiratory disease and, **I**:7–8  
 cancer epidemiology, **XII**:47–50  
 lung cancer in welders and, **XIV**:36
- Sodium fluoride  
 fume generation rates and electrode composition, **VI**:5, 19–20  
 particle analysis, **VI**:23
- Sodium intake  
 electrode coatings, **XIV**:11, 24  
 electrode fume generation, **V**:6, **VII**:4  
 occupational asthma, **XI**:34–35
- Soil studies, chromium levels, **IX**:5
- Solar retinitis. *See* Photoretinitis
- Solar retinopathy, epidemiologic studies, **XII**:17, 54–55
- Solderers, Non-Hodgkins lymphoma in, **XIII**:8–9
- Solid phase extraction/ion chromatography fluoride analysis, **X**:7, 21
- Solubilization and leaching, lung toxicity studies, **II**:9, 29
- Solvent compounds, systemic sclerosis and exposure to, **XIV**:15, 41
- SOS test, *in vitro* studies, **VII**:12, 46
- Source extraction, fume exposure and, **VIII**:11
- South Korean welders  
 chromium exposure in, **XIII**:31, 111–112  
 Parkinson’s disease in, **XIV**:86
- Spanish welders, pancreatic cancer studies, **XIII**:8, 23, 80–81
- Spearman rank correlation, pulmonary retention and clearance studies, **V**:19
- Sperm analysis  
 animal studies, **IX**:55, **X**:17, 69–70  
 fertility in welders, **IX**:4, 12, 48–49, **XIII**:12, 30  
 fume exposure and, **X**:14–15, 56–58  
 manganese exposure and, **XI**:13  
 reproductive function studies, **VIII**:7, 38–39, **XIV**:9–10, 18–19
- Spheroid degeneration in welders, **IX**:11, 41, **XIV**:39–40
- Spina bifida, children of welders, **XI**:13, 51, **XII**:65–66
- Spirometric measurements  
 asthma in welders, **XIV**:3, 31  
 interstitial pulmonary fibrosis, **XIV**:33–34  
 pulmonary function testing, **III**:8–10, **VI**:29–32, **VII**:27–29, **VIII**:29, **X**:29–32, **XI**:26–30, **XIII**:60–61, **XIV**:3, 13, 27–30, 81  
 respiratory disease in welders, **V**:11–12, 19
- Spontaneous abortion  
 fertility studies of welders and, **X**:4, 14–15, 57–58  
 in welders’ families, **IX**:12, 46, 48–49, **XIV**:54
- Sputnic air sampling unit, chromium analysis, **X**:20–21
- Sputtering techniques, particle analysis, **VII**:17–18
- Sputum analysis  
 alveolar macrophages, **VII**:7  
 health effects of welding and, **IV**:25  
 lung cancer screening with, **VII**:34  
 oxidative stress biomarkers, **XIV**:6  
 pulmonary function testing, **XIV**:3  
 respiratory disease studies, **V**:16–17
- Squamous cell carcinoma (SCC), epidemiologic studies, **XII**:16–17, 53
- Squamous cell epithelioma, ultraviolet radiation overexposure and, **I**:40
- Stainless-steel SPRAY welding, fume exposure and lung disease, **XI**:57–59
- Stainless steel (SS) welding  
 acute respiratory diseases and, **III**:6  
 alveolar macrophages, **VIII**:6  
 animal studies, **V**:4, 40, **VI**:11  
 fibrosis, **XIV**:20–21, 63–66  
 fume exposure, **XI**:14  
 fume inhalation studies in rats, **I**:86  
 infectivity and inflammation, **XIV**:20, 60–63  
 inflammation and fibrosis, **VII**:11  
 manganese exposure, **XIV**:66  
 pneumonia epidemiology, **XIV**:1  
 pulmonary retention and clearance studies, **V**:40, **VII**:43–44  
 toxicology studies, **IV**:xviii
- asthma and bronchitis incidence, **X**:10, 33–34, **XIV**:31  
 biological monitoring studies, **V**:22–23, **VI**:10, 41–43, **VII**:10–11, 42, **XIII**:114–115, **XIV**:89  
 blood analysis, **I**:42–43  
 carcinogenicity studies, **VI**:7–8, 13–14, 32–34, **VIII**:33, **IX**:4, 33, **X**:1  
 cell transformation assays, **V**:41  
 challenge test results, **XII**:41  
 chromium exposure measurements, **I**:3, 69–70, **III**:3, **VI**:15, 20, **IX**:51, **X**:16, 43, **XIII**:37–38, **XIV**:11, 55  
 chronic respiratory disease and, **I**:13–14  
 chronic bronchitis and, **IX**:9, 30  
 electrode composition, **VI**:19–20, **VIII**:12  
 fertility studies, **IX**:48–49, **X**:57–58  
 fume exposure studies, **VII**:5, **IX**:7  
 analytic techniques, **VII**:16–17  
 animal studies, **VI**:11  
 biological monitoring techniques, **VI**:10  
 chromium exposure, **VII**:16  
 fume generation studies, **I**:66–67, **II**:2, **XIV**:11  
 during GMAW, **IX**:20–21  
 gas tungsten arc welding, thoriated electrodes, **XIV**:11  
 genotoxicity studies, **XIII**:31, 110–111  
 hexavalent chromium exposure, **V**:8–9  
 job-exposure matrix, **XII**:37–38  
 kidney function and, **V**:3, **VII**:39  
 laryngeal cancer epidemiologic studies, **V**:26–27  
 lung cancer epidemiology, **XII**:5, 16, 48–50, **XIV**:35, 83

- lung cancer incidence, **IV**:17–19, **V**:29, **VII**:33, **IX**:36, **X**:4, 11–12, 41, 43, **XIII**:7
- manganese exposure studies, **XIV**:9
- rat studies, **XIV**:66
- mutagenesis assays, **V**:40–41
- neurodegenerative disease and, **XIV**:9
- nickel compounds in, **I**:3, 70, **VI**:41–43, **XIV**:55
- oxidative stress and inflammation and, **XIV**:88
- particle analysis, **V**:7
- particle size distribution, **I**:3, 70–71, **IV**:3–4
- pneumonia risk and, **XIV**:1, 7
- pulmonary function testing, **V**:3, **VI**:28–32, **IX**:30–31, **X**:9–10, **XI**:9, 26–30, **XII**:39–40
- pulmonary inflammation, **XII**:6, 21, 72–75
- pulmonary fibrosis, **XIV**:4
- pulmonary retention and clearance studies, **VII**:7, 25–26
- radiation from, **I**:4
- reproductive function and, **XIV**:10, 54
- respiratory changes and, **I**:xxi–xxii, **V**:12–13, 19, **XII**:4
- ultraviolet radiation exposure, **I**:77, **VI**:24
- ventilation requirements, **XIII**:19
- in vitro* studies, **V**:4
- bacterial assays, **VII**:12
- carcinogenicity studies, **II**:32–33
- cytotoxicity, **VII**:47
- mammalian cell cultures, **VII**:12
- workplace exposure limits, **IX**:23, **XIII**:18, 48–51
- Standardized hospitalization ratio (SHR)
- cardiac disease in welders, **X**:55
- neurodegenerative disease in welders and, **XIV**:47–49
- Standardized incidence ratio (SIR)
- brain cancer epidemiology, **VII**:33
- cancer epidemiology, **XII**:46–50
- lung cancer epidemiology, **IX**:33–34, **X**:41, **XI**:37–40, **XIII**:77–79
- Standardized mortality ratios (SMR)
- cancer epidemiology, **XII**:47–50, **XIII**:75
- cardiovascular disease in welders, **XIII**:101–103
- lung cancer epidemiology, **IV**:xiv–xvii, 16–17, **V**:28–30, **IX**:33–34, **X**:40–44, **XI**:38–40, **XIII**:75–79, **XIV**:36
- mesothelioma incidence and, **V**:30–31
- pancreatic cancer, **VII**:32
- pneumonia fatalities in welders, **X**:36
- respiratory disease studies, **V**:14–15
- Statistics, epidemiologic studies, **VIII**:30, 32
- Steadiness test, aluminum exposure and neuromotor function, **XIII**:98
- Steel welding
- asthma and, **XIV**:4
- lead, incidental exposure studies, **XIII**:42
- manganese exposure
- neuropsychological function, **XIV**:44
- mesothelioma incidence and, **XIV**:36–37
- pneumonia risk and, **XIV**:6–7
- shielded metal arc welding, fume composition, **I**:1–2, 59–60
- thoriated electrodes, exposure studies, **XIV**:24
- workplace exposure analysis, **XIII**:17–18
- Stellite welding
- asthma incidence and, **XIV**:82
- pulmonary function testing, **XI**:3
- workplace exposure studies, **XI**:8
- Still births, in welders' families, **IX**:12, 46, 48–49
- Stomach cancer, epidemiologic studies, **VII**:9, 31–33, **X**:12
- Streak sampling techniques, particle analysis, **IV**:4
- Streptococcal pneumonia, in welders, **XIII**:22
- Stress
- epidemiological studies, **IX**:8
- musculoskeletal effects of welding and, **IX**:11–12
- during welding process, **I**:4
- working conditions and, **IX**:29
- Stroop Color-Word Test
- aluminum exposure and cognitive function in welders and, **XIV**:42–43
- manganese exposure studies, **XIV**:85
- Subchronic toxicity of chromium compounds, **V**:39–40
- Subclinical conditions, fume exposure, **II**:xiii
- Subcutaneous effects of welding, **I**:102–103
- Submerged arc welding (SAW)
- chronic fluorosis and, **I**:xix
- conjunctivitis and, **IX**:11, 41
- electrode composition, **I**:2, 67
- electromagnetic field exposure studies, **X**:8
- fume generation, **I**:67, **III**:, **IX**:20
- ozone production, **I**:4
- radiation exposure studies, **IX**:26–27
- ultraviolet radiation from, **I**:77
- Subtilisin, blood and urine analysis with, **X**:8, 21
- “Sudden movement” injuries, **IX**:43–45
- Suffocation, welding and, **I**:29
- Superconducting quantum interference device (SQUID)
- epidemiologic studies, **XI**:11, 42–43
- particle analysis, **VIII**:6, 27
- Superoxide dismutase
- current research, **X**:5, 61
- immune function in welders, **XIII**:29, 105–106
- oxidative stress and inflammation in welders and, **XIV**:17–18, 50–52, 88
- pulmonary function testing, **XIV**:13, 29
- Supplemental fluxing compounds, fume composition and, **XIII**:14, 35–37
- Supraspinatus tendonitis
- epidemiologic studies, **IV**:xvii, 22, **VI**:38
- welding injuries and, **IX**:44–45
- Surface plasma formation, laser radiation hazards, **VIII**:15–16
- Surveillance of Work-related and Occupational Respiratory Disease (SWORD) study, **X**:10, 35, **XIV**:30
- asthma, **XI**:33–35
- Susceptibility bridge measurements, pulmonary retention and clearance studies, **V**:19, **VII**:7, 25–26
- Swedish fume box technique, fume composition studies, **X**:19–20
- Swedish welders
- aluminum exposure, **IX**:52–53
- asthma in, **XI**:3–4, 33–35, **XII**:40–42
- brain cancer in, **V**:2, 32
- breathing zone particle concentrations, **X**:33–34
- cancer in, **XII**:45–50
- endocrine gland tumors in, **XIV**:38

incidental exposure studies, **IX**:53–54  
 ischemic heart disease in, **XIII**:28, 101–103  
 kidney cancer in, **V**:2, 31  
 kidney disease in, **V**:20–21  
 leukemia and brain tumors in, **IX**:38, **XIII**:86–87  
 lung cancer incidence and smoking in, **XIII**:6–7, **XIII**:76–79  
 lymphomas among, **X**:46  
 mesothelioma and, **V**:30–31  
 multiple sclerosis incidence, **X**:52  
 musculoskeletal disorders in, **IX**:43  
 neurodegenerative disease in, **XIV**:9, 42, 48  
 nasal cancer epidemiologic studies, **V**:24–25  
 pulmonary function testing and, **X**:30–32  
 thoriated electrode exposure studies, **XIV**:11, 24  
 ventilation studies of, **X**:9, 28  
 “Sweet’s syndrome,” **XIII**:26, 94–95  
 Syrian hamster embryo (SHE) cell cultures  
 cell transformation assays, **V**:41  
 fume exposure studies, **VI**:11, 47–49  
 mammalian cell studies, **VIII**:41–43  
*in vitro* studies of welding and, **V**:4  
 Systemic sclerosis in welders, **XIII**:26, 95–96, **XIV**:15, 41

## T

Tack-welding practices  
 fume exposure studies, **IX**:8  
 ventilation and air cleaning equipment, **IX**:27  
 Taiwanese welders  
 eye injuries in, **XIV**:15, 84  
 lead levels in, **XIV**:19, 57  
 photokeratitis in, **XIV**:39  
 pulmonary function testing, **XIV**:81  
 Tannery workers, genotoxicity studies, **XIV**:20, 59  
 Tanzanian welders, epidemiologic studies of, **XIV**:19, 54–55  
 Teeth  
 epidemiologic studies, **IV**:xvii–xviii, 23, **IX**:12, 49  
 fume exposure studies, **VI**:9, 40  
 metal compound exposures and, **II**:15  
 welding effects on, **III**:14, **VII**:10, 39–40  
 Telemetric measurement, noise exposure studies, **VII**:20–22  
 Temporary threshold shifts (TTS), noise exposure studies, **VIII**:34–36  
 Testes, welding carcinogenicity studies, **VI**:34  
 Tetrachloroethylene, as degreasing solvent, **I**:76  
 Tetrafluoroethane, hydrogen fluoride exposure, **XIV**:12  
 Thailand welders, manganese exposure in, **XIV**:57  
 Thermal degradation products, of production coatings, fume exposure studies, **VI**:26  
 Thermal exposure studies, **X**:27  
 fertility in welders and, **X**:56–57  
 temperature measurements, **X**:9  
 Thermal injuries  
 corneal burns, **I**:26–27  
 epidemiologic studies, **X**:13, 50  
 eye injuries, **VIII**:36–37  
 retinal damage, **III**:12  
 Thermal spray welding, biological monitoring, **XIV**:89  
 Thermoluminescence dosimetry  
 thorium exposure studies, **XII**:29–31  
 ultraviolet emissions, **XIV**:11, 24  
 Thiobarbituric acid reactive substances (TBARs)  
 oxidative stress and, **XIV**:6  
 pulmonary function testing and, **XIV**:13, 29  
 Thiocyanate levels, lung cancer screening, **VII**:34  
 Thoracic magnetic moment measurements, pulmonary retention and clearance studies, **VIII**:27  
 Thiols  
 oxidative stress and, **XIV**:6  
 pulmonary function testing and, **XIV**:29  
 pulmonary function testing and levels of, **XIV**:13  
 Thoriated electrodes  
 cancer epidemiology and, **X**:12  
 exposure studies, **XIV**:11, 24  
 lung cancer incidence, **X**:44–45  
 Thorium oxide exposure studies, **XII**:12, 29–31, **XIII**:38–39  
 chromatographic analysis, **XIII**:15  
 gas tungsten arc welding, **I**:65–67, **III**:5, **XIV**:24  
 Threshold limit values-time-weighted averages (TLV-TWA), workplace exposure analysis, **XI**:18–20  
 Threshold limit value (TLV) index  
 chromium generation studies, **IV**:4–5  
 dioxin exposure, **XII**:28–29  
 fume-gas-vapor interactions and, **IV**:xx, 8  
 fume generation rates and, **III**:2, 19  
 animal studies, **VI**:10–11  
 ventilation conditions, **VI**:15  
 welding emissions, **VI**:13  
 iron oxide exposure, **XII**:28  
 laser welding hazards, **X**:23–25  
 manganese exposure, **XII**:59–61  
 local exhaust ventilation systems, **XIII**:3–4  
 ventilation design, **XIV**:12, 26  
 OSHA standard, **I**:79  
 ultraviolet exposure, **XIII**:3, 15, 41  
 workplace exposure analysis, **IX**:23, 18–20, **XIII**:17–18, **XIII**:18, 45–51  
 Throat cancer, epidemiologic studies, **XII**:5, 51  
 Thyrotropin levels in welders, **XIII**:29, 104  
 Thyroxin levels in welders, **XIII**:29, 104  
 Tidal volume (TV)  
 pulmonary function testing, **I**:82  
 shielded metal arc welding and, **XIV**:4  
 Time-to-pregnancy (TTP) approach, reproductive function studies, **XII**:8, 62–65  
 Time-weighted air chromium concentrations, **V**:22–23  
 Time-weighted average (TWA) exposure  
 iron oxide, **XII**:28  
 lead, incidental exposure studies, **XIII**:16, 42  
 manganese poisoning, **XII**:69  
 Tin  
 fume exposure studies, **IX**:7  
 fume generation rates, **IX**:20  
 in paints, exposure studies, **VI**:25–26  
 T lymphocytes, welding effects, **XII**:8–9  
 Total antioxidant status (TAS), pulmonary function testing, **XIV**:29



- Total fume exposure, respiratory symptoms, **XIV**:3
- Total Gas Volume, pulmonary function testing, **VIII**:29
- Total lung capacity (TLC)  
pre-employment vs. adult values, **X**:29–30  
pulmonary function testing, **I**:82, **VII**:26–29, **X**:32  
role of, in respiratory disease studies, **V**:17
- Toxicity effects  
animal studies, **II**:xxii, 23, **III**:16–18, 23–30, **IV**:xvii–xix, 25–28, **VII**:11–12, 44–45  
fume-gas-vapor interactions and, **IV**:xx  
manganese exposure, **XII**:18  
overview, **VIII**:7  
*in vitro* studies, **IV**:29, **V**:42
- Toxicokinetics  
fume generation, **II**:xxi  
welding toxicity studies, **II**:xiii
- Trace metals, biological monitoring, **XII**:20, 69–70
- Tracheal carcinoma, epidemiologic studies, **XI**:11, 40
- Training and education  
exhaust equipment use, **X**:9, 28  
hygiene and work practices, **XII**:13, 37–38  
risk reduction with, **VII**:7, 12, 24
- Transcranial sonography (TCS), Parkinson's disease and parkinsonism in welders, summary of studies, **XIV**:86–87
- Transferrin, iron exposure and, **IX**:13, 50, **XIV**:57
- Transmission electron microscopy (TEM)  
aerosol analysis, **VIII**:13  
animal studies, **VII**:43–44  
biological monitoring studies, **VII**:17
- Trapped gas volume, pulmonary function testing, **X**:9
- Traumatic injury  
hygiene and work practices, **XI**:8–9  
work practices and, **XI**:23–24
- Trichloroethane compounds  
accidents with, **VII**:6–7, 21, 23  
ignition hazard studies, **VIII**:20  
incidental exposure in welders, **IX**:14, 53  
photochemical decomposition from UV radiation, **VI**:6, 14, 26–27
- Trichloroethylene  
as degreasing solvent, **I**:75–76  
incidental exposure in welders, **IX**:14, 53  
photochemical decomposition from UV radiation, **VI**:6, 14, 26–27
- Trichlorofluoromethane, degreasing agents, fume exposure studies, **VI**:26
- Tritium, radiation exposure studies, **IX**:27
- Trivalent chromium (CrIII). *See also* Chromium exposure, Hexavalent chromium  
aerosol measurements, **XI**:16–17  
analytical methods for, **X**:7, 20  
animal studies of fertility, **X**:69–70  
biological monitoring, **VII**:4, **XI**:55  
DNA-protein cross-links, **XI**:56  
exposure analysis, **XII**:23–24  
fertility and welding, **IX**:4  
genotoxicity studies, **XIV**:58–59  
fume composition studies, **XII**:11  
ozone measurements, **XI**:17  
ventilation systems analysis, **XIII**:56–59  
workplace exposure studies, **X**:8
- TRIVA test (Time required for restoration of visual acuity), radiation-related eye injury, **VI**:37
- Tuberculosis  
animal fume inhalation studies, **I**:104  
incidence of, in welders, **I**:49, **V**:12  
pneumoconiosis incidence and, **X**:36–37
- Tumor antigens  
duration of exposure and presence of, **XI**:5  
in welders, **XI**:54
- Tumor necrosis factor (TNF)  
animal studies, **X**:72–74, **XII**:71–72  
infectivity and inflammation, **XIV**:60–63  
cell cultures, **XII**:71–72  
duration of exposure and presence of, **XI**:5–6  
fume exposure and lung disease, **XI**:57–59  
metal fume fever and, **IX**:10, 39, **X**:5, **XII**:5–6, 17
- Tungsten carbide, hard metal coatings, **X**:39–40
- Tungsten electrodes vs. thoriated electrodes, **X**:44–45
- Tungsten inert gas (TIG) welding. *See* Gas tungsten arc welding (GTAW)
- Tunneling projects, workplace exposure analysis in, **XIII**:17–18, 47–51
- Turkish welders  
pneumothorax in, **XIV**:14  
pulmonary function testing in, **XIV**:13, 28–29
- Twin studies, asthma epidemiology, **X**:30
- Two-compartment elimination model, chromium compound biological monitoring, **V**:3
- Tympanic membrane injury, epidemiologic studies, **XIV**:15, 41
- Type A personality characteristics, musculoskeletal injury and, **VIII**:9, 38
- Type O blood, ischemic heart disease in welders and, **XIII**:28, 102–103

## U

- Ulcerative disease, welding and, **I**:xix
- Ultrafine particle analysis  
current research on, **XIII**:71–74  
sampling strategies, **XIV**:11, 23–24
- Ultraviolet (UV) radiation  
analytic techniques used on, **V**:1  
animal studies, **I**:105–106  
cancer in welders and, **IX**:10, 38–39  
carcinogenicity of, **I**:xvi  
cataracts and, **IX**:40  
chronic actinic dermatitis, **X**:13, 51  
contact dermatitis, **VI**:8, 37  
degreasing agents  
incidental exposure, **IX**:53  
photochemical decomposition, **VI**:6, 14, 26–27  
dermatosis, **XI**:44–45  
electric current, **I**:77  
electrode coatings, **XIV**:11  
epidemiologic studies, **III**:16, **XI**:8, 21–22

- exposure studies, **II**:4, **III**:xiii, **IV**:xv–xvi, 9–10, **V**:10, **VI**:6, 24–25, **VII**:6, 19–20, **VIII**:5, 14–16, **IX**:8, 25–26, **XII**:31–32, **XIII**:2–3, 15, 40–41  
 eye cancer epidemiology and, **XI**:40–41, **XIII**:9, 23, 84, **XIV**:5  
 eye drop protection for, **XII**:17, 55–56  
 eye injury due to, **I**:xviii–xix, 26, **II**:12–13, **III**:xiv, **IV**:19–20, **VI**:8, 35–37, **VII**:35–36, **XIV**:15, 39  
 fume composition analysis, **XII**:25  
 fume generation linked with, **III**:5  
 hexavalent chromium exposure and, **XII**:11  
 laser welding exposure, **X**:23–25  
 maximum permissible exposure (MPE) limit, **XII**:12–13  
 ocular melanoma risk in welders and, **XIII**:9, **XIII**:23, **XIV**:5, 14, 37  
 ozone generation, **I**:3–4, 6, 72–74, **IV**:6–7, **VI**:23, **VII**:19, **IX**:24–25  
 permissible exposure levels, **VII**:19–20  
 photokeratitis and, **IX**:40–41, **XIII**:93  
 photosensitivity in welders and, **XIII**:13  
 process differences, **I**:77  
 protective gear for, **I**:77, **VII**:7, **X**:9, 29  
 reflection, **I**:77  
 retinal damage from, **III**:12  
 shielded metal arc welding, **I**:4, **XIV**:24  
 skin cancer epidemiology, **I**:24–25, 40, **II**:17, **X**:12, **XII**:52–53, **XIII**:84–85  
 skin conditions and injuries, **XIII**:26  
 skin injuries due to, **II**:13, **III**:13, **IV**:xvii, 20, **VII**:37, **IX**:11, 42  
 spectral variation, **I**:76  
 workplace exposure studies, **XII**:3, **XIII**:46–51  
 Underwater electric arc welding  
   effects on teeth, **VII**:10, 39–40  
   ELF exposure studies, **VIII**:16  
   fume exposure studies, **VI**:9, 40  
   hyperbaric pressure studies, **VI**:9, 40, **VII**:48  
   radiation exposure minimization, **VIII**:17–18  
   *in vitro* studies, **VII**:48, **VIII**:43  
 United Kingdom  
   asthma incidence in welders from, **X**:10, 35, **XIII**:4–5, 61–64, **XIV**:13, 30, 82  
   breathing zone studies in, **VIII**:11  
   bronchitis in welder in, **X**:10, 35, **XIII**:4–5, 61–64  
   eye injuries, **IX**:11, 41  
   hand-arm vibration syndrome in Scottish welders, **XIII**:28, 103–104  
   manganese exposure in welders, **XIII**:11  
   pneumonia among welders in, **X**:3, 10, 36, **XIV**:34–35  
   respiratory disease in, **V**:13, **IX**:30  
 Unresolved hazards, eye injuries and, **VIII**:9  
 Unscheduled DNA synthesis (UDS), genotoxicity studies, **X**:17, 66–68, 107  
 Upper digestive tract cancers, epidemiologic studies, **XII**:5  
 Uptake-reduction model of chromium reactions, **VIII**:34  
 Urinary coproporphyrin levels, lead exposure studies, **VI**:10, 43–44  
 Urine analysis  
   aluminum exposure, **V**:3, **VI**:43, **VII**:40, **IX**:52–53, **X**:52–53, **XII**:11, 23, **XIV**:85, 89  
   animal studies  
     fume exposure studies, **VI**:11  
     inflammation and fibrosis, **VII**:11  
     pneumoconiosis, **V**:38–39  
     whole-body effects, **V**:39–40  
   barium exposure, **X**:16, 61–62  
   biochemical studies, **II**:16, **IV**:24  
     metal compound analysis, **III**:14–15, **IV**:xviii, 24–25  
   biological monitoring techniques, **V**:22–23, **VI**:9–10, **VII**:4, 10–11, **VIII**:7, **XIII**:32, **XIV**:89  
     aluminum, **VIII**:40  
     chromium, **VI**:41–43, **VII**:4, 40–41, **VIII**:40–41, **XIV**:19, 55  
     nickel, **VI**:41–43, **VIII**:41, **XIV**:19  
     polycyclic aromatic hydrocarbon, **XIV**:19, 55–57  
   cadmium exposure, **VI**:38–39, **VII**:38–39, **IX**:46–48, **X**:16, 62–63  
     kidney function and, **XIV**:53  
   chromium exposure, **X**:8, 63, **XII**:67–68, **XIV**:19  
   cobalt exposure, **X**:16, 63–65  
   fertility studies, **X**:56  
   Finnish Biological Action Limits, chromium and nickel, **X**:8, 22–23  
   fluoride levels, **II**:xvi  
     toxicity studies, **III**:15  
   fume exposure studies, **I**:41, 43–44, **II**:14–15  
     animal studies, **VI**:11  
     biological monitoring techniques, **VI**:9–10  
   genotoxicity studies, **X**:67–68, **XIV**:58–59  
   incidental exposure to degreasing agents, **IX**:53  
   kidney disease in welders and, **X**:16, 54–55  
   lead exposure studies, **II**:16, **X**:60–61  
   manganese exposure, **IV**:21, **X**:16, 62–63, **XII**:18, manganese exposure, **XIV**:85–87, 89  
   mercury exposure, **X**:15, 59–60, 65–66  
   metallic compound studies, **II**:xiii–xiv, xxi, xxiii, **IX**:13, **X**:21  
   metals analysis in, **X**:21  
   nervous system studies, **IV**:xvii  
   nickel compounds, **III**:xiv, xv, 15, **IV**:xiv–xviii, **V**:3, **XIV**:19  
     biological monitoring techniques, **VI**:41–43, **VIII**:41, **XIV**:55  
     exposure studies, **IX**:31  
   oxidative DNA damage and, **XIV**:18, 88  
   plutonium exposure, **X**:16, 66–68  
   pneumoconiosis, **V**:38–39  
   pulmonary function testing, **X**:12, 31  
   pulmonary retention and clearance studies, **IV**:12–13  
   respiratory disease studies, **V**:13  
   thoriated electrode exposure, **X**:45  
   toxicity studies with, **III**:14–15  
   urogenital tract studies, **VIII**:7, 39–40  
   workplace exposure studies, **X**:16, 22–23  
     biological monitoring techniques, **VI**:41–43, **VII**:4, 40–41  
     biomarkers, **IX**:50–51

chromium compounds, **II**:xvi, **IV**:xiv, **V**:3  
 exposure studies, **IX**:5, 13, 31, 46, 51–52, **X**:8, 63  
 toxicity studies, **III**:15  
 Urogenital tract. *See also* Kidneys, Reproductive function  
 cancer, welders and, **IX**:37  
 epidemiological studies in welders of, **VII**:4, 10, 38–39,  
**VIII**:7, 39–40  
 fume exposure studies, **I**:31, **VI**:9, 38–39  
 Urticarial reactions, in welders, **IX**:14, 54  
 Uveal melanoma  
 epidemiologic studies, **XI**:40  
 UV radiation in welders and, **IX**:39

## V

Valeur moyenne d'exposition (VME)  
 iron oxide, **XII**:69  
 manganese poisoning, **XII**:69  
 Vanadium  
 biological monitoring of, **XIII**:32, 114–115, **XIV**:55–57  
 particle retention studies, **VIII**:26–27  
 pentoxide exposures, respiratory disease studies, **V**:18  
 relative fume formation rate (RFFR) and, **IX**:20  
 Vapor-barrier garments, research on, **VII**:7  
 Vaporization, fume component studies, **IX**:19, **XI**:15–17  
 Ventilation design and requirements  
 airflow requirements, **IV**:xv  
 electrode composition and, **IV**:2  
 air quality studies and, **X**:9  
 dilution ventilation, **XIV**:12  
 exhaust rate studies, **XIV**:12  
 fume exposure studies, **II**:xix, **VIII**:11, **IX**:8  
 fume generation rates and, **II**:1, **VI**:15  
 hygiene and work practices, **IX**:27, **X**:27–29, **XIII**:18–19,  
 51–57  
 incidence of kidney disease and, **V**:20–21  
 laryngeal cancer epidemiologic studies, **V**:26  
 low exhaust ventilation, **XIII**:3–4  
 lung transfer factor studies, **X**:3  
 manganese exposure, **XIV**:44, 86  
 particle analysis, **IV**:4, **XIV**:25  
 pneumonia risk and, **XIV**:89  
 push-pull ventilation systems, fume exposure studies,  
**XIV**:12  
 reproductive system disorders and, **X**:15  
 respiratory tract studies, **V**:18  
 ventilatory parameters, **IX**:3  
 siderofibrosis risk and, **XIV**:4  
 Vertebral epiphysitis, in welders, **IX**:45  
 Vestibulopathy, welding, **VIII**:37–38  
 Vibration disorders, epidemiologic studies of, **IV**:21–22  
 Vibration-induced white finger (VWF), epidemiologic studies,  
**X**:13, 55, **XI**:13, 50  
 Video-based evaluation techniques, lower back pain, **XI**:47  
 Visible light  
 exposure measurements, **VIII**:14–16  
 eye injuries and, **VI**:35–37  
 radiation exposure studies, **II**:xix–xx, 4, 12, **VI**:25,  
**VII**:19–20

retinal damage from, **III**:xiii, 12  
 Visual acuity and loss. *See also* Eye injuries  
 acuity assessment, **I**:27, **XIII**:25, 91–92  
 aerosol analysis, **VIII**:13  
 effects of welding on, **I**:xviii–xix, xxii, 27–28, **II**:xx, **III**:xiv,  
 12, **VII**:9, 19–20, 35–37  
 epidemiologic studies, **IV**:xvii, 19–20, **VII**:9, **VIII**:6,  
 35–37, **X**:13, 50, **XIV**:15, 39  
 manganese exposure studies, **XIV**:85–86  
 radiation exposure studies, **VI**:8, 35–37  
 retinal injury (*See* Retinal injury)  
 Visual evoked potentials (VEP)  
 manganese exposure studies, **XIV**:7–9, 16  
 neurophysiological effects, **XIV**:43  
 Vital capacity (VC) measurements  
 chronic respiratory disease, **I**:20–21  
 manganese exposure, neurophysiological effects, **XIV**:43  
 pulmonary function testing, **I**:82, **IV**:15, **VII**:26–29  
 respiratory disease studies, **V**:17–18  
 Vitamin B1  
 animal studies of UV radiation and, **I**:105  
 visual acuity in welders and, **I**:27  
 Voice, effects of welding on, **VII**:11, 40  
 Volatile organic compounds, incidental exposure studies,  
**XIV**:11–12, 25  
 Voltage  
 fume composition and, **VI**:15  
 fume emissions linked with, **IV**:2, **V**:1  
 fume generation rates (FGR), **II**:1, **V**:5–6, **VII**:15–19  
 ozone exposure studies, **V**:9–10  
 particle generation and, **IV**:4  
 ultraviolet (UV) radiation and, **VII**:19–20  
 von Hippel-Lindau gene, renal cell carcinoma in welders and,  
**XIII**:8, 23, 80  
 VTG, pulmonary function testing, **X**:31–32

## W

Wales, pneumonia incidence in welders in, **X**:3, 36  
 “Wastage” variable in welding disability studies, **X**:33  
 Wavelength-dispersive X-ray fluorescence, fume composition  
 analysis, **X**:7, 20  
 Wechsler Memory Scale, aluminum exposure and cognitive  
 function in welders and, **XIV**:42–43  
 Weight change, animal fume inhalation studies  
 in rabbits, **I**:91  
 in rats, **I**:84–85, 95–97  
 Welder’s flash. *See also* Photokeratitis  
 Welding arc maculopathy, **XIV**:40, 84  
 Welding byproducts, chemical and physical agents, **I**:57  
 Welding cowl, use of, in animal studies, **II**:24  
 Welding helmet, protective properties of, **XI**:23  
 Welding processes, most widely used processes, **III**:2  
 Welding screens and curtains, specification studies, **X**:9  
 Weld inspection, radiation exposure studies, **VIII**:17–18  
 Weld-pool surface, fume generation from, **XI**:15–17  
 Wet chemistry technique, X-ray fluorescence spectrometry,  
**VIII**:14  
 Wet impingement techniques, fume exposure studies, **VII**:5, 16

Wheezing, pulmonary function testing, **XIV**:3  
 “White finger syndrome,” incidence of, in welders, **IV**:21  
 White spirit exposure, scleroderma incidence, **XIV**:41  
 Whole-body effects of welding, animal studies, **V**:39–40  
 Wilm’s tumor  
   in children of welders, **IX**:37  
   epidemiologic studies, **VIII**:6, 32  
 Women welders  
   asthma epidemiology in, **XIII**:62–64, **XIV**:30–31  
   cancer in, **XIV**:83  
   cardiovascular disease in, **X**:55  
   connective tissue effects in, **XIV**:41  
   hazard analysis for, **XI**:9, 24–25  
   health and safety studies, **XI**:3  
   lung cancer epidemiology, **X**:4, 11, 43  
   metal fume fever in, **XIV**:31  
   neurodegenerative disease in, **XIV**:42–49  
   photokeratitis in, **XIV**:39  
   pregnancy risks in, **XIV**:88  
   renal cell carcinoma in, **XIII**:79–80  
   reproductive disorders in, **X**:1  
   workplace exposure analysis, **XIII**:48–51  
 Work experience, health risks of welding and, **III**:1  
 Working conditions  
   accidents, incidence of, **II**:7, **VII**:6–7, 221, 23, **IX**:28–29  
   analytical techniques, **X**:22–23  
   asthma incidence, **XIV**:30  
   biological monitoring of disease, **V**:22–23  
   cancer risk studies and, **IV**:xix  
   carpal tunnel syndrome (CTS) in welders and, **IX**:12  
   chronic respiratory disease, **I**:9, 17–18  
   electrode composition, **VIII**:12  
   electromagnetic radiation, **XII**:3  
   in epidemiologic studies, **V**:1  
   exposure studies, **IX**:22–24, **X**:9, **XI**:17–21, **XII**:11–12, **XIII**:17–18, 45–51, **XIV**:12, 25  
   fume exposure studies, **III**:4, **VII**:6–7, **IX**:8, **XI**:7–8  
   fume generation rates, **VI**:15  
   fume sampling procedures, **XII**:3  
   hazard reduction in, **III**:1  
   hygiene practices, **XI**:8–9, **XIII**:18–20  
   incidental exposure studies, **IX**:8  
   laryngeal cancer epidemiologic studies, **V**:26  
   lead exposure, **X**:8  
   local exhaust ventilation, **XII**:3–4  
   lung cancer incidence and, **IV**:17–19  
   musculoskeletal injury prevention and, **X**:53–54  
   neck and shoulder disorders, **VII**:38  
   noise levels and, **V**:1  
   particle generation studies, **IV**:4  
   particle size distribution, **XII**:25–27  
   protective gear and equipment, **IX**:27–28, **XI**:23  
   radiation reduction and, **III**:5  
   recommendations for improvement of, **III**:20  
   risks to welders in, **VIII**:9  
   safety and accident prevention, **IV**:xx, **VIII**:6, **XI**:24–25  
   shoulder pain in welders and, **IV**:22, **VII**:38  
   stress, **IX**:29  
   traumatic injuries, **XI**:23–24

ultrafine particle analysis in, **XIII**:73–74  
 ventilation and air cleaning equipment, **IX**:27  
 workplace design, accident rates and, **IX**:28–29  
 work position and musculoskeletal injuries, **VIII**:38

## X

X-ray diffraction analysis  
   pulmonary retention and clearance studies, **VII**:7, 26  
   welding particles, **V**:7, **VI**:22  
 X-ray fluorescence (XRF)  
   aerosol analysis, **VIII**:14  
   bone lead measurements, **X**:59–60  
   chromium compound exposure studies, **V**:7–9  
   electrode composition analysis, **VI**:19–20, **VII**:16  
   fume components, **VII**:5, 16–17  
   metals analysis, **X**:20  
   particle studies and, **IV**:3  
 X-ray microanalysis  
   animal studies, **VII**:43–44  
   biological monitoring studies, **VII**:17  
   workplace exposure studies, **XI**:20–21  
 X-ray photoelectron spectroscopy (XPS)  
   aerosol analysis, **VIII**:13–14  
   particle analysis, **VI**:23  
 X-rays. *See also e.g.*, Energy dispersive X-ray analysis (EDXA), specific types of x-ray analysis  
   chest X-rays  
     age and working conditions and, **I**:8–11  
     fume exposure studies, respiratory system, **VI**:28–32  
     opacities in, **VII**:7–8, 24  
     particle accumulation studies, **VI**:27–28  
     pulmonary function testing, **VIII**:28  
   chronic lung conditions, **I**:xv–xviii  
   epidemiologic studies, respiratory disease, **V**:11–20  
   fume carcinogenicity, skin cancer, **II**:17  
   lung cancer incidence and, **IV**:17–19, **VII**:34  
   metal fume fever studies, **IV**:xviii  
   pneumoconiosis in welders, **VI**:7  
   pulmonary fibrosis studies, **IV**:13  
   pulmonary function testing, **IV**:15, **VII**:7–8, 24, 27–29, **X**:31–32  
   research methodology, **III**:11–12  
   respiratory disease, **IV**:xiii, xv, 12–13, 25, **V**:2, 11–20  
     opacities and shadows, **VII**:3  
   work position and musculoskeletal injuries, **VIII**:38

## Z

Zeeman atomic absorption spectrometry (AAS) blood and urine analysis, **X**:8, 21  
 Zinc compounds  
   animal exposure studies, **V**:39–40, **VI**:45  
   biochemical effects, **II**:16–17  
   biological monitoring of disease, **V**:22–23, **IX**:13, 53  
   blood level studies, **I**:30–31, **II**:xv  
   brain cancer and, **II**:xxi, 17–18  
   braze welding fume composition, **X**:19–20

- case reports, **X**:38–39
  - electrode composition, **IV**:2
  - epidemiologic study design, **II**:19
  - fume composition analysis, **X**:7
  - fume exposure studies, **IX**:7
  - fume generation studies, **I**:3, 70, **III**:3, **IX**:20
    - electrode composition, **V**:6
  - metal fume fever, **I**:xv, **V**:3, 13, 20, **VI**:34–35, **VII**:9, 34–35, **VIII**:6, 34, **IX**:39, **XIII**:88–89
  - in paints, fume exposure studies, **VI**:26
  - production coatings, **VII**:30, **VIII**:19
  - protective coatings, **IV**:7
  - respiratory disease and, **III**:11
  - whole-body effects of, animal studies, **V**:39–40
  - workplace exposure limits, **IX**:23
- Zinc erythrocyte protoporphyrin (ZEP) measurement, lead exposure studies, **VI**:10, 43–44
  - Zinc fever. *See* Metal fume fever
  - Zinc oxide
    - animal studies and cell cultures, **XII**:71–72
    - inflammation and oxidative stress and, **XIV**:88
    - metal fume fever, **XII**:5–6, 17, 53–54, **XIV**:15
      - animal studies, **XIII**:118–120
      - pneumonitis incidence and, **XII**:15
  - Zinc oxide particles
    - animal studies, **X**:18, 70, 73–74
    - metal fume fever and, **X**:48
    - production coatings, **X**:26–27
    - protein synthesis induction and, **X**:5
    - “Z-plasty” technique, skin rashes, **II**:13

